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Rheumatoid arthritis (RA) is a chronic autoimmune disease of the joints, that 
affects 0.5-1% of the population globally. While primarily affecting the joints, 
systemic inflammation impacts other organs and the disease has a significant 
socioeconomic burden. While there are a wide range of medications to 
pharmacologically manage RA, it is a largely heterogeneous disease and the 
current treatment strategy does not consider the heterogeneity between patients. 
As such, precision medicine approaches to treatment are desired. A 5-loop 
chromosome conformation signature (CCS) was identified that had 90% specificity 
at predicting non-response to methotrexate (MTX) in early RA. These epigenetic 
biomarkers offer a novel strategy for improving patient care, and provide insight 
into disease pathogenesis.   
 
The aim of the work presented in this thesis was to further characterise this novel 
epigenetic biomarker. Investigation of this biomarker also offered the opportunity 
to hypothesise about underlying pathogenesis. A combination of molecular analysis 
of patient samples, and in-silico methodologies were applied to investigate these 
aims. 
 
In the first instance, the CCS was validated as a biomarker for identifying MTX 
responders using bioinformatic tools. Preliminary work was also carried out to 
identify the optimal method for detecting chromosome loops from the signature in 
the lab. Quantitative PCR was thoroughly explored, but excluded as a reliable and 
robust method of loop detection for our signature of interest. It was also found 
that the CCS was MTX specific, and alternative signatures would be required for 
prediction of response to other csDMARDs. Further validation of the signature, 
using an independent clinical cohort, revealed that specific loops from the CCS 
held stratification potential while others did not. In-silico investigations revealed 
different epigenetic landscapes exist between loops associated with responders 
and non-responders to MTX. Specifically, data suggests loops associated with 
responders exist in an environment which enhances gene transcription, while loops 
associated with non-responders have an environment indicating potential for gene 
repression. Differences in chromatin architecture, revealed through a discovery 
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microarray, have indicated that 3D epigenetic endotypes exist within the early RA 
population. Further investigations suggested each endotype have different, unique 
pathways that are highly regulated. Furthermore, results revealed that there is a 
stable RA chromatin signature that exists, which highlights the importance of the 
3D epigenome underpinning disease.  
 
In summation, this body of work has shown CCS to be promising biomarker for the 
stratification of the early RA population. Furthermore, thorough investigation of 
this signature highlighted novel pathways that may be involved in disease 
pathogenesis. This work has exciting potential to contribute to improved RA 
treatment in the future.  
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Chapter 1 Introduction 
 




Rheumatic diseases are characterised by damage to joints and connective 
tissues, which is often accompanied by complications for multiple other vital 
organs1. Rheumatoid arthritis (RA) is a disease of this type, and is the most 
common inflammatory arthritis2. RA is prevalent in approximately 0.5-1%3 of the 
population, and females are affected more than males with a ratio of 6.45:14. 
The most common age of onset is between 45 and 655, however it can occur at 
any age, with under 16s receiving a diagnosis of juvenile idiopathic arthritis 
(JIA)6. RA is an autoimmune and inflammatory condition, with chronic 
inflammation originating from the synovium leading to eventual joint 
destruction7.  
 
RA presents with symptoms of pain, fatigue and symmetrical swollen joints, with 
the smaller peripheral joints, such as the hands and feet, affected first8. 
Systemic inflammation can impact the eyes, lungs and blood vessels9 . If left 
uncontrolled, RA is a progressively disabling disease, which can impact on all 
parts of everyday life. Comorbidities such as heart disease and infection are 
often experienced, and can result in early mortality10. Cases of anxiety and 
depression are also known to be higher in those with RA, compared to healthy 
age and sex matched individuals11. In working-age adults with RA, the 
prevalence of depression has been found to be around 25%12. Interestingly, these 
comorbidities have not decreased with the better pharmacological management 
of RA11. It has also been found that those who experience psychiatric 
comorbidities are more likely to be impacted by other comorbidities that have 
been discussed13. Psychological symptoms have also been shown to negatively 








The development of RA is caused by a loss of immune tolerance to the joints, 
the exact trigger of which is unknown. However, there are various well-known 
genetic and environmental factors that increase susceptibility to the 
development and severity of disease15. These contributions result in a 
phenotypically heterogeneous RA population. RA heritability has been 
demonstrated through twin studies; monozygotic twins have shown to both have 
an RA diagnosis in 12-15% of cases, 10% more than non-zygotic twins2. There are 
currently over 100 genetic loci known to be associated with RA16. The allele 
associated with the highest risk is HLA-DR, which is an allele part of the major 
histocompatibility (MHC) locus. Modifications in DR4 and DR14 are most common, 
with changes in these alleles present in approximately 90% of people with RA2. 
Non-MHC genes with well documented risk for RA susceptibly are protein 
tyrosine phosphatase non-receptor 22 gene (PTPN22) and peptidyl arginine 
deiminase 4 (PADI4)17. A suggested mechanism by which these genes are a risk 
for RA, is the increased citrullination18.  
 
The relatively low genetic susceptibility, illustrated by twin studies, indicates 
the considerable environmental component involved in RA development. It has 
been proposed that the environment can impact disease susceptibly via the 
microbiome, primarily the lungs, oral mucosa and gut19. Numerous studies have 
also proposed that mucosal sites are where RA begins. Cigarette smoking is one 
of the biggest contributing environmental risk factors for RA susceptibility and 
severity, and is known to impact these mucosal sites20. The risk of RA 
development in smokers is twice that of non-smokers, with a slightly higher risk 
in women than men. It is largely believed that the more somebody smokes, the 
higher the risk, yet even light smokers are known to have an increased chance of 
development. Some of the risks associated with smoking may be due to its 
effects on the immune system which include oxidative stress, inflammation and 
epigenetic changes20. The oxidative stress can be attributed to the free radicals 
contained in smoke, in addition to nicotine effects on mitochondria21. The 
effects of smoking extend to the ability to respond well to RA treatment, which 
has been largely documented in biologic therapy22. Periodontal disease is 
another well-known environmental risk factor for the development of RA23. This 
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also has the ability to cause epigenetic changes to the genome which results in 
the damage observed in the disease24. Aspects of the diet have also been shown 
to be an environmental risk factor for RA. These include low vitamin D, and high 
sugar and sodium intake25-27. The gap in the knowledge of heritability and 
environmental influence has meant the diagnosis, prognosis and pharmacological 
management of the disease is not always correct for the patient28. These 
potential changes to the genome caused by environmental influence remain to 
be thoroughly explored. 
 
1.1.3 Socio-economic burden 
 
Approximately 80% of working adults with RA experience pain, joint stiffness and 
reduced functionality, ultimately limiting the ability to work as normal, and 
carry out everyday tasks29. As such, RA is a disease with a considerable socio-
economic burden. Work disability is a risk, even in early disease30. There are 
several risk factors for the development of workplace disability, which include 
the nature of the job, disease activity and age of onset31. When evaluating the 
economic burden of RA, three main cost categories are explored: direct, indirect 
and non-monetary29. Direct costs refer to costs to the healthcare system such as 
medication, and other costs which are incurred by the affected person and their 
families. This can include adapted transportation or living arrangements. 
Indirect costs are those which are incurred by employers for example. These 
include the cost of sick-leave or reduced productivity. Additionally, the large 
proportion of people who remain unresponsive to RA treatment add to this 
burden32. Non-responders (NR) to treatment often lose more days at work 
compared to responders (R), and are likely to have higher healthcare costs, due 
to side-effects or from continued inflammatory symptoms32. The cases of 
depression in working adults with RA is also a considerable contributor to the 
economic burden. One study from the US revealed that those with RA and 
depression were 20% more likely to be unemployed than those without 
depression, and had approximately £4000 more in healthcare costs12. It was also 
documented that those with depression were more likely to experience pain, 
which may have an impact on ability to attend work12. There are also the non-
monetary costs, which are arguably the most important. Those are costs that 
impact quality of life for those affected by RA. Often these non-monetary costs 
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are left unmeasured in studies calculating the ‘cost’ of RA due to the difficulty 
in measuring this reliably29.  
 
1.1.4 Immunopathogenesis  
 
The immunopathogenesis of RA is a complex, stepwise process ranging from pre-
diagnosis to chronic inflammation33. This is driven by a host of innate and 
adaptive immune mechanisms, in addition to the stromal compartment2. The 
synovial membrane (SM) lines the joint capsules and secretes synovial fluid (SF) 
which is essential for maintaining joint function. In RA, the SM is one of the most 
affected tissues and undergoes significant structural changes. In healthy 
individuals, the synovial membrane is 1-2 cells thick and is comprised of blood 
vessels and adipocytes, as well as low levels of macrophages and fibroblasts34. 
The synovial fluid is comprised of nutrients and cytokines. In RA, the SM 
increases in thickness to form a pannus, around 10-12 cells thick with infiltrates 
from both innate and adaptive immune systems including macrophages, natural 
killer (NK) cells, B cells and T cells2. Fibroblast-like synoviocytes (FLS) are 
central players in synovial inflammation and mediate many of the processes in 
the RA synovium35.  
 
When FLS are activated they produce IL-6, which contributes to damage36. IL-6 is 
one of the major drivers of disease and exerts its effects on multiple other cells 
and molecules. IL-6 signals via an IL-6 specific receptor and surface glycoprotein 
named gp130. There are two types of IL-6 signalling, named classical and trans-
signalling, which correspond to IL-6 binding to a surface or soluble receptor, 
respectively36. TNFα is another pro-inflammatory cytokine that drives disease. 
Macrophages in the joint are the main producers of this, but is it also released 
by activated T lymphocytes37. Two receptors exist for TNFα to bind to, these are 
named CD120a and CD120b38. TNFα is found in higher concentrations in the RA 
synovium compared to healthy, and studies have shown it to be associated with 
increased bone erosion39.   
 
The dysregulated synovium reduces the oxygen supply, resulting in a hypoxic 
environment, changing from around 8% oxygen to 1%40. This environment induces 
altered cellular metabolism, which in turn increases reactive oxygen species 
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which perpetuates the inflammation. In response to a hypoxic environment, 
immune cells activate proinflammatory signalling pathways such as NFkB41 and 
hypoxia-inducible factors (HIF). HIF are transcriptional factors that are highly 
expressed in the RA synovium, and accumulating evidence suggests that HIFs 
helps to maintain the inflammatory environment in RA42. For example, HIF1α can 
upregulate TLR-4 on macrophages. Moreover, HIF1α has been shown to regulate 
mediators of angiogenesis, another known characteristic of RA pathogenesis43. 
This aggressive, inflamed synovial environment invades the proximal cartilage 
and bone, leading to destruction40. Synoviocytes become chronically activated 
and epigenetically changed, driving this inflammation further. These changes 
also occur in the infiltrating immune cells40.  
 
In RA specifically, the adaptive immune response is contributed to by 
autoantibodies44. These include rheumatoid factor (RF), an antibody against IgG, 
and anti-citrullinated protein antibodies (ACPA) that are mounted against post-
translationally modified proteins44. Interestingly, these antibodies can exist 
before disease presentation. People with RA are classed as sero-positive or sero-
negative, based on the presence or absence of these antibodies, respectively. 
Approximately 50-80% of RA patients are sero-positive to some extent45. The 
binding of these autoantibodies to the Fc receptor within synovium may trigger 
innate immune mechanisms such as the complement pathway.  
 
The erosion of bone is another process which occurs during inflammation, and 
begins early, triggered by the inflamed synovial environment and 
proinflammatory cytokines. This results in the activation of the receptor 
activator NFkB ligand (RANKL). Fibroblasts expressing RANKL are stimulated by 
macrophage-colony stimulating factor (M-CSF) resulting in the differentiation of 
pre-osteoclasts into osteoclasts, which break down bone46. Monocytes in the 
synovial compartment can also differentiate into osteoclasts with stimulation 
from IL-6, TNFα and IL-17. This inflammatory environment can suppress the 
differentiation of osteoblasts, preventing the capacity to form new bone to 
counteract increased osteoclast activity47. Bone erosion in RA is irreversible, 
thus placing high importance on early intervention and appropriate treatment.  
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1.1.4.1 Peripheral Blood Mononuclear Cells 
 
Peripheral Blood Mononuclear Cells (PBMCs) are circulating immune cells within 
blood, with a round nucleus48. PBMCs are comprised of members of both the 
innate and adaptive immune system49. In general, the majority of cells are T 
cells at around 70%, with B cells, monocytes and NK cells making up the other 
15%, 10% and 5%, respectively50. The composition of cell subtypes within PBMCs 
can be influenced by several factors including hormone levels and state of 
inflammation51. The peripheral blood in those with RA has been shown to differ 
in numerous ways from those without, in factors such as cytokine production, 
cell phenotype and methylation status52. In the absence of an antigen, most 
PBMCs circulate as naïve cells without a specific function. The activation state 
and composition of PBMCs can reflect the wider immune condition of someone 
with RA, and thus present an appropriate population of cells to interrogate for 
insights into immunopathogenesis53. Moreover, this circulating population of cells 
are highly important from a research perspective, particularly when 
investigating the influence of pharmacological intervention49.    
 
1.1.4.2 Monocytes  
 
Monocytes make up 10% of circulating peripheral blood cells54 and they originate 
from the bone marrow55. Both in states of homeostasis and inflammation, 
monocytes migrate from the bloodstream into tissues56. In RA, monocytes can 
migrate into the synovium through interaction between CCR2 and CX3CR1 
receptors and CCL2 and CX3CL1 ligands55. Three main populations of monocytes 
exist based on their surface markers. 90% of monocytes, otherwise known as the 
‘classical’ type, belong to one population and are CD14+CD16-. The other 
populations of monocytes are CD14+CD16+ and CD14-CD16+, otherwise known as 
‘intermediate’ and ‘non-classical’ subsets respectively57. Each subpopulation can 
mediate inflammatory processes in a different way. Monocytes play an important 
part in the innate immune system, with various roles including phagocytosis and 
antigen presentation54. While monocytes are great scavenger cells and 
protective in that way, they also have pathogenic mechanisms in inflammatory 
diseases such as atherosclerosis and RA54. Monocytes have the capacity to 
differentiate into macrophages and dendritic cells (DCs)56. In the RA joint, 
monocytes produce a variety of pro-inflammatory cytokines which result in 
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processes such as polarisation of CD4+ T cells56. In addition, monocytes can also 
differentiate to osteoclasts, which contribute to the destruction of bone via 




1.1.4.3 T cells 
 
T cells make up approximately 70-90% of the PBMC population, most of which 
are CD3+. Within the CD3+ population, there are two main types of T cell: CD4+ 
and CD8+ T cells, the ratio of which is around 2:151. In the normal state, T cells 
will circulate within the PBMC population as naïve or memory cells, without an 
effector function51. If a T cell encounters an antigen, it can differentiate and 
produce effector functions. T cells have been shown to play a significant role in 
RA pathogenesis, what type, and at what stage remains unclear as evidenced 
through risk genes which are involved in T cell activation3. Success of Abatacept, 
which targets T-cell co-stimulatory molecule CTLA4 in the treatment of RA, also 
demonstrates their pathogenic role59. CD4+ T cells have a wide range of 
differentiated phenotypes including, T helper 1 (Th1), Th2, Th17 and Th2251. 
Th2 cells are known to induct antibody responses in B cells, influencing the 
generation of RF and ACPA60. Th17 cells also play a large role in RA 
pathogenesis, after being activated by antigen presenting cells (APCs) and 
cytokines including IL-6 and IL-2161. Th17 discovery shed new light onto RA 
pathogenesis, which was originally believed to be a Th1 driven disease. Th17 
cells produce the cytokines IL17A, IL-17F, IL-21, IL-22 and IL-2662. Th17 cells can 
reside in the gut without eliciting pathogenic effects. However, if self-reactive 
Th cells are primed to become Th17 cells, they can become pathogenic and 
induce a pro-inflammatory response towards a specific organ, such as the joint61. 
Other pro-inflammatory cytokines IL-1 and IL23 have been shown to regulate and 
enhance the Th17 response in animal models of autoimmune diseases63.  
 
1.1.4.4 B cells 
  
B cells play several important immunological roles as part of the adaptive 
immune system; acting as antigen presenting cells (APCs), and producing 
antibodies are just two of these vital roles64. As with other immune cells, with 
the loss of self-tolerance, B cells can ultimately cause harm to the body. For 
example, B cells are known to have a pathogenic role in several autoimmune 
diseases, including systemic lupus erythematosus (SLE) and RA. Specifically, 
experiments with murine models, and the success of rituximab (causes B cell 
depletion) in the treatment of RA, highlight the crucial role of B cells in the 
pathogenesis 65,66. Moreover, the production of cytokine and chemokines, such as 
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CXCL13 and IL4 and IL6 by B cells facilitates the infiltration of other immune 
cells into the joint67. Furthermore, B cells work closely with T cells to exert 
their pathogenic effects, such as the activation of autoreactive T cells64.  
 
1.1.5 Diagnosis   
 
Over the last couple of decades, extensive research has demonstrated that early 
diagnosis of RA, and subsequent pharmacological intervention provides the 
optimal window for successful treatment and offers the best chance of achieving 
a good long-term outcome68,69. There is no diagnostic test which can diagnose 
RA, instead diagnosis is made by a clinician, based on a set of criteria initially 
set out in 1987. With an emphasis on the importance of early diagnosis, the 1987 
RA classification criteria required updating. This was due to the fact the criteria 
were developed in those with established RA, and thus had poor sensitivity for 
those with early synovitis70. As such, the main RA clinical consortiums, The 
European League Against Rheumatism (EULAR) and the American College of 
Rheumatology (ACR) updated their diagnosis guidelines in 201071. Through many 
validation studies, these new criteria have shown to have increased sensitivity 
from previous guidelines, from 31.9% to 72.3%. However, there was a reduction 
in specificity from 92.4% to 83.2%. The overall diagnostic ability is considered 
moderate72. The criteria for diagnosis considers 4 categories: 1) joint 
involvement, 2) the presence of serological markers, RF and ACPA, 3) 
measurements of the acute phase reactants, c-reactive protein (CRP) and 
erythrocyte sedimentation rate (ESR) and 4) duration of symptoms73 (Table 1.1). 
Each category has points assigned for severity. A total score of 6 or more results 
in a diagnosis of RA74. Capturing those who may have had symptoms for less than 
6 weeks, but have other symptoms present, aims to capture people early and 
fulfil the aim to get treatment initiated as soon as possible. Of note, anybody 
presenting with bone erosions does not need the classification criteria to obtain 




Table 1.1 2010 ACR/EULAR classification criteria 
These criteria consider symptom information from 4 domains: A) joint involvement, B) 
the presence of serological markers, rheumatoid factor (RF) and anti-citrullinated 
protein antibodies (ACPA), C) measurements of the acute phase reactants, c-reactive 
protein (CRP) and erythrocyte sedimentation rate (ESR) and D) duration of symptoms. A 
total score ≥6 results in an RA diagnosis. Adapted from Kay and Upchurch, 201274 
ACPA, anti-citrullinated protein antibodies; CRP, C-reactive protein; ESR, erythrocyte 






1.2.1 Treatment Overview  
 
RA treatment aims to control pain and inflammation, reduce joint destruction 
and achieve remission75. While there is currently no cure for RA, there are a 
wide variety of pharmacological therapies available to try and manage the 
disease. These include non-steroidal anti-inflammatory drugs (NSAIDs) and 
disease modifying anti-rheumatic drugs (DMARDs), both non-biologic and 
biologic. Non-biologic DMARDs offer broad immunosuppression functions, while 
biologic DMARDs (bDMARDs) target immune cells and mediators, such as B cells 
(Rituximab), IL-6 (Tocilizumab) and TNFα (Etanercept) involved in RA 
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pathology76,77. For a drug to be classed as a DMARD in the treatment of RA, it has 
to have demonstrated a reduction in the radiographic progression of disease78. 
Historically, NSAIDs were the only treatment option, and while these eased the 
pain of symptoms, they did not slow progression of disease79. The development 
of biologics over the past 2 decades has significantly improved disease outcome 
for many patients80. It should be noted that until the emergence of the biologics, 
many of the drugs used in RA were not created specifically for the disease and 
unsurprisingly this has contributed to the variation in efficacy of treatment in 
patients (Figure 1.1). Moreover, the heterogeneity between patients further 
influences the disparity in drug response.  
 
The drugs themselves have not only developed over the last couple of decades, 
but the treatment strategy has also changed. RA clinics now adopt a treat to 
target strategy (T2T), developed in 201081 which aims to get patients into 
clinical remission, or at the very least, low disease activity (LDA). Disease 
activity is quantified by various clinical scores. The Clinical Disease Activity 
Index (CDAI) is widely used and considers the number of tender and swollen 
joints, as well the patient and clinician assessment of disease. Another widely 
use measure of disease activity is the Disease Activity Score (DAS) 28 of which 
there are several variations. The number of tender and swollen joints is always 
considered, and other inflammatory markers such as ESR and CRP can be 
interchanged. The T2T strategy involves changing treatment if disease activity is 
not improving within a designated duration82. The T2T approach can be adapted 
to any medication, which may vary from country to country, and it encourages 
an accelerated approach at treatment initiation, which has shown to be optimal 
in RA treatment for the long term83 (Figure 1.2). The RA treatment regimen in 
newly diagnosed patients is particularly structured and during the periods of 
drug assessment, irreversible joint destruction often occurs in the individuals 
that are not responding to therapy. Currently, determining 1st line therapy does 
not consider underlying molecular mechanisms of disease but is based on clinical 
symptoms in addition to economics. bDMARDs are considerably more expensive 





Figure 1.1 RA treatment history  
Schematic illustrating the timeline over which drugs were implemented in the 
treatment of RA. Adapted from reflections on ‘older’ drugs: learning new lessons in 
rheumatology.84 
bDMARDs, biological disease modifying anti-rheumatic drugs; NSAIDs, non-steroidal anti-




Figure 1.2 T2T Strategy  
Schematic demonstrating current T2T strategy in the treatment of RA, A) T2T strategy, 
clinical diagnosis as defined by ACR/EULAR 2010 criteria, desired target is remission, or 
if remission not possible, low disease activity. B) Representation of targeting overall 
inflammation and lack of specific target. C) representation of rituximab targeting CD20 
on B cells. D) Representation of etanercept targeting CTLA4 molecule. E) representation 
of anti-TNF targeting TNF molecule.  Adapted from EULAR recommendations for the 
management of rheumatoid arthritis with synthetic and biological disease-modifying 
anti-rheumatic drugs: 2019 update.82 
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bDMARD disease modifying anti-rheumatic drugs; csDMARDs disease modifying  
anti-rheumatic drugs; HCQ, hydroxychloroquine; JAK, janus kinase, LEF, leflunomide;  
MTX, methotrexate; RA, rheumatoid arthritis, SSZ, sulphasalazine  
 
 
1.2.2 Current Treatment 
 
1.2.2.1 csDMARDs  
 
The nomenclature for RA drug treatment was updated in 2014. Conventional 
Synthetic DMARDs (csDMARDs) are the most common first-line therapy in the 
treatment of RA. This group of drugs comprises of methotrexate (MTX), 
hydroxychloroquine (HCQ), sulphasalazine (SSZ) and leflunomide (LEF). These 
can be given with or without glucocorticoids85. This group of drugs does not have 




MTX, once known as amethopterin, has been used in the treatment of RA since 
FDA approval in 1986 and is now considered the ‘anchor drug’ in RA86,87. MTX can 
be found on the list of the WHO essential medications due to the number of uses 
for which it was not the original indication87. This drug was originally used as an 
anti-cancer agent and the exact mechanism in the treatment RA remains 
unclear, despite 40 years of use in this indication88. The mechanism of action in 
the treatment of Leukaemia, and the most documented mechanism of action in 
RA is folate antagonism, by inhibiting the enzyme dihydrofolate reductase 
(DFTR), essential for production of folate. For leukaemia treatment, MTX has to 
be given in high doses, however at lower doses it was found to be effective in 
RA89. This mechanism reduces purine synthesis and thus causes cell death. This 
has been shown to have effect on T cells90. Folic acid supplementation in RA is 
crucial, to compensate for the reduction in folate91. Many studies have explored 
the addition of folic acid on efficacy of MTX and it was found to have little 
effect, suggesting that folate inhibition is not the only mechanism by which 
inflammation is reduced87. Adenosine signalling and reduction of reactive oxygen 
species are other suggested mechanisms of MTX in the treatment of RA88.  
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MTX has become an anchor drug due to its superior efficacy and tolerability 
compared to other csDMARDs92 and is now the most popular 1st line treatment in 
the world93. It is often given as a monotherapy, but in some cases with the 
addition of other csDMARDs, HCQ or SSZ94,95 and can be given either orally, or 
subcutaneously. While MTX is considered an effective therapy in RA, it is a drug 
with many side effects and some patients need to change drug due to 
intolerability. One of the most commonly documented side effect is problems 
with the gastrointestinal (GI) tract, with approximately 20-70% of people on MTX 
experiencing them96. Nausea is the most common GI tract side effect, with 
vomiting and abdominal pain also widely documented. Interestingly, Calasan and 
others have shown that MTX GI side effects can be associative or anticipatory96. 
Other known side effects include infections, as well as toxicity in the pulmonary, 
haematological and hepatic systems97. Side effects may contribute to non-
compliance with medication, and thus contribute to the known efficacy of the 
drug. A recent study explored MTX adherence and found that often it is not 
optimal and various demographic factors lead to non-adherence98.  
 
While effective in a large proportion of recipients, MTX is not effective in every 
individual, with around 30% of patients switching drug within 12 months, some 
due to inefficacy, and some due to side effects99. A benefit of using MTX as first 
line, and an anchor drug with other medications, is the cost-effectiveness100. 
With MTX being unsuitable in approximately 30%, a biomarker for MTX response 
would be extremely valuable. Furthermore, as discussed previously, it is well 
established that the sooner effective therapy is initiated, the better the long-
term outcome for the patient77. Currently, there is an assay that exists to try 
and determine MTX response in patients. This assay is used to genotype 
thiopurine S-methyltransferase (TPMT) which is involved in the MTX metabolism 
pathway. However, this assay has yet to achieve widespread clinical 
implementation101. This is due to evidence of interaction with other medications 
and varying results between laboratories102.   
  
1.2.2.3 Hydroxychloroquine  
 
HCQ is another of the csDMARDs used in the treatment of RA and is another drug 
with a previous original indication. HCQ was first used in the treatment of 
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malaria. However, after it was found to have immunomodulatory properties, it 
was used in the treatment of autoimmune conditions such as systemic lupus 
erythematosus (SLE) and RA103. HCQ was developed though chemical adjustments 
to Atabrine, one of the first antimalarial drugs, after Atabrine caused severe 
side effects. HCQ has been found to be less efficacious than MTX or SSZ, and 
thus is rarely given as monotherapy, unless it’s in cases of more mild disease or 
in combination with the other csDMARDs103. Similar to MTX, the mechanism by 
which HCQ reduces inflammation in RA is not fully understood104. HCQ is known 
to inhibit ion channels and Schroeder et al have shown that HCQ can inhibit 
calcium dependent potassium channels, which may lead to impaired 
inflammasome activity104. Another study has demonstrated the ability of HCQ to 
supress the inflammatory responses of class-switched B cells105. HCQ achieved 
this effect via TLR9, providing evidence of HCQ on toll-like receptors. T 
follicular helper cells have also been shown to be influenced by HCQ 
treatment106. Many studies have found benefits of HCQ on comorbidities of RA 
associated with the cardiovascular and metabolic systems107. In a mouse model 
of arthritis, HCQ had protective effects against atherosclerosis and a human 
population-based study demonstrated HCQ use was associated with a decreased 
risk of coronary artery diseases compared to non-users108,109. HCQ also has 
associated side effects, one of the main effects being retinopathy. Studies 
remain ongoing to determine an effective dose of HCQ that will not increase risk 
of retinopathy110. Like MTX, as HCQ is used in the early stages of disease, ability 
to predict drug response before use would be beneficial.    
 
1.2.2.4 Sulphasalazine  
 
SSZ is a csDMARD made in 1930 for use in the treatment of ulcerative colitis (UC) 
and RA. SSZ is a drug which combines the antibiotic sulphapyridine and the 
NSAID 5-aminosalicyliac acid111. It has been found to have similar efficacy to 
MTX, however is normally given in triple combination with MTX and HCQ112. One 
of the mechanisms of action of SSZ is inhibition of platelet thromboxane111. SSZ 
has been known to induce sulphonamide hypersensitivity reactions in people 
with RA, higher than that in the normal population113. Like the other csDMARDs 
in RA, the mechanism of action is not fully comprehended. One study has 
illustrated the effect of SSZ on endothelial cell chemotaxis114. This study also 
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demonstrated expression of ICAM-1, IL-8 and MCP-1, known genes involved in 
angiogenesis114. While SSZ is efficacious in UC, the drug effects on the humoral 
immune system in RA is not clear. One study has suggested that in RA, SSZ exerts 
its effects systemically115. This study illustrated reduction of IL-6, in serum of 
patients treated with SSZ. It is thought this contributed to the serum reduction 
on IgA and IgM115. These results came after a previous study showed similar 
results which revealed a reduction in IL-6 levels, 4 months post-SSZ treatment, 
which correlated with a reduction in disease activity116.  
 
1.2.2.5 Combination therapy 
 
The csDMARDs, MTX, HCQ and SSZ are sometimes given in conjunction to treat 
RA, referred to as triple therapy. If 1st line monotherapy MTX is unsuccessful, as 
an alternative to bDMARDs, a combination of csDMARDs can be used. This 
approach has been shown to be more efficacious that MTX alone or combination 
of HCQ and SSZ117. Several clinical trials have tested whether triple csDMARD 
therapy is better or worse than MTX with the addition of the bDMARD, 
etanercept and have found them to be comparable in treating RA118. In terms of 
drug cost, triple csDMARD therapy is superior. However, when assessing Quality 
Adjusted Life Years (QALYs), csDMARD triple therapy is inferior to the MTX-
Etanercept combination119. These two treatment strategies have also been 
studied to understand whether other combinations are less likely to cause side 
effects such as infections and GI disturbances. A study by Quanch et al revealed 
that those treated with triple therapy were more likely to suffer GI side effects 
than those with MTX-etanercept, however they were less likely to suffer from 
infections120. Overall, the literature demonstrates that both these approaches 
work well for the treatment of RA, and in such a heterogeneous population, both 
approaches are beneficial. Yet there is still space for improvement as not all will 




bDMARDs have been designed to target specific molecular structures involved in 
RA pathology121. The first bDMARD was developed against TNFα. A neutralising, 
chimeric monoclonal antibody was tested in a clinical trial and patients 
responded well to the treatment with considerable reductions in disease activity 
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measurements. The discovery of the efficacy of this type of treatment in RA 
paved the way for other bDMARDs targeting other molecules involved in 
inflammation122. Since then, 5 anti-TNFα medications have been licenced for use 
in the treatment of RA. Infliximab was the first of these to be used in 
patients123. This a monoclonal antibody that works by inhibiting TNFα from 
triggering the TNF receptor complex. Adalimumab is a monoclonal antibody that 
works in the same way. Both have been shown to have increased efficacy when 
given with MTX. Rituximab (RTX) is another widely used bDMARD used to treat 
RA. RTX is a monoclonal antibody against the CD-20 molecule, which is found on 
B cells. RTX uses a variety of mechanisms to deplete B cells, including apoptosis 
and complement-dependent cytotoxicity124. Complete B cell depletion occurs in 
the blood, but B cells in synovial tissue and bone marrow are only depleted in 
part. As such, response to RTX has been found to correlate with B cell levels in 
synovial tissue125. There is also a bDMARD that targets IL-6. Tocilizumab (TCZ) is 
a monoclonal antibody which targets soluble and membrane bound IL-6 
receptor126. This stops IL-6 binding to the receptor and the signal transducer 
glycoprotein 130 complex, stopping downstream activation of the Janus Kinase 
signal transducer and activator of transcription (JAK-STAT) pathway. While 
bDMARDs have dramatically changed the treatment of RA, they can cost up to 
10x more than csDMARDs127. As such, it is not cost-effective to initiate bDMARD 
therapy for everyone in early disease since csDMARDs are efficacious in many. 
This emphasises the need to find a way to establish who would benefit from 




There is now a new drug class called the targeted synthetic DMARDs (tsDMARD), 
which target other small molecules involved in pathogenic pathways in RA. One 
such pathway is the JAK-STAT signalling pathway. This pathway is essential for 
many cytokines128. Upon cytokine stimulation, JAKs are activated and 
phosphorylate STATS. There are 2 drugs that target this pathway currently in 
clinical use. Tofacitinib primarily targets JAK1 and JAK3 family members in vivo 
129 while baricitinib provides reversible inhibition of JAK1 and JAK2 family 
members130. Blocking of these kinases effects the downstream cytokines IL-2, IL-
4, IL-9, IL-15 and IL-21. Tofacitinib has shown efficacy and safety and been 
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effective as monotherapy or in combination with MTX. The RA-BEAM clinical trial 
investigated the safety and efficacy of baricitinib compared to placebo and 
adalimumab131. Baricitinib achieved a reduction in disease activity, with more 
patients having an ACR20 response over placebo at 12 weeks. Baricitinib also 
inhibited radiographic progression of joint damage. The emergence of the 
tsDMARDs has provided an alternative to the conventional DMARDs and may be 
useful for treatment in those who are unresponsive to the csDMARDs.  
 
1.3 The Human Genome  
 
1.3.1 Genome Organisation   
 
The size of the human genome is approximately 3100 million base pairs (bp)132. 
Packaging this DNA into  6µm of a cell nucleus presents a significant structural 
challenge133. As such, the DNA is packaged into a highly-organised structure 
(Figure 1.3)134. This intricate organisation not only serves a structural purpose, 
but a functional one. DNA has three main layers of organisation within the 
cell135. The baseline structure of DNA is the well-known double-helix, consisting 
of 4 bases, joined by a hydrogen bond with a sugar-phosphate backbone (Figure 
1.3A)136. This double-helix is then wrapped around proteins known as histones. 
Multiple histones create nucleosomes, first described in 1974, which can be 
considered the core building block of the genome (Figure 1.3B). A nucleosome 
consists of 147 bp of DNA wound around an octamer of histone proteins137. This 
octamer is made from 2 of each type of histone protein: H2A, H2B, H3 and H4138. 
The DNA can then be wound into a higher order structure called chromatin 
(Figure 1.3C). This level is often referred to as ‘beads-on-a-string’, with the 
beads representing nucleosomes. The chromatin itself is then looped in a 
functional manner (Figure 1.3D). Chromosomes are then arranged into 
topologically associated domains (TADs), which facilitate increased DNA 
interaction between genes within a TAD by regulating enhancer-promotor 
contacts (Figure 1.3E)139. The boundaries of TADs are generally made up of 
highly-expressed genes. While TADs promote gene expression with genes in 
close-proximity, chromatin is also able to be regulated by features from a far 
topological distance. The dynamic chromatin structure allows regulatory factors 
to access the chromatin only when required and ensures there is no unrestrained 
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gene expression137. Finally, the DNA forms chromosome territories. The location 
of the chromosomes in these territories may resemble well-recognised 
positions132. A technique named chromosomal painting helped visualise these 
chromosome territories140. These studies demonstrated that genes on one 
chromosome interacted with genes on the same chromosome, more than they 
would interact with genes on another chromosome. In more recent years, these 
findings have been replicated with higher resolution technologies141. 
Euchromatin refers to chromatin in an open conformation, thus facilitating gene 




Figure 1.3 Schematic of Genome Organisation 
Schematic illustrating the multiple layers of genome organisation within a cell. A) DNA 
double-helix. B) Nucleosomes composed of 147bp of DNA wrapped around 8 histone 
proteins (2x H2A, H2B, H3 &H4). C) 30nm fibre chromatin (beads-on-a-string). D) 
Chromatin loops. E) Topologically associated domains (TADs) consisting of chromosomes. 
F) Chromosome territories which form the 23 chromosomes in the human genome. G) 
DNA organised within the cell nucleus 
 
 
1.3.2 Epigenome  
 
The genome is packaged into every cell in the human body, yet cells can be 
phenotypically different. This can be explained in part by epigenetic 
mechanisms. Historically, epigenetics was defined as changes to the DNA that do 
not alter the DNA sequence itself, and that result in a stable, heritable 
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phenotype143. The definition of epigenetics has become more diverse and it is 
now considered that epigenetics encompasses changes to the chromatin, that 
may involve addition or removal of proteins, or changes to the chromatin 
structure itself144. Others have described epigenetics as ‘the structural 
adaptation of chromosomal regions so as to register, signal or perpetuate altered 
activity states’145. It appears that the evolution of the definition focuses on the 
influence of structure, and consequential influence on gene function. In the 
1990s, research on imprinting genes introduced DNA methylation into the 
‘epigenetics’ definition, followed later by histone modifications146. Epigenetic 
changes include DNA methylation, histone modification and changes to the 
chromosome architecture147.The tails of histone proteins are often susceptible to 
these epigenetic changes in the form of post-translational modifications such as 
methylation and phosphorylation. These modifications can have a direct effect 
on the structure of the chromatin which then results in the overall gene 
expression and thus phenotype, and studies have been able to illustrate this148.  
 
The epigenetic process is highly complex and is reflective of the environment’s 
interaction with the genome 149. Epigenetics have significant influence on 
cellular processes and often vary between different cell types150. With many 
unanswered questions left in genome research, many propose these questions 
could be answered from findings in the growing epigenomic research domain. 
Recently, epigenome wide association studies (EWAS), which are similar to 
genome wide association studies (GWAS) have been used to explore the genome 
for epigenetic impact in disease151. EWAS has an additional level of complexity 
over GWAS due to the dynamic, reversible nature of the epigenome. It is also 
believed that studies of the genome which have taken place already could be 
enhanced with additional epigenetic data149. Some epigenetic changes are 
associated with increased gene expression but in contrast some are associated 
with repression of gene expression. In general, both epigenetic ‘writer’ and 
‘eraser’ proteins have been described that control these changes in gene 
expression. ‘Writer’ proteins cause changes to gene expression and transcription 
and ‘eraser’ proteins remove these epigenetic modifications24.  
 
Research has shown that epigenetic changes can be a contributory factor in the 
development of many autoimmune diseases147. In this case, epigenetic 
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modifications can influence processes such as immune cell function. Epigenetics 
could reveal a link between the known combined influence of genes and 
environment in RA24. The rheumatology field has seen considerable advances in 
epigenetics in recent years due to the development of many technologies 
allowing high-throughput analysis of data152. The epigenome is susceptible to 
changing characteristics of disease, as well as different therapies used to treat 
conditions such as RA. This presents a wide spectrum where epigenetics could be 
consulted for precision medicine application153. It is widely believed that 
understanding these mechanisms will contribute to the better management of 






DNA methylation, with the most technologies available to explore, is the best 
understood epigenetic modification155. Methylation is generally considered to be 
a stable epigenetic modification which is also heritable and can be a mechanism 
of regulation in cellular processes such as differentiation153. This epigenetic 
change has been well documented and has been observed in autoimmune 
diseases such as RA. DNA methylation is caused by the addition of a methyl 
group to the cytosine or adenine at position 5. Methylation of DNA is prevalent in 
several cell types involved in RA pathogenesis with synovial fibroblasts being one 
type affected156. The consequence of DNA methylation varies and can affect 
repression of transcription which can result in disease pathology. Glant et al 
performed one of the first studies into epigenetic modifiers in RA. This was a 
genome wide methylation profiling study which took place in PBMCs. The study 
indicated that methylation changes at the MHC locus increased the risk of 
developing RA154. It was shown that enzymes that can modify chromatin were 
found in genes that are known to be expressed in RA. These include 
acetyltransferases, methyltransfersases and histone kinases154. Another study has 
illustrated the major impact that one minor epigenetic change can have in RA. 
They showed that methylation at a single site in the promoter region for CTLA-4 
in regulatory T cells (Tregs) could ultimately result in the failed activation of the 
immune modulatory kynurenine pathway157. It has also been recognised that 
methylation has an influence in RA by developing apoptosis resistant FLS80. Many 
of the methylation studies carried out to this day have lacked substantial 
numbers and have therefore been considered preliminary. 
 
1.3.2.2 Histone Modification 
 
Histone modifications refer to the post-translational addition or removal of 
proteins on the histone NH-2 terminus, or histone ‘tail’. A histone code 
hypothesis was proposed in 2000, which suggested patterns of these 
modifications could influence downstream biological processes in different 
ways158. Histone modifications include methylation, acetylation, 
phosphorylation, ubiquitination and sumoylation. Depending on the combination 
and number of these modifications, genes can become 1 of 4 states that are 
termed active, poised, bivalent or repressed. These states have been shown in 
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studies in CD8+ T cells159.  
 
The functional implications of methylation on histones has been widely 
investigated, and has shown methylation can result in repression or activation of 
genes. Methylation occurs on lysine or arginine residues on the histone tail. 
Mono-, di or tri-methylation has been shown to indicate enhancers; in contrast 
trimethylation of H3K27 (H3K27me3) which is a known repressor mark. Histone 
methlytransferases are the enzymes responsible for facilitating the transfer of 
methyl groups. Acetylation of histone tails is widely considered to be a mark of 
gene activation. H3K27ac is a well characterised histone mark found enriched at 
active enhancer sites160. Histone modifications of the genome are regulated by 2 
enzymes, histone acetyltransferase (HAT) and histone deacetylase (HDAC)161. 
Phosphorylation occurs to threonine or serine residues and is another 
modification known to be associated with activation162. Ubiquitination occurs to 
lysine residues and can be associated with either transcriptional repression or 
activation.  
 
Many studies of histone modifications in RA have taken place in the synovial 
compartment. Studies in synovial fluid have illustrated reduced HDAC activity in 
RA compared to healthy controls163. Research in PBMCs has shown there is an 
alternative equilibrium of these enzymes in PBMCs of RA patients compared to 
the healthy population161. A study by Gillespie et al illustrated increased levels 
of HDAC in PBMCs164. Levels of these enzymes can give an indication of the levels 
of transcription of cytokines responsible for inflammatory responses in RA. 
Research by Toussirot et al has suggested that different RA therapies can exert 
varying epigenetic modifications in the form of histone acetylation and 
deacetylation24. In this study they showed that TNFα inhibitors such as Infliximab 
increased histone acetylation in the nucleus but alternatively, RTX, increased 
both acetylation and deacetylation enzymes161. Despite this research, the 
consequences of the changing levels of these enzymes with RA treatment 
remains to be fully investigated. 
 
1.3.3.3 Chromatin loops  
 
Chromatin architecture is the overarching epigenetic feature to the marks 
already described. As discussed, chromatin loops can be considered the third 
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level of organisation within the nucleus (Figure 1.3D). Chromatin loops offer an 
interesting mechanism to investigate the epigenome, as they can encompass 
methylation sites, histone modifications and miRNAs and can regulate how these 
features interact with each other. Study of chromatin loops clearly demonstrates 
the intricate relationship between genome structure and function. Simply, 
chromatin loops are formed when 2 parts of the genome, separated by an 
intermediate DNA sequence, are brought into close physical proximity165. Gene 
regulatory sequences are often not located beside the gene they control. When 
necessary, loops allow promotors and enhancers to be brought into proximity to 
a specific gene to permit activation and transcription165. Studies have 
demonstrated this, showing DNA is enriched with chromatin loops at active 
enhancer and promotor sites and are less are likely to be found at inactive sites 
or sites with histone modifications that cause repression166. Research into the 
drosophila genome indicated that loops were approximately 80kb in size, and 
comprised of 400 nucleosomes on average167. It was once considered that 
chromosome looping could only occur in cis, within a chromosome. However, 
studies have demonstrated regulation of a gene could occur from regulatory 
elements located several megabases (mb) away168. These larger distance, 
interchromosomal interactions are known as trans.  
 
Investigations into the β-globin cluster were the first to provide insight into 
distal regulation of the genome. The interest in the β-globin loci, mainly due to 
its involvement in the blood disorder Thalassemia, provided the opportunity to 
discover the role of chromatin looping in human gene regulation169. Deletions in 
the DNA far away from the location of the β-globin gene still resulted in the 
development of Thalasemmia alluding to the role of distal regulation170. It was 
through this finding that the locus control region (LCR) was found. This is a 
group on β -globin gene arranged in a way on the chromosome that facilities 
development in a timely manner. A study by Cater et al was the first to show 
evidence of chromatin looping in LCR-β-globin gene contact171.  
 
One of the first demonstrations of interchromosomal interactions was in the 
alternative expression of cytokine genes. The study by Charalampos et al 
revealed that dynamic chromatin organisation allowed the promotor of the IFNy, 
located on chromosome 10 to interact with regulatory elements of IL-4, located 
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on chromosome 11. This interaction has implications for the polarisation of CD4+ 
T cells to Th1 or Th2172,173. 
 
Following on from these studies, proteins which are involved in the formation of 
chromatin loops were discovered. These are called boundary elements, or 
insulator proteins174. CCCTC-binding factor (CTCF) is one of the best documented 
insulator proteins175. It has been found to be a highly conserved nucleic acid 
binding protein, with approximately 40,000 binding sites throughout the human 
genome176. CTCF has been found to separate TAD boundaries177. The 11 zinc 
fingers of CTCF means it can interact with DNA in various ways. Studies have 
explored this binding and identified two motifs, M1 and M2. The M1 motif 
engages 4-7 zinc fingers, and M2 is found upstream with 9-11 zinc fingers. Where 
both these motifs can be found, it has been shown that CTCF is bound to DNA 
with very high affinity178. Along with insulator function, CTCF can facilitate 
chromatin looping. Tens of thousands of the CTCF sites throughout the genome 
have been found to be co-occupied by a protein complex called cohesin179. 
Cohesin is a ring-shaped complex made from multiple proteins that plays a role 
in DNA replication. The cohesin ring ensures chromosome segregation during 
mitosis and meiosis, protecting the genetic information that gets passed on180. It 
was also discovered that cohesin can bind to CTCF and facilitate chromatin 
looping181.  
 
In most cases, chromatin loops are believed to support gene transcription by 
priming genes to contact their promotors, however loops have also been known to 
play an inhibitory role165. Loops can also serve a purpose of bringing a promotor 
into proximity with its terminator. This has been demonstrated in a study with the 
breast cancer associated, BRCA1 gene and the maternal Igf2 gene. This should a 
chromatin loop can ensure the gene promotor is kept separate from its 
enhancer182,183. Regulated DNA architecture has also been shown to have a role in 
DNA repair184. Research has suggested that these chromatin loops, or when taken 
together known as chromatin conformation signatures (CCS), are more informative 
and stable epigenetic marks than other alterations to the genome148.  
 
There is evidence in the literature that demonstrates chromosome loops can both 
be stable and dynamic structures. Challenges in understanding these two positions 
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lies with the technologies currently available. While high-resolution ‘C’ 
technologies have their advantages, they can only provide a snapshot of the 
epigenome132. Studies with CTCF demonstrated that while CTCF and cohesin 
facilitate stable chromatin loop structures, they are dynamic and the 
conformation can be lost when CTCF and cohesin disassociate185. Studies of the 
human pituitary growth hormone have demonstrated patterns of stable of human 
gene expression, as facilitated by DNA architecture186. The reproducibility of TAD 
maps in studies has also strengthened the hypothesis that chromatin loops are 
stable. However, live cell imaging has illustrated the dynamic nature of loops. 
Overall, evidence suggests most chromatin is stable for a short period of time, 
before transforming. Many questions remain to be answered, particularly 
chromatin dynamics in the context of disease.  
 
1.4 Precision Medicine  
 
Precision medicine is a concept of basing clinical decision on measurable 
molecular biomarkers. It could be argued that medicine has always aimed to be 
‘precise’, and this has been successfully demonstrated in blood transfusion and 
organ transplantation for decades. However, it has only been in recent years 
that the genome has been investigated for clues to prognosis of disease or 
treatment response. Treatment of the individual is the ultimate aim for 
clinicians, yet due to the nature of current clinical trials that are catered to a 
population, this can prove difficult187. The completion of The Human Genome 
project in 2003 significantly contributed to the explosion of genomic exploration 
188. The percentage of the genome that contributes to drug response is thought 
to range between 20% and 95%150. Studies involving this type of genetic 
exploration combine three important areas: the right population, the suitable 
technology, and finally, the collection of data150. Biomarkers that are identified 
can be incorporated into algorithms to predict prognosis or response to 
treatment for patients. Studies have shown that it is becoming increasingly 
straightforward to interrogate the genome but the translation of important 
findings into the clinic has proven challenging. This type of research has led to 
the current era of ‘big data’ with large datasets, which incorporate genomic 
information and patient characteristics. Some have described this time as a 
“biomarker revolution” and this has resulted in approved biomarkers in some 
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cancers. Despite this, it is thought that much of the germ line genetic variation 
available currently is not suitable for the implementation of precision medicine 
clinically. GWAS and identification of single nucleotide polymorphisms (SNPs) 
were one of the first types of study in precision medicine. These look to identify 
variant alleles which are associated with disease189. 
 
With the advancement of many genomic technologies, determining biomarkers is 
becoming easier than before. For a biomarker to be successful there is a certain 
number of criteria that must be met and studies must successfully illustrate this. 
For a biomarker to be clinically useful it must be consistently accurate, easily 
quantifiable, easily replicated and economically viable. Importantly, the 
biomarker to diagnose disease or predict treatment response must be superior to 
any existing methods190. Biomarker kinetics is an area of the precision medicine 
field that has not been investigated by many up until now. It is important to 
understand that biomarkers are dynamic and can change over time. 
Furthermore, enough statistical power is fundamental in biomarker studies. This 
means that specificity and sensitivity must be high enough i.e. as little as 
possible false negatives or false positives results, respectively190.  
 
1.4.1 Precision Medicine Technologies  
 
1.4.1.1 Microarray   
 
Microarrays have existed since 1995 when they were first documented by Schena 
et al191. Many technologies have been developed since, yet microarrays are still 
used today, and some consider them to be one of the fastest growing genomic 
technology192.The DNA microarray provided a more straight-forward and high-
throughput way to investigate the genome than normal sequence analysis, and 
could be termed sequencing by hybridisation193. Microarrays can be used to 
explore differences in gene expression, aiding biomarker research. The three 
main types of array are DNA, RNA and protein. The basis of the array is 
complementary hybridisation of DNA from a sample, to short complimentary 
probes printed in large numbers on a chip. The first microarrays conducted by 
Schena and others used complimentary DNA on a glass slide, however, now 
shorter oligonucleotides can be used which have a higher specificity194. This 
reaction creates images which can be analysed. There is both an in-silico, and 
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‘wet lab’ approach involved in microarray experiments. The in-silico part is 
involved in the array design, with the ‘wet lab’ part applying the desired 
samples to the microarray. One of the two main approaches of making DNA 
arrays are light-directed chemical synthesis and microarray spotting195. The 
light-directed chemical synthesis was first documented by the founder of 
Affymetrix in 1991 for a peptide array. This led to the generation of the first 
oligonucleotide array prepared in this way193. The first array was 1.25cm2 in size 
and was printed with 256 oligonucleotides. Microarray technology is still being 
developed and it expected that the platforms for microarrays will be reduced in 
size, creating ‘nanoarrays’196.   
 
1.4.1.2 3C technologies  
 
In the last decade, analysis of the complex chromosome architecture and the 
influence it has on gene expression has increased our understanding of the 
epigenetic influence in drug response. Epigenetic research has benefited from 
the progress of genomic technologies, and genomic architecture can now be 
visualised in enhanced detail. Originally, loops had to be visualised through 
laborious, lower–throughput, methods such as electron or light microscopy. 
Fluorescence in situ hybridisation (FISH) offers an opportunity to view multiple 
loops at one time, however, the protocol for staining may impact the chromatin 
conformation197. One method of this enhanced visualisation, named chromosome 
conformation capture (3C), first described in 2002, has allowed loops in DNA to 
be investigated197 (Figure 1.4). 3C is based on formaldehyde cross-linking of 
proteins and DNA. Cross-linking will be achieved for areas of the genome that 
are physically touching. 3C measures the frequency with which areas of the 
genome are cross-linked. A restriction enzyme is then applied to the cross-linked 
DNA, followed by ligation. The cross-linked DNA will be more likely to ligate over 
non-cross-linked, i.e. physically touching DNA will be ligated. These ligated 
fragments are subjected to a PCR reaction and gel electrophoresis allows 
visualisation of ligated fragments, which were once loops in the genome. 3C can 
be used to understand spatial organisation within the genome, as well as 
interactions between regulatory elements198. Since the first ‘C’ technology was 
published in 2002, there has been a rapid expansion of ‘C’ technologies. Often 
3C is referred to as a one-to-one technology, and other C technologies have 
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allowed one-to-all (4C) and all-to-all (Hi-C)199 visualisation. 3C was firstly carried 
out in yeast, followed by the mouse human β-globin loci200. RA 3C has also been 
used to demonstrate how chromatin looping regulates expression of Th2 
cytokines IL-4 and IL-13 in T cells201. While many other ‘C’ technologies have 
overlapped the original 3C, it still has place in biomarker discovery and precision 
medicine implementation. The protocol for 3C is less complex and laborious, and 
therefore economical. 
 
Figure 1.4 Schematic of Chromosome Conformation Capture (3C) protocol 
Schematic representing the stages involved in the generation and visualisation of 3C 
DNA libraries. A) Formaldehyde is used to cross-link physically touching DNA. B) A 
restriction enzyme is used. C) a ligation enzyme is used to ligate the 2 DNA pieces 
together. D) a non-genomic, 3C template, representing a chromatin loop, is generated 
from the 2 physically touching DNA regions. E) Primers designed for both parts of the 
loop are used to amplify the template. F) PCR products are visualised on a gel, a band 
at the expected size represents the existence of the loop  




1.4.2 Liquid Biopsy  
 
The ‘liquid biopsy’ is a concept most commonly known in the detection of cancer 
biomarkers, however is becoming more popular in other diseases such as 
Alzheimer’s and autoimmune conditions202,203. Liquid biopsies use the blood as 
the source of genetic information. The blood holds a vast range of biomarker 
candidates including DNA, RNA, miRNA and circulating tumour DNA204. Blood 
samples as biomarkers provide advantages over tissue biopsies. These include a 
normally less invasive procedure and therefore more comfortable experience for 
the patient, and often less reliable on complex tissue imaging equipment203. 
Moreover, a blood sample offers the opportunity for additional testing which 
may lead to a more confident molecular analysis, and blood processing protocols 
are widely used across the globe in the clinical and industrial setting202. It has 
been suggested that liquid biopsies will provide a health economic benefit, for 
the ability to better provide earlier diagnoses and detect poor response to 
treatment205. In RA, it could be considered that the equivalent to a tumour 
biopsy is the synovial biopsy. This involves removal of a small part of the 
synovial lining in the joint. As with tumour biopsies, this is an invasive procedure 
and can cause discomfort, in an already inflamed joint. However, synovial 
biopsies have been used in precision medicine studies in RA. These have profiled 
lymphocytes, macrophages, FLS and cytokines from the synovium206. While these 
have yielded results, some researchers have transitioned to looking at liquid 
biopsy from the blood in the hope of identifying better predictive biomarkers. 
Circulating immune cells in RA can be considered as a liquid biopsy, and they 
have the potential to reveal much about the disease state. From an RA liquid 
biopsy, various methods have been applied such as gene expression profiling and 
immunophenotyping. Some promising results have been achieved from this work, 
such as the discovery that a group of interferon response genes could predict 
non-response to RTX207 and the correlation of decreased circulating CD28+ T cells 
with abatacept response208. Nevertheless, there is still no clinically validated 





1.4.3 Precision medicine in Rheumatoid Arthritis  
 
It has been recognised that there are a significant lack of biological markers for 
RA75. Physicians are becoming increasingly aware that the genome or 
alternatively the epigenome could be consulted to improve the treatment 
regimen and long-term outcome for patients80. It is hoped that by increasing the 
understanding of the underlying molecular mechanisms of disease that 
biomarkers could be identified with the potential of predicting prognosis of 
disease or more excitingly the response to therapy. Ultimately, epigenetics 
alone is not responsible for the development of RA, it is a multifactorial disease 
influenced by the environment, risk genes and aging. RA is an extremely 
complex autoimmune disease and patients are subject to a unique combination 
of contributory factors which can alter their response to treatment, thus 
exemplifying the need for precision medicine. Despite the barriers and 
reservations to this, the transformational impact of precision medicine in 
oncology practices should hopefully pave the way for other disease areas which 
have the potential to see the benefit in the future. GWAS studies have 
successfully identified over 100 genetic loci that can be associated with RA. 
However, these loci do not always help to gain a better understanding of 
underlying disease mechanisms and therefore novel therapies are rarely 
produced. Moreover, cell types where changes in genetic loci exist cannot be 
identified through GWAS209. Although considerable GWAS have taken place in RA, 
there remains a large proportion of the heritable component of RA to be 
explained. The biggest challenge in genomic research in RA is linking different 
components together, i.e. matching the genomic data together in addition to 
potential proteomic and metabolomics data. Unique methods will need to be 
found to address this challenge. For precision medicine to be a success, 
researchers, healthcare professionals and industry representatives will have to 
collaborate successfully. The most plausible predictor of precision medicine 
clinically will not only include genetic information but will include other clinical 
markers and take into consideration epidemiological data. 
 
Precision medicine approaches have been explored to predict prognosis, disease 
severity and treatment response. A recent study used ‘-omic’ approaches to 
investigate a potential biomarker for pannus formation. They revealed 
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epigenetic alternations correlate with the aggressive RA phenotype, however 
exact mechanisms need to be clarified210. Predictive models using clinical and 
demographic characteristics have been investigated. Hyrich et al found males on 
concomitant MTX responded better to anti-TNFα therapy, etanercept and 
infliximab. Current smokers with high Health Assessment Questionnaire (HAQ) 
scores were predicted to be non-responders to anti-TNF therapies22. However, 
these characteristics alone would not be able to predict response with enough 
certainty. One study investigated the RA synovium for levels of TNFα transcripts. 
They found that high levels of TNFα transcripts correlated with high disease 
activity, and a worse response to first-line therapy211. This study alludes to the 
benefit of including synovial markers in the stratification of treatment in RA, 
however is dependent on standardisation of synovial biopsies. A more recent 
study by Humby et al. investigated cellular and molecular biomarkers from the 
synovium. They showed that in treatment of naïve patients, 3 synovial signatures 
existed in RA patients. These three subtypes were classed as lympho-myeloid, 
diffuse-myeloid and pauci-immune (few immune cells with dominant stromal 
cells)212. The discovery of these biomarkers was aided by immunohistochemistry 
methods, which is not the most high-throughput precision medicine tool.  
 
Several studies have been conducted to find a biomarker for csDMARDs. One 
study analysed naïve T cell subsets in PBMCs from people with early RA. They 
found patients with a higher naive T cell frequency responded better to MTX 
than those with lower T cell frequencies. However, this study was limited by 
patient numbers213. A recent study combined demographic, clinical and 
psychological variables in an attempt to predict MTX non-response in the 
Rheumatoid Arthritis Medication Study (RAMS)99. This study aimed to capture the 
‘real-world’ RA population. Limitations of this study include the high-level of 
non-response, which may be due to deviations from the normal RA treatment 
regimen of MTX escalation. The classification models did not achieve suitable 
sensitivity and specificity values99.  Overall, the epigenetic research landscape in 
RA looks very promising. Costs of this research are decreasing dramatically, 
alongside increased throughput and resolution of genomic technologies214. It is 
quite likely the RA treatment regime will include DNA analysis in the future. This 
addition should ensure a much more positive outlook for RA patients worldwide.  
 
	 50	
1.4.4 EpiSwitch™  
 
EpiSwitch™ is proprietary technology, developed by Oxford BioDynamics Plc 
(OBD) to facilitate the discovery of the blood based biomarker, specifically 
chromosome conformation. This platform has been used successfully to identify 
biomarkers in several cancers including thyroid cancer and melanoma, as well as 
neurodegenerative disorders such as Amyotrophic lateral Sclerosis (ALS) and 
Huntingtons disease215 216-218. This proprietary technology uses algorithms to 
predict sites in the genome where chromosomal loops are likely to occur. This 
differs to other CCS discovery, and by eliminating the need for a genome wide 
screen, allows more specific biological questions to be asked. The optimised 
discovery pipeline begins with the algorithmic approach for EpiSwitchTM sites, 
then identification of areas of the genome possibly implicated in the disease in 
question. A microarray platform is then utilised to observe chromosome 
conformation in samples of interest. This is followed by statistical analysis to 
inform about the most appropriate biomarker to take forward. Once these 
candidates are chosen, PCR primers are designed and PCR performed. Next, 
extensive statistical analysis is undertaken to find a CCS with the best potential 
for clinically relevant stratification. Finally, this can then be validated in an 
independent cohort. Importantly, this pipeline was successfully used to identify 
a 5-loop CCS with the ability to predict response or non-response to MTX in a 
treatment naïve RA cohort219 (Figure 1.5). This technology aims to generate 
informative CCS biomarkers from discovery to clinical validation and ultimately 
clinical implementation. These biomarkers can be prognostic, diagnostic or 
predictive. If biomarkers can be used to stratify patients before entering into 




1.4.5 EpiSwitch™ in Rheumatoid Arthritis 
 
The MTX response CCS is made up of 5 loci (IL17A, CXCL13, IL21R, IL23 and 
IFNAR1)(Figure 1.5), known to be involved in RA pathogenesis219. These signature 
loci are primarily involved in cytokine and chemokine pathways. This biomarker 
could predict MTX non-response with 90% sensitivity. The discovery cohort was 
made up of 59 patients (30 responders and 29 non-responders), and the blinded-
validation cohort, 19 patients. All patients were from the Scottish Early 
Rheumatoid Arthritis (SERA) cohort. This is a pan-Scotland, inception cohort of 
over 1,200 patients. Various clinical samples and information were taken and 
recorded from baseline, every 6 months. This biomarker was refined from a list 
of over 13,000 loop anchor sites across 309 genetic loci, many of which are 
known to be associated with RA. Statistical refinement reduced 100 to 30 loci. 
These were then reduced to the final 5. This study was the proof-of-principle 
that the structural epigenome could be used to predict MTX response in 
treatment naïve patients. This study opens the opportunity for investigating the 
relationship between chromatin conformation structure and function in RA, and 
a basis for validating this biomarker in other cohorts. While the biomarker 
discovery approach is considered robust, the sample number used in discovery 
and validation cohort could be considered small. Therefore, there is merit for 
exploring the signature in a higher number of patient samples. Moreover, the 
consequence or cause of these loops in RA patients is not known. Various 
methods could be used to shed light on this, which could reveal more about 





Figure 1.5 CCS for MTX response prediction 
This 5-loci CCS has the capacity to differentiate responders and non-responders to MTX 
in treatment-naïve patients with RA with 90% sensitivity. Schematic of CCS is 
representing the signature in both response groups. Numbers represent EpiSwitchTM sites 
on the genome. A) CXCL13 loop is present in non-responders, Chr 4. B) IL17A loop is 
present in non-responders, Chr 6.C) IFNAR1 loop is present in responders, Chr 21. D) 
IL21R loop is present in responders, Chr 16. E) IL23 loop is present in responders, Chr 




IL17A is part of the IL17 family, that has 5 other members (IL17B-F). IL17A 
signals through the IL17 receptor on Th17 cells. The receptor exists as a 
heterodimer with IL17C220.This heterodimer has been found on fibroblasts, 
endothelial and epithelial cells221. A number of cells from the adaptive immune 
compartment can produce IL17A, namely CD3+, CD4+ and CD8+ T cells, NK cells, 
and Th17 cells222. IL17A production has several pathogenic implications in RA, 
including maturation of osteoclasts and fibroblast-like synoviocytes, as well as 
activation of macrophages, neutrophils and B cells223. Studies have suggested 
that presence of IL17A in RA synovium is a predictor of disease progression224. 
While IL17A blockade has been shown to be very effective in the treatment of 
autoimmune conditions such as psoriatic arthritis and psoriasis, blockade in RA 
has been less successful. Trials of secukinumab, an IL17A monoclonal antibody, 
did not have as profound therapeutic effects that other cytokine blockade 
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therapies have had, such as IL-6 and TNFα223. One study demonstrated that 
secukinumab was better than placebo in RA, but not superior to anti-TNFα 





CXCL13 is a chemokine that belongs to the CXC family. This chemokine is 
chemotactic for B cells and interacts with the receptor CXCR5 on B cells to have 
its effect226. The role of this chemokine in B cell chemotaxis places it in position 
of RA pathogenesis. The levels of CXCL13 in RA serum has been shown to high in 
both early and established RA227. Jones et al believe CXCL13 to be correlated 
with RF in RA patients but show no correlation to other demographic or 
serological markers such as ACPA. One study has demonstrated that CXCL13 
works synergistically with CCL20 to recruit B cells to the synovium228. Lymphoid 
neogenesis is another process which implicates CXCL13 in RA pathogenesis229. 
Several studies have been conducted which demonstrate CXCL13 role in this 
process. CXCL13 can also be produced by CD4+ T cells, another cell type 
important in RA pathogenesis230. This study aimed to understand the mechanism 
by which CXCL13 is produced by CD4+ T cells. They found SOX4 was a 
fundamental transcription factor for this process and has associated this with the 
formation of FLS at inflammatory sites in human, such as synovium in people 
with RA. Similarly, Kobayashi et al demonstrated that CD4+ T cells can produce 
CXCL13 and are involved in ectopic lymphoid neogenesis at inflammatory 
sites231. The CXCL13 receptor CXCR5, is also expressed on Tfh cells and it has 
been suggested that this essential for the development of RA. Interestingly, 
CXCR5 deficient mice are unable to develop Collagen induced arthritis (CIA)232. 
This study has shown the potential for targeting of the CXCR5 receptor for 
treatment in RA. As the only known ligand for the receptor is CXCL13, an 
antagonist for the receptor would have little pharmacological competition232,233.  
 
CXCL13 has shown promise of its predictive potential in several studies to date. 
Mainly, it has been identified as marker for predicting disease activity or 
potential outcome234,28. Largely, this may be due to the high levels of CXCL13 in 
synovial tissue and fluid in individuals with RA232. Additionally, several studies 
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have attributed CXCL13 to predictive capacity to TNFα inhibitors in the 




IL21R belongs to the IL-2 cytokine family. The receptor is a heterodimer, 
consisting of an alpha and gamma chain which is shared by other cytokines 
including IL-2, IL-4 and IL-9236. The IL21R is structurally similar to IL-2R and IL-
15R (Li et al., 2006). The IL-21 receptor can be found on multiple immune cells 
including DCs, NK cells, T cells and B cells237. IL-21 is mainly produced by CD4+ T 
cells and NK cells and is proinflammatory in nature238. IL-21 signals through the 
IL21R, inducing the STAT pathway239. Activation of this pathway results in 
expansion of B cells and downstream production of antibodies, class switching 
and plasma cell differentiation240,239. IL21R expression has been found to be 
higher in RA and systemic sclerosis compared to controls241. More recently, IL21R 
has been enhanced in other inflammatory conditions such as tendinopathy238. 
IL21R has also been found to be upregulated in synovial tissues of people with RA 
but not osteoarthritis (OA)241. There have been studies investigating the efficacy 
of IL21R blockade in the treatment of RA and other autoimmune diseases. 
Animal models have demonstrated that blockade of the IL-21/IL21R pathway was 
effective in reducing RA disease activity as well as having an inhibitory effect on 
cytokine production in vitro242. Mouse models lacking IL21R were found to be 
unable to develop spontaneous autoimmune disease. Humoral immunity was also 
comprised in these mice, highlighting the role of IL-21 in antibody production243. 
A recent study demonstrated an increase of IL21R on naive and memory B cells 
in RA in comparison to healthy controls. This was associated with an increase in 




IL23 exists on the Th17 axis along with IL-21 and IL17A. IL23 is a member of the 
IL-12 family of cytokines245. The structure of the cytokine consists of 2 subunits: 
IL23 p19, which is exclusive and the IL-12p40 subunit which is shared with 
IL12246. Antigen presenting cells, monocytes, macrophages and DCs are the cell 
types that produce IL23 the most. When IL23 binds to its receptor, IL23R, it 
activates the JAK-STAT pathway, specifically JAK2 and subsequent STAT3 and 
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STAT4245. The receptor is made up of IL23 -R and IL-12R-αβ1 complex246. This 
leads to the release of pro-inflammatory cytokines, IL17A and RORγt247. It is 
thought the role for IL23 is maintenance, development and survival of Th17 cells 
via a positive feedback loop that involves TNFα, IL-6 and IL-1β247. Studies 
involving the EAE model were crucial in revealing that the IL12-IFNy axis was not 
responsible for initiation of autoimmunity, but was in fact the IL17-23 axis248,249. 
This cytokine can be found in the synovial fluid and serum of those with RA, and 
studies have found it to be significantly higher than healthy individuals250. The 
levels of IL23 in the serum have been shown to correlate with severity of disease 
activity246. The implication of IL23 in inflammatory arthritis has been evidenced 
in the CIA model of arthritis. Overexpression leads to development of CIA while 
reduction is protective of CIA. This study showed that while IL23 plays a role in 
the development of disease, once established, IL23 has less of a role. This was 
shown by inhibition during disease not reducing disease severity251. IL23 has also 
been shown to have a role in the production of autoantibodies, hence its role in 
the early stages of disease251. In addition to its role in disease onset, it has been 
suggested that IL23 could play a role in disease flare. This is due to successful 
reduction of disease severity with blockade of IL23 251. Studies have also shown 
IL23 to have osteoclastogenic activity, contributing to the bone erosion in RA. 
While it’s role in RA pathogenesis has been demonstrated, pharmacological 
targeting of IL23 has been unsuccessful in showing any benefit clinically. Two 
antibodies have been tested in a stage II clinical trial. One was a monoclonal 
antibody targeting the IL23 12/23 p40 complex, and the other targeting the p19 




The IFNAR receptor is the receptor for the antiviral cytokines, named 
interferons. IFNAR1 and IFNAR2 make up the single-membrane spanning IFNAR 
receptor which is ubiquitously expressed253. The IFN receptors act by increasing 
binding of ligands. Once the receptor is activated, intracellular signalling 
cascades are activated which results in the activation of the STAT pathway254. 
There are three types of interferons in humans, classed as type I, type II and 
type III. They all signal through the IFNAR receptor, with differing binding 
affinities255. Type I interferons are heavily involved in the regulation of both the 
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innate and adaptive immune response. Namely, macrophages, NK cells, B cells, 
T cells and DCs are aided in their differentiation and proliferation by type I 
interferons256. IFNAR1 has been investigated in various autoimmune conditions. 
One study found some patients with RA have a higher proportion of interferon 
response genes compared to other patients257. Several studies have indicated the 
presence of a type 1 interferon signature in RA. One study has shown that one 
subgroup in RA, with upregulated activity in the innate immune system, 
complement cascades and fatty acid metabolism258. Another study reported 
IFNAR1 blockade has been utilised in lyme arthritis259. The involvement of IFN 
signalling in the development of lyme arthritis was also studied using IFNAR1 -/- 
mice. Severity of arthritis was reduced in the KO. Many cell types have been 
found to contribute to the IFN response, including primarily myeloid cells, 
resident in joint tissues, in addition to fibroblasts and endothelial cells259.  
 
1.5 Aims  
 
Despite efforts, there is no molecular biomarker currently used at diagnosis to 
stratify RA patients and ensure they are on the right treatment from the outset. 
The development of technologies able to interrogate the genome, as well as the 
growth in biobanks, has made the study of molecular biomarkers for RA more 
accessible.  
While the discovery of a biomarker for MTX response in the treatment of RA is an 
important and interesting finding, biomarkers require further validation until 
they can be considered for adoption into a clinical setting. Additionally, research 
has demonstrated that chromatin conformation reveals insight into gene 
regulation, therefore there is scope that this MTX CCS could increase 
understanding about the underlying mechanisms that dictate ability to respond, 
or not respond to MTX treatment. Moreover, with the EpiSwitchTM pipeline 
incorporating additional, more informative methods of biomarker discovery, 
there is the potential of discovering additional CCS with the capacity to further 
stratify the RA population.  
This body of work aimed to:  
1) Validate the MTX CCS bioinformatically and in an independent clinical cohort, 
as well as establish the efficacy to predict response to other csDMARDs.  
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2) Understand the relationship between CCS and disease pathogenesis. 
3) Determine if underlying epigenetic endotypes exist in the early RA population 




Chapter 2 Materials and Methods  
 
2.1 Patient Cohorts  
 
2.1.1 Patient Identification - SERA 
 
The Scottish Rheumatoid Arthritis (SERA) cohort is a pan-Scotland inception, 
longitudinal cohort of patients with early rheumatoid arthritis (RA). Samples 
were obtained at 6-month intervals, from baseline of treatment. All patients 
were conventional synthetic disease modifying anti-rheumatic drug (csDMARD) 
naïve at baseline. Healthy samples came from demographically matched friends 
or family of enrolled patients. Patients of interest in this study were identified 
by their response to DMARD therapy. This was done by calculating disease 
activity using clinical disease activity index (CDAI) and disease activity score 28 
(DAS28) measurements at baseline, 6 months and 12 months. These calculations 
take into consideration swollen (SJC28) and tender joint (TJC28) counts from 28 
joints (Figure 2.1). Patient assessment of disease activity (dasVAS) and physician 
(GlobalVAS) assessment of global health from a visual analogue scale (VAS) of 0-
10cm is also included. The closer to 10cm on the scale, the worse the disease 
activity. Some DAS scores take the inflammatory markers, erythrocyte 
sedimentation rate (ESR) and c-reactive (CRP) protein into account.  
 
 
Figure 2.1 Joints included in swollen and tender joint counts 
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Disease activity calculations used were: 
• Clinical disease activity index (CDAI) – (DasVAS/10) + (GlobalVAS/10) + SJC28 + 
TJC28 
• Disease activity score 28 with c-reactive protein (DAS28 CRP) - 0.56*SQRT(TJC28) 
+ 0.28*SQRT(SJC28) + 0.36*ln(CRP+1) + 0.014*GH + 0.96 
• Disease activity score 28 with erythrocyte sedimentation rate (DAS28 ESR) 0.56* 
square root (SQRT)(TJC28) + 0.28* SQRT(SJC28) +0.7*LN(ESR) *1.08+0.16 
 
For the work in this thesis, a combination of patients were chosen: some had 
reduced disease activity, from high disease activity (HDA) at baseline, to low 
disease activity (LDA) or remission after 6 months of therapy, and others had 
minimal, or no reduction in disease activity, representing responders and non-
responders respectively. All patients chosen were identified as having HDA at 
baseline (Table 2.1). 
  
Table 2.1 Categories of Disease Activity Score  
CDAI, clinical disease activity index; DAS, disease activity score 
 
 
2.1.2 Patient Identification – TACERA  
 
The Towards A Cure for Early Rheumatoid Arthritis (TACERA) cohort is an early 
RA cohort that is part of the larger RA-MAP consortium. Like SERA, TACERA is an 
early RA, longitudinal cohort and patients were DMARD naive at enrollment. The 
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online knowledge management platform, TranSMART, was used to identify 
patients that were given monotherapy methotrexate (MTX) at baseline. Samples 
from this cohort were used for the blinded validation of the MTX signature, 
originally generated in the SERA cohort, and therefore the only data required at 
the selection stage was treatment at baseline.  
 
2.1.3 Sample Type - SERA 
 
From the patients identified as per section 2.1.1 in the SERA cohort, frozen 
buffy coat (BC) samples from baseline, 6-month and 12-month time points were 
identified and selected. Clinical information was obtained alongside the clinical 
samples. Of note, this includes age, BMI, smoking status and disease activity 
measurements.  
 
2.1.4 Sample Type - TACERA 
 
From the patients identified as per section 2.1.2 in the TACERA cohort, 
peripheral blood mononuclear cells (PBMCs) from csDMARD naïve patients at 
baseline were identified and selected. Disease activity data were also available, 
but this was not retrieved until the blinded analysis was complete (See 2.2.1).  
 
2.1.5 Sample retrieval - SERA 
 
Samples were collected on dry ice from the SERA storage facility at Yorkhill 
Biorepository. On return to the Glasgow Biomedical Research Centre (GBRC) 
samples were logged in using unique barcodes on each sample tube. Samples 
were subsequently thawed and then aliquoted into 110µl aliquots and stored at -
80°C until required.  
 
2.1.6 Sample retrieval – TACERA 
 
TACERA samples were retrieved from the UK Biocentre on dry ice before 
shipment to Oxford Biodynamics Plc (OBD) where they were subsequently stored 





2.1.7 Sample storage  
 
The laboratory information management system (LIMS) was used to identify 
samples for retrieval from the SERA biobank. Sample barcodes were scanned and 
recorded on an excel spreadsheet which documented sample location in -80°C 
freezer. This information was stored in a password protected folder.   
 
2.1.8 Ethical Approval - SERA  
 
Samples were obtained with written consent and under appropriate ethical 
approval. Ethical approval for the SERA study was obtained on 28/05/2010, 
under REC approval number 10/S0704/20. A sample access application was 
submitted to the SERA Access Committee to achieve approval to access the 
requested samples and associated clinical information on several occasions 
throughout this study. These applications were approved on 23/08/2017, 
07/08/2018, 18/02/2019.  
 
2.1.9 Ethical Approval - TACERA  
 
Samples were obtained with written consent and under appropriate ethical 
approval. Ethical approval for the TACERA samples was obtained on 02/05/12 
under REC approval no 12/LO/0469.  
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2.2 Chromosome Conformation Capture 
 
Prior to using Chromosome Conformation Capture (3C) on valuable patient 
samples, the protocol had to be optimised in my own hands using healthy samples. 
Once optimised, the steps described (2.2.3 - 2.2.7) were performed using RA 
patient samples. This section describes the original 3C protocol and the methods 
used to determine if quantitative PCR could be used to capture the MTX 
chromosome conformation signature (CCS) loci.  
 
2.2.1 PBMC Isolation  
 
Healthy buffy coat donors were provided from the Scottish National Blood 
Transfusion service (SNBTS). PBMCs were isolated by density gradient 
centrifugation with Ficoll (GE Healthcare). PBMCs were re-suspended in PBS 
(Sigma) or cell separation buffer (PBS 1% Fetal Bovine Serum(FBS), 2mM EDTA). 
Cells were frozen at 2x107 in freeze buffer (10% Dimethyl Sulphoxide (DMSO), 
90% fetal calf serum (FCS)) and stored at -80°C for short term storage or in liquid 
nitrogen for samples getting stored for longer periods.  
2.2.2 CD4+ T cell Isolation 
 
PBMCs isolated as described in section 2.2.1, were re-suspended in cell 
separation buffer and CD4+ T cells were separated by positive selection using 
magnetic bead separation as described by manufacturer (T cells - Miltenyi 
Biotec). Briefly, PBMCs were mixed by pipetting with 20µl CD4+ magnetic 
microbeads in 80µl of cell separation buffer per 10
7 cells for 15 minutes at 4°C. 
To wash off excess labelling, 10ml of cell separation buffer was added and tube 
centrifuged at 300g for 10 minutes at room temperature (RT). Supernatant was 
removed and cells resuspended in 500µl cell separation buffer. Cells were then 
appropriately labelled and could be passed through a magnetic separation 
column. A column was placed on the appropriate MidiMACSTM Separator and 
rinsed with cell separation buffer. The labelled cells were applied to the 
column, and the column rinsed three times with 3ml of cell separation buffer. 
The column was removed from the magnet and 5ml of cell separation buffer 
added. Using a plunger, cells were forced through the column. This, the positive 
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fraction containing CD4+ T cells, was then available for use in future 
experiments. 
 
2.2.3 Flow Cytometry Purity Check 
 
For surface staining, 1 x 106
 
cells were resuspended in flow cytometry buffer 
(PBS with 2% FBS and 5mM EDTA) into 6ml FACs tubes (BD Biosciences). Cells 
were centrifuged at 400g for 5 minutes before adding CD4-APC antibody 
(BioLegend). Tubes were incubated at room temperature for 20 minutes in the 
dark. Cells were fixed in diluted fix buffer (BD Biosciences) and kept at 4°C until 
they were run on the LSR II flow cytometer. Data was then analysed using FlowJo 
v10 software. 
 
2.2.4 DNA extraction  
 
PBMCs from healthy donors or patient BC samples were removed from -80°C prior 
to DNA extraction and thawed at 4°C. This was carried out as per OBD protocol 
using the EpiswitchTM proprietary reagents. A starting volume of 50µl (1 million 
cells) patient sample was used for each DNA extraction. Briefly, cells were fixed 
with EpiMix Buffer DE-A (Thermofisher Scientific) and quenched with EpiMix Buffer 
DE-B. This was followed by cell lysis with 10x EpiMix Buffer DE-C and the nuclei 
were purified by density cushion centrifugation. Taq1 (Thermofisher Scientific) 
and T4 DNA ligase (Takara) were used to restrict and ligate the DNA followed by 
the addition of proteinase K (Roche) to remove any proteins. Incubations with 
these reagents were carried out on the Veriti thermocycler, see Table 2.2 for 
thermocycler conditions. 
 
An updated extraction protocol (Protocol 2) was implemented after quantitative 
PCR was introduced. This was carried out as described above, with the addition 
of protease inhibitors (Sigma) prior to EpiMix Buffer DE-A treatment and during 
lysis. During the EpiMix Buffer DE-A step, a non-fixation (NF) control was 
generated with the addition of water instead of EpiMix Buffer DE-A. See Table 2.3 
for cycling conditions associated with the updated protocol. Once extraction was 
complete, the sample was pelleted using density centrifugation and the pellet 
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then purified using the QIAamp FFPE tissue kit (Qiagen) as per manufacturer’s 
instructions.  
 





Table 2.3 Thermocycler conditions for 3C – Protocol 2  
 
2.2.5 DNA Quantification – Picogreen  
 
After DNA extraction and the preparation of 3C libraries, the DNA had to be 
quantified. The first method of quantification used Picogreen. Here, 20x Tris-
EDTA (TE) buffer was diluted with 200x Quant-iT Picrogreen to make a 1 in 10 
working solution. Volumes of working solution were dependent on the number of 
DNA samples being analysed. A 1 in 2 serial dilution of 100µg/ml lambda DNA 
was created to act as a standard. All standards and samples were diluted 1:100. 
Next, 100µl of diluted samples were added to a 96-well ELISA plate in triplicate 
and the 100µl of 1x TE-Picogreen mix was added. The plate was incubated at RT 
for 5 minutes then read on a Tecan M200 Pro at 480nm.  
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2.2.6 DNA Quantification – Qubit  
 
The Qubit DNA quantification kit was used as an alternative method of 
quantification to Picogreen. The Qubit high sensitivity (HS) double-stranded 
(ds)DNA kit (Thermofisher Scientific) was used. A working solution was prepared 
by diluting Qubit dsDNA HS reagent 1:200 in Qubit dsDNA HS buffer. For samples, 
2µl was added to 198µl of working solution and for standards, 10µl was added to 
190 µl of working solution. Standards and samples were briefly vortexed and 
incubated at RT for 2 minutes before being read on the Qubit 3.0 Flourometer 
(Thermofisher Scientific). The Qubit dsDNA broad range (BR) kit (protocol as 
described for HS kit) was implemented if the DNA concentration was out with 
the range of the HS kit.  
 
 
2.2.7 Nested PCR 
 
After the DNA quantification, nested PCR was carried out using primers listed in 
Table 2.4. Primers for nested PCR were designed by OBD using Primer3 software. 
Primers were stored at -20°C until needed, at which point they were thawed at 
RT. Samples were normalised to a concentration of 1µg/µl in nuclease free water. 
A master mix of 16.5µl, nuclease free water (Thermo Fisher Scientific), 4µl of both 
outer primers and 12.5µl kappa blood mix was made. 37µl of master mix was added 
to 0.2ml tubes followed by 13µl of diluted template. A non-template control (NTC) 
was created by adding nuclease free water instead of DNA sample to the mix. 
Samples were added to the thermocycler for the 1st round. For the 2nd round, 
master mixes were prepared as before with 24.5µl nuclease free water and inner 
primers. 45µl of master mix was added to a new set of 0.2ml tubes and 5µl of 
template (from the 1st round) was added. The tubes were added to the 





















Table 2.5 Nested PCR Cycling Conditions 
 
 
2.2.8 qPCR product purification  
 
After DNA extraction of samples intended for qPCR using the method described in 
2.2.3 (Protocol 2), the Qiagen FFPE tissue kit was used for purification prior to 
qPCR. In brief, 1-8 pellets from each sample were suspended in ATL buffer and 
transferred to DNA LoBind tubes with the addition of 20µl Proteinase K. These 
were incubated on a heat block for 1 hour at 56°C followed by 1 hour at 90°C. 
Samples were cooled to RT after which 2µl RNase was added followed by RT 
incubation for 2 minutes. A master mix of 1:1 AL buffer and 200 proof ethanol was 
made. 400µl of the AL/ethanol mix was added to the samples which were then 
transferred to MiniElute columns. 500µl of AW1 buffer from the kit was added to 
the columns, followed by a 6000g spin in a centrifuge for 1 minute. After flow 
through was discarded, 500µl of buffer AW2 was added to the column and had a 
6000g spin in a centrifuge for 1 minute. For elution, 30µl 1x TE buffer was added 
to the columns, which were incubated for 5 minutes at RT. This was followed by 
a 20000g spin for 1 minute. DNA concentration could then be measured by the 
Qubit dsDNA HS kit, as described in section 2.2.5.   
 
Primers for qPCR were designed using the PrimerQuest tool within Integrated DNA 
Technologies (IDT). The default primer option for intercalating dyes was selected. 
This considers primer characteristics such as an optimum melting temperature of 
62°C, a GC content of 50%, primer size of 22 nucleotides (nts) and amplicon of 
100nts. Once designed, primer specificity was tested using NCBI Blast 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi). All qPCR primers were then tested 
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experimentally. A master mix was made from 5µl 2x kappa probe force, 0.25µl of 
each forward and reverse primer (stock 100µM; see Table 2.6), and 0.5µl of 20x 
PowerSYBR green (Invitrogen). Patient samples were pooled together once 
normalised to 10ng/µl. These samples, along with NF control (generated as 
described in 2.2.3), genomic control (PE Biosystems), a loading buffer control (TE) 
and non-template control (NTC) were prepared. The master mix was plated in a 
96-well plate and 4µl of template was added in duplicate to make a 10µl reaction. 
One CCS loci was tested per 96-well plate, primers shown in Table 2.6. Once 
prepared, the plates were sealed and centrifuged for 30 seconds. Plates were run 
on Applied Biosystems StepOne Plus or QuantStudio 7 Flex Real-Time System. The 
qPCR block set with 6 annealing temperatures of 68°C, 67.5°C, 66.4°C, 64.4°C, 
62°C, 60°C to determine the optimal annealing temperature for each primer. A 
melt curve was also generated per run to identify the presence of only a single 
product without evidence of primer dimerization. The cycling conditions are 









Table 0 qPCR cycling conditions 
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2.2.9 Gel electrophoresis 
 
The amplified nested PCR products were visualised using gel electrophoresis. A 
1.5% agarose gel was prepared with 1x tris-acetate-EDTA (TAE) buffer with 1x 
Ethidium Bromide (1µg/ml). A 1kb+ ladder (Thermofisher Scientific) was used 
and gels were run until this ladder had migrated adequately through the gel. The 
gels were imaged with UV light and the image was captured using the Gel Logic 
200 imaging system.  
 
2.2.10 Gel Purification  
 
The qPCR amplified products of interest were run on a 1% agarose gel, which was 
prepared with 1x Ethidum Bromide. The gels were imaged with UV light and once 
products of interest were confirmed, bands were excised for purification. The 
excised gel was then put into a labelled 1.5 ml microcentrifuge tube for weighing 
and images were captured using the Gel Logic 200 imaging system.	The excised 
product of interest was then processed for sequencing. In brief, solubilization and 
binding buffer (GQ) was added to each 100mg of gel. This was then incubated tor 
10 minutes at 15°C to dissolve the gel.  Following this, 100µl of isopropanol was 
added to the sample and mixed. To bind the DNA, the sample was applied the 
sample to a QIAquick column, and centrifuge at 18,000g for 1 minute. Run-through 
was discarded and the column was added to a clean tube with 15ul TE buffer to 
elute the DNA.  
 
After gel purification, samples had to be sent for sequencing. Gel purification as 
described above did not yield the required concentration of DNA for sequencing. 
To increase the yield, the optimisation steps included GQ incubation for 15 
minutes with shaking every 2 minutes, and incubation with elution buffer (10 mM 
Tris-Cl, pH 8.5) for 3 minutes. Additionally, DNA was eluted into heated buffer 
(37oC water bath). 
 
2.2.11 LabChip GX 
 
As an alternative to gel electrophoresis as described above (2.2.8, 2.2.9), the 
LabChiP GX microfluidic system was used to visualise PCR products in high 
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throughput at a later stage in the study. The 1K reagent kit was used as per 
manufacturer’s instructions. In brief, the LabChip was washed and reagents 
filled in the appropriate wells. Subsequently, a 96-well plate was prepared with 
samples in triplicate. The LabChip and the plate were loaded onto the LabChip 
GX Touch Nucleic Acid Analyzer, which was run for 3 hours, changing LabChip 
reagents after 1.5 hours. The samples were analysed using the LabChip GX 
software. Product band sizes were observed to confirm presence or absence of 
loop of interest.  
 
2.2.12 Tubeseq  
 
After qPCR products were purified, they had to be sent for sequencing to confirm 
that it was our product of interest. qPCR products were sent to Eurofins genomic 
sequencing to confirm the qPCR product of interest. The Tubeseq service was 
used. Samples were prepared at 1ng/µl for the 150-300bp products. The total 
volume of sample was 17µl, made up of 15µl of DNA sample at appropriate 
concentration, and 2µl primer at 10pmol/µl. Samples were prepared in 1.5ml 
tubes and labelled with unique Tubeseq barcodes for identification. Samples were 
transferred at RT to the Eurofins sequencing facility. Sequencing results were 
emailed several days after samples arrived at the facility.  It should be noted that 
the first sequencing run was unsuccessful, and optimisation steps were required, 
see section 2.2.12 and 2.2.13 below.  
 
2.2.13 Cloning  
 
The first set of qPCR samples that were sent for sequencing were not successfully 
sequenced as the sample was of poor quality.  As such, cloning of the qPCR product 
was introduced to increase quality. In brief, the chosen qPCR product was inserted 
into the TOPO 2.1 vector (Thermofisher) and incubated for 5 minutes at RT. This 
was then transformed into OneShot cells and plated on agar plates coated with 
kanamycin (50µg/µl). These were incubated overnight at 37°C. White clones were 
chosen and placed in liquid culture in a shaking incubator (200rpm) overnight. The 
plasmid was then isolated using the purelink miniprep kit as per manufacturer’s 
instructions. The plasmid was then analysed for inserts by restriction digest with 
EcoR1. Inserts were identified by running an ethidium bromide gel (see section 
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2.2.8) and looking for a product 300 bp in length. This is based on the plasmid size 
of 3.9kb, EcoR1 restriction size of ~3kb. 
 
2.2.14 PolyA tailing 
 
Cloning alone was unsuccessful in achieving product of interest during restriction 
digest, and optimisation of sequencing preparation was carried out. A polyA tail 
was added to the qPCR product with the aim of generating a more stable product 
for future steps in the cloning protocol. Briefly, a master mix was created by 
adding, 2µl of 5x GoTaq reaction buffer, 2µl of 1mM dATP, 1µl GoTaq flexi DNA 
polymerase and 0.6µl of 25mM MgCl2. 2µl of purified blunt-ended DNA fragment 
was added and nuclease free water was added to bring the final volume to 10µl. 
This was incubated at 70°C for 15-30 minutes in a water bath. PolyA tailing alone 
was unsuccessful, and success of generating a restriction product involved 







 2.3 Validation of MTX CCS in TACERA Cohort  
 
Data was analysed with Ewan Hunter and Christina Koutsothanasi, OBD. 3C 
libraries were created and nested PCR was carried out as described in 2.2.3 and 
2.2.6 on 70 PBMC samples chosen from the TACERA cohort (2.1.2). Briefly, two 
machine learning algorithms were employed to test the ability of the MTX CCS to 
stratify R and NR to MTX. Both models, namely XGBoost 
(https://xgboost.readthedocs.io/en/latest/) and LightGBM 
(https://lightgbm.readthedocs.io/en/latest/), utilise a gradient boosting 
decision tree algorithm and were used via R studio. 47 samples were unblinded 
(R vs NR status revealed) for classification; 23 samples remained blinded during 
analysis. R and NR status was determined by disease activity (CDAI) at 6 months 
after treatment.  
 
2.4 In-silico data analysis of MTX CCS epigenomic 
environment 
 
 2.4.1 DeepBlue Data retrieval   
 
Online datasets were utilised for these investigations. Namely the DeepBlue 
Epigenomic Data Server and the Promotor-Capture HiC (PCHiC) dataset, 
generated by Javierre et al260 . To analyse the data, a combination of Microsoft 
Excel and packages within R and R studio were used. From the DeepBlue 
Epigenomic Server, various datasets were downloaded dependent on the 
epigenetic feature of interest. Specifically, data from Chromatin 
immunoprecipitation followed by sequencing (ChIP-Seq) experiments identifying 
H3K27ac, H3K4me3, H3K4me1, H3K27me3, H3K36me3 and K3K9me3, in addition 
to data from Bisulphite–Seq and DNase-Seq to identify methylation marks and 











2.4.2 DeepBlue data analysis  
 
Once downloaded, the files were processed in R to identify if the marks were 
present in the regions of interest (MTX CCS loci). Dependent on the dataset 
downloaded, either hg38 or hg19 coordinates (Table 2.8) were used in the analysis 
script (Appendix). Regions of the genome 500 kb upstream of the first anchor site 
and 500 kb downstream of the second anchor site of chromosome loops were also 
investigated. Outputs from R were then quantified to understand enrichment of 
different epigenetic marks at each chromatin loop site.   
 
2.5 Discovery Microarray  
 
2.5.1 Microarray Set-up  
 
For this analysis 54 buffy layer samples from the SERA cohort were used. Here, 
18 healthy samples were used as a pooled standard on the array. 4x180k, custom 
Agilent microarrays were designed by OBD and run at their facility. OBD 
proprietary EpiSwitchTM pattern recognition algorithm was used to identify high 
probability chromatin folding interactions in combination with findings from 
Walsh et al209 were used to generate a list of probes that were functionally 
relevant in RA.  
 
Each probe was present in quadruplicate on the EpiSwitchTM microarray. The 
Agilent protocol for enzymatic labelling was followed. In brief, the standard 
EpiSwitchTM extraction as described previously (2.2.3) was used to generate the 
Table 2.8 DeepBlue coordinates  
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3C library for each sample. Subsequently, the DNA concentration of each sample 
was determined using the absorbable nanoquant plate on the Tecan Infinate 
M200 Pro. 800ng DNA was used per sample. A pool of the healthy samples was 
generated by determining DNA concentration as before and adding 6.2ng of each 
together. An ethanol precipitation step was then conducted to clean the sample 
before beginning the sample labelling. The Agilent DNA enzymatic labelling kit 
(Agilent p/n 5190-0449) was used to label the DNA library. This kit uses random 
primers and exo-Klenow fragments to label the DNA with fluorescently labelled 
nucleotides using cyanine 3-dUTP and cyanine 5-dUTP dyes. Samples were spun 
for 1 min at 6000g in a centrifuge. 5µl of random primers were then added and 
the samples were incubated at 95°C in a thermocycler for 3 minutes. Samples 
were again spun at 6000g for 1 min in a thermocycler. A master mix of Cy3 and 
Cy5 was prepared by mixing nuclease free water, 5xbuffer, 10xdNTP, Cy3 or Cy5 
and Exo-Klenow fragment. 19µl of master mix was added to each reaction tube, 
giving a total of 50µl. Samples were then incubated at 37°C for 2 hours, 65°C for 
10 mins then held at 4°C. The hybridisation master mix was then prepared by 
mixing cot-1 DNA, Agilent 10x Blocking reagent and 2x Hi-RPM buffer. The 
master mix was incubated at 95°C for 3 minutes, then 37°C for 30 minutes. After 
incubation, samples were spun at 6000g for 1 minute in a centrifuge.  
2.5.2 Microarray processing and feature extraction 
100µl of hybridisation sample (section 2.5.1) was dispensed onto a clean gasket 
slide in the Agilent SureHub chamber base. The assembled chamber slide was 
placed in the rotator rack in the hybridisation oven at 65°C, 20 rotations per 
minute (rpm) and left for 24 hours. Then, the slide staining dishes, rack and bars 
were washed thoroughly with milli-Q water to remove any contaminated 
material. The slide rack and bar were then added to the slide staining dish, 
which was filled with 100% acetonitrile. The magnetic stir plate was set to a 
speed of 4 and washed for 5 mins at RT. The step was repeated and then the 
plate was dried in a fume hood. To wash the array slides, the first 2 staining 
dishes were filled with Oligo aCGH wash buffer 1 at RT and placed on magnetic 
stir plate. The pre-warmed glass dish filled with water and containing slide 
staining dish 3 was also placed on the magnetic stir plate. Staining dish 3 was 
filled with Oligo aCGH wash buffer 2, which had been warmed to 37°C. A 4th 
staining dish with acetonitrile was placed in a fume food with a magnetic stir bar 
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added and placed on magnetic stir plate. A 5th staining dish was filled in the 
fume hood with hybridisation and drying solution, and was place on magnetic stir 
plate with magnetic bar. The hybridisation chamber was disassembled and the 
array slide placed in staining dish 1 and this was repeated for further slides. 
Slides were then transferred to staining dish 2 and stirred on setting 4 for 5 
minutes. Slides were then transferred to dish 3 for 1 min, and dish 4 for 10 
seconds and dish 5 for 30 seconds. Slides were removed with barcode facing 
upwards with a slide cover was placed on top. Slides then were immediately 
scanned using the SureScan DA model.  
Features were then extracted using feature extraction software and images were 
extracted as .tif. A QC report was carried out to ensure each extraction was 
completed successfully.  
2.5.3 Microarray analysis - Limma  
 
Once the array was completed, feature extraction data was downloaded from 
the raw OBD server. Data was analysed using several packages within R studio, 
namely, Limma and RankProd 2.0. Appropriate target files were generated for 
each analysis run. The use of the common reference healthy control sample 
allowed comparison of the loop expression across all RA samples. Target and raw 
data files were read into the R package (Appendix). Briefly, agilent control 
probes were removed first followed by probes that had a saturation signal above 
65525. The Limma background correction and the data was then normalised 
within arrays using the locally weighted polynomial regression (Loess) method. A 
log matrix of log2 ratios of fluorescence intensities was generated from the 
normalised data. Since duplicate probes were used on the array, a matrix was 
generated from the mean, median and cv values that could be taken forward in 
the analysis. The log median matrix was used for the analysis. A design matrix, 
followed by a contrast matrix were generated and a linear regression model was 
then fitted to the data based on the design. Statistics were then computed using 
the empirical bayes method (ebayes). A table of probes (loops) could then be 
extracted that had differential abundance between samples. Extra filtration 
could be implemented if desired, such as a specified number of loops to be 
output, and filtering on adjusted P.value (FDR correction) and abundance scores 
(AS), such as adj.P.Val ≤0.05 and AS -1.1≤ or ≥1.1.  
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2.5.4 Microarray analysis - RankProd  
 
Data was analysed with assistance from Ewan Hunter and Christina 
Koutsothanasi, OBD. After exploration of the data using Limma, it was decided a 
more stringent method of analysis should be implemented to differentiate the 3 
responder groups. For this, the RankProd package 2.0 was used to subsequently 
analyse the data. The Rank Product (RP) is a statistical technique which is used 
to find differentially expressed marks from molecular profiling studies. The 
RankProd package utilises this technique. The RP and Rank Sum (RS) are non-
parametric tests which can determine up or downregulated variables in repeat 
experiments. The P value for RP has strict bounds and calculated in a 
computationally fast manner. For this analysis, firstly data was normalised 
(Loess) and an expression matrix produced. Data were then filtered on adjusted 
P value and abundance scores (AS); loops with an adjusted P value ≤0.05 and of -
1.1≤ or ≥1.1 were carried forward for further analysis.  
 
2.5.5 Microarray Analysis – Searchlight  
 
Data was also analysed using Searchlight 
(https://github.com/Searchlight2/Searchlight2), an automated, platform for the 
analysis and visualization of RNAseq data, which was adapted for our microarray 
dataset. Data was analysed by John Cole, University of Glasgow. Searchlight 
provided an alternative way to analyse our data from the microarray 
experiment, and provided a streamlined, expedited way to facilitate deep 
exploration of the data that could not be achieved with RankProd in the same 
time frame. In summation, the three types of analysis performed were:  
• Expression – how much of a loop was present in a sample 
• Differential expression – how did the loop abundance differ between 2 
groups  
• Signature analysis – did groups of differently abundant loops generate a 
signature that would allude to a predictive biomarker 
The normalised expression matrix data was used for this analysis, and was 
generated as described above (2.5.3). To generate differential expression 
signatures, numpy was used to generate mean expression values and differential 
expression of loop abundance. Comparisons were: R vs NR, NR vs IR and R vs IR 
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at each time point. To determine signatures, each loop was classified by its 
starting signature based on the differential expression from the comparisons 
described. Expression values for each loop was converted to a z-score which 
allowed metagene expression for all samples. 2 expression metagenes were 
correlated to each other using the Spearman Correlation Coefficient to find 
signatures with similar expression profiles.  
 
 2.5.6 Microarray Biological Interpretation - Bedtools  
 
To begin biological exploration of array data the Bedtools programme was used. 
This was implemented via the terminal to analyse protein coding loci in 
proximity to loops of interest, found via Limma and RankProd analysis pipelines. 
The Bedtools closest function was used to identify the closest three protein 
coding loci to each loop of interest. Once a list of loci was produced, these were 
put through the online tool, Hugo Gene Nomenclature Committee, to filter and 
ensure all information was captured. This list was then entered into the online 
platform, GeneAnalytics to identify functional enrichment of genes and other 
genomic features. GeneAnalytics aims to identify potential associations of gene 
sets with pathways, compounds and Gene Ontology (GO) terms (biological 
process and molecular function). The results are ranked by relevance to the 
analysed gene set. 
 
 
 2.5.7 Microarray Biological Interpretation - STRING  
 
Gene lists of interest generated by GeneAnalytics were analysed further using 
the Search Tool for Retrieval of Interacting Genes/Proteins (STRING) 
(https://string-db.org) version 11.0, a database consisting of over 9 million 
known and predicted protein sequences. Gene lists corresponding to various 
analyses were entered into the online STRING platform and interaction networks 
were generated. Network nodes within the string represent proteins and the 
edges indicate functional associations between proteins. Proteins that are 
grouped based only on shared homology are excluded. The PPI enrichment value 
identified if the network had significantly more enrichment than expected. The 
interaction scores are given from zero to 1 and are based on the confidence that 
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the interaction/association is true. Other information such as enriched biological 
processes were extracted as .csv files, in addition to downloading the networks 
as images (Appendix).  
 
2.5.8 Microarray Biological Interpretation – Cytoscape 
 
Based on additional functionality, Cytoscape version 3.7.2 
(https://cytoscape.org) was used to conduct further network analysis of protein 
networks generated using STRING. Cytoscape represents genes or molecular 
marks as nodes and edges represent interactions between them. The network 
.csv file taken from STRING was loaded into the Cytoscape software. The 
network analysis tool was implemented to identify the network nodes with the 
most connected edges. The most connected nodes were identified as those with 
the most directed edges in the network.  
 
2.5.9 Microarray Biological Interpretation - IGV  
 
The Integrated Genome Viewer (IGV) 
(https://software.broadinstitute.org/software/igv/) was used for the 
exploration and visualisation of loops of interest, in addition to other genomic 
and epigenomic features. Files of interest were prepared in ‘.bed’ format and 
loaded into IGV version 2.4.14. Files are represented as ‘tracks’ on the viewer. 
Files included in the analysis included the Janssen expression quantitative trait 
loci (eQTL) files, and loop anchor sites. Images could be saved from analyses.  
 
2.5.10 EpiSwitchTM Data Portal  
 
The longitudinal data from the RankProd analysis was uploaded to the 
EpiSwitchTM data portal (https://episwitch3dgenomicsportal.com), an interactive 
interface to allow for easy manipulation and visualisation of the 3D genome 
data. The portal incorporates Bedtools functionality, described above (2.5.6) as 
well as IGV visualisation software that has also been described above (2.5.9). 





2.6 Statistical Analysis 
 
Statistical analysis not already described above was conducted in GraphPad 
Prism 6 software. Tests were chosen based on the distribution of the data and 
the desired comparisons to be made. Figure legends detail the exact statistical 
test used on each data set. In this study 0.05 was considered significant, with * 
P<0.05, ** P<0.01, ***P<0.001, *** P<0.0001. 
Chapter 3 Validation and Further Characterisation of 
Methotrexate Chromosome Conformation Signature and 




Previous work from our lab, in collaboration with Oxford BioDynamics Plc (OBD), 
produced a chromosome conformation signature (CCS) with promising capacity 
to differentiate responders (R) and non-responders (NR) to methotrexate (MTX) 
in an early rheumatoid arthritis (RA) population219. The discovery and validation 
populations both came from the Scottish Early Rheumatoid Arthritis (SERA) 
cohort. This signature was developed to be exclusive to RA patients, and was not 
in the same conformation in healthy samples. While molecular biomarker 
investigations can show promise in the discovery and preliminary validation 
stages, studies have shown subsequent validation can produce less efficacious 
results261. Therefore, before clinical implementation, it is fundamental that a 
biomarker is validated, proving the efficacy and ensuring it is a true 
representation of a heterogeneous disease population262. RA is a well-
characterised heterogeneous population, and it must be established if the MTX 
CCS can predict response in other early RA cohorts, and identify any potential 
confounding factors that may impact the predictive ability of the biomarker262. 
Validation in a completely independent cohort that is demographically matched 
to SERA would be both interesting and clinically important.  
 
While the results from Carini et al219  demonstrate the potential of a MTX 
biomarker, it is not only MTX that is given at baseline of RA treatment. Some 
patients cannot tolerate the therapy and suffer side effects such as nausea and 
hepatotoxicity, or in the case of around 50%, will not respond clinically to 
MTX263,264,265,266. Other conventional synthetic disease modifying anti-rheumatic 
drugs (csDMARDs), primarily hydroxychloroquine (HCQ) and sulphasalazine (SSZ) 
exist as alternative first-line therapies. Despite investigations to find biomarkers 
of treatment response to these csDMARDs, there has yet to be a clinically 
implementable finding and often studies investigate HCQ and SSZ in combination 
with MTX267,268. The study by Kremers et al., identified HCQ and MTX as having 
better retention than other treatments. However, this was predicted using 
survival analysis techniques, taking into consideration comorbidities and disease 
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characteristics such as duration of disease, instead of employing molecular 
biology methodologies268. Molecular biomarker studies for HCQ alone are limited. 
One study investigating SSZ, as part of triple csDMARD therapy, suggested gene 
variants in NAT2 and ABCG2 were associated with a limited response to SSZ112. 
This study has yet to be validated. Predictors of response to csDMARD treatment 
as a whole have been attempted. One recent study investigated the ability of 
both molecular and synovial signatures to predict response to csDMARDs. They 
identified cellular synovial and molecular signatures that had the potential to 
predict disease progression and treatment response. This study offers the 
potential for a blood based pan-DMARD predictor that would be of clinical 
benefit212. However, this study incorporated low-throughput techniques that 
would not be advantageous in a clinical setting. Therefore, it would be valuable 
to know if the MTX CCS biomarker has the capacity to predict response to 
csDMARD treatment, regardless of which monotherapy or combination therapy is 
assigned.  
 
The work for the MTX CCS study was carried out at OBD where the EpiSwitchTM 
proprietary technology exists. The work in this thesis required the establishment 
of this 3C propriety protocol at the University of Glasgow. This chapter details 
the steps taken to ensure efficient establishment of this technique, which 
included exploring transition to a higher throughput method of chromosomal 
loop detection. The nested PCR method used in the MTX CCS discovery study 
could be considered low throughput. Moreover, quantification capabilities are 
limited with gel electrophoresis outputs and there is difficulty in determining 
any weak 3C signals269. Implementing a quantitative PCR (qPCR) method would 
not only be of benefit in our study, but in future clinical use. It would be higher 
throughput and offer the opportunity of multiplexing270. qPCR has been 
successfully used in the study of the mouse HoxB1 loci271. The process of qPCR 
implementation in the work in this thesis followed the Minimum Information for 
Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines for 
primer design to ensure accuracy and robust results moving forward. These 
guidelines state the in-silico and wet lab steps required to create publishable-
qPCR results272. As such, this chapter explores the investigation into qPCR as a 
method of loop detection, adhering to the MIQE guidelines.  
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The aim of the work in this chapter was to further characterise the predictive 
ability of the MTX CCS and identify the optimal way to investigate the chromatin 
architecture of samples throughout this study. To achieve this, the aims were: 
 
1) Validate the MTX CCS both bioinformatically and experimentally using an 
independent clinical RA cohort  
 
2) Set up 3C protocol independently and determine the optimal method for loop 
detection through exploration of different PCR methodologies 
 
3) Assess whether MTX CCS is stable after treatment and if it can accurately 




 3.2 Results  
 
 3.2.1 Bioinformatic validation of MTX CCS 
 
Validating the prior MTX CCS signature in-silico by independently analysing the 
data was an important first step in this study. The initial step to achieve this was 
to use a Limma-based analysis to interrogate the quality of the microarray-
generated data (Figure 3.1). Limma is a package that facilitates the analysis of 
gene expression arising from microarray or RNA-Seq experiments. Limma utilises 
linear models to identify differential expression. In the case of data in our study, 
Limma was used to identify abundance changes of loops between healthy and RA 
samples. The starting data file was the intensity of each spot on the array, 
which had been extracted by the Agilent Feature Extraction Software. The red-
green density plots were used to visualise the signal distribution across the 
arrays. The density plot before normalisation indicated that the signals had an 
expected distribution and there were no outliers (Figure 3.1A). Moreover, the 
dye intensity of both red and green dyes were similar, indicating the absence of 
dye bias. The ‘within array’ normalisation step was successful by bringing the 
signal distributions closer together (Figure 3.1B). Loess normalisation was used, 
which is a type of Generalised Additive Model (GAM). MA plots were then used to 
understand the relationship between the red-green intensity log ratio (M) and 
average intensity of a spot on the array (A). Figures 3.1C and Figure 3.1D 
highlight the successful normalisation, by the flattening of the line around the M 
value of 0. A boxplot was then produced to illustrate the distribution of M values 
across all 8 arrays (Figure 3.1E). The normalisation brought the medians close 
together and the range of M values can still be visualised. Most of the M values 
are distributed around 0. This analysis supported the concept that the data was 




Figure 3.1 Quality Control Assessment of MTX CCS Microarray Data 
Series of plots demonstrating quality of raw microarray data and the influence of 
normalisation. 8 dual-colour arrays in total. Array 1-4 compared R and NR, array 5+6 
compared HC and R, array 7+8 compared HC and NR. 13,322 EpiSwitchTM sites across 123 
loci were analysed. A) Red-green density histogram before normalisation. B) Red-green 
density histogram after ‘within array’ locally weighted polynomial regression (Loess) 
normalisation. C) MA plot before normalisation. D) MA plot after ‘within array’ Loess 
normalisation. E) Boxplot illustrating M value (log-ratios) distribution after Loess 
normalisation. Plots created using Limma package on R studio. 
A, mean average; HC, healthy control; M, log ratio; R, responder; NR, non-responder 
 
After using multiple plots to visualise that the MTX CCS data was of good quality 
and normalisation procedures were effective, it was important to find out if the 
predictive loops would be replicated using the original nested PCR dataset 
(Figure 3.2). Limma was used to apply a linear model to the data to identify 
loops that could differentiate responders (R), non-responders (NR) and healthy 
controls (HC). The results shown for the MTX CCS genomic regions indicate the 
potential for stratification. Differences of loop abundance was used as a 
measure of stratification potential with a positive value associated with the 
condition on the left of the contrast model, and a negative value associated with 
the condition on the right side of the model (Figure 3.2A). The first output from 
the Limma contrast model, contrasting NR and R, illustrated that IL17A and 
CXCL13 had a positive fold change. In contrast, IL21R, IL23 and IFNAR1 had 
negative fold change values. This demonstrated the association of IL17A and 
CXCL13 with NR and IL21R, IL23 and IFNAR1 with R as per the MTX CCS. Next, a 
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classification model was used to test the predictive value of the signature. A 
Random Forest method was used to test the data that was taken from the nested 
PCR results from 55 RA patients, collected at the time of the study by Carini et 
al219. The model successfully predicted 26 R, and 22 NR correctly (Figure 3.2B). 
This resulted in a true positive rate of 0.96 and 0.79 for R and NR, respectively 
which gave an overall accuracy of 87%.  
 
 
Figure 3.2 Statistical Validation of MTX CCS  
Limma linear model results and validation using PCR data from 55 RA patients using 5-
loop MTX CCS. A) Limma linear model results of contrast model between R and NR. B) 
Binary classifier model conducted in Weka using Random Forest classification. C) ROC 
curve illustrating relationship between sensitivity and specificity. ROC curve generated 
using web-based calculator which utilises JROCFIT program. 
 
3.2.2 Technical optimisation of 3C in peripheral blood from 
healthy donors 
 
The first step in establishing the EpiSwitchTM 3C assay in house was to use a 
range of primary cells from human donors. It should be noted that the original 
MTX CCS was generated in peripheral blood mononuclear cells (PBMCs) from RA 
patients. However, given the precious nature of clinical samples, for the 3C 
technical optimisation it was not deemed appropriate to use RA patient samples. 
Thus, PBMCs were isolated from healthy buffy coat (BC) donors. Flow cytometry 
analysis was performed to check cell purity prior to further analysis (Figure 3.3). 
70.2% of PBMCs were lymphocytes. Analysis revealed that 56.5% of PBMCs were 
CD4+ T cells, and after isolation by magnetic bead separation, 92.5% were CD4+ T 
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Figure 3.3 PBMC Isolation Purity Check   
Purity of the isolation was examined using flow cytometry. Representative flourescence-
activated cell sorting (FACS) plots of PBMCs and CD4+ T cells from healthy BC donors. 
PBMCs and T cells stained with CD4-APC antibody. A) Gate demonstrating defined 
population of single cells within PBMCs, percentage of gate is displayed within plot. B) 
Percentage of lymphocytes in total PBMCs. C) Percentage of CD4+ T cells in single cells. 
D) Percentage of CD4+ T cells after CD4+ magnetic separation.  
 
Once PBMCs (and purified CD4+ T cells) were successfully isolated, 3C DNA 
extraction was carried out (See Section 2.2). After extraction, the DNA library 
concentration had to be measured to confirm successful isolation of DNA, and to 
determine a reference for the normalisation in later protocol stages. The Quant-
iT PicoGreen DNA quantification assay was initially used to determine DNA 
concentration in PBMCs, as this was an optimised methodology used at OBD and 
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suitable for our sample type. This method revealed samples contained more than 
20ng/µl of DNA (Figure 3.4).   
 
 
Figure 3.4 3C DNA Library Isolation Check  
Confirmation of successful extraction of DNA library from PBMCs. A) Representative 
FACS plot of PBMCs used for DNA library preparation. B) DNA concentration of first DNA    
 
 
During the course of the optimisation, it was anticipated that fewer samples 
would be processed at one time than generally occurs at OBD, and thus, the 
Quant-iT PicoGreen assay (tailored for large sample number) was not optimal. 
The Qubit High Sensitivity (HS) double-stranded DNA (dsDNA) kit was chosen as a 
suitable alternative quantification method, based on sample number 
requirements, speed of protocol and rapid reading capabilities. To confirm that 
this was an appropriate alternative quantification method, samples were run in 
parallel using both methods, enabling the comparison of the techniques to 
determine if that resulted in consistent in DNA concentrations. Surprisingly, the 
resulting DNA concentrations calculated from the two methods were not 
comparable, producing different concentrations in the same sample (Figure 3.5). 
Consequently, this experiment was repeated to determine if the methods 
continued to produce different results. Each experiment produced different 
concentrations per sample, with the Quant-iT PicoGreen assay consistently 
measuring higher concentrations of DNA compared to the Qubit. Experiment 1 
demonstrated a significant difference between the two methods. Additionally, 
there was a significant difference between the concentrations measured by 
Quant-iT PicoGreen between experiment 1 and experiment 2. Combining the 
results from all experiments (Figure 3.5B), there was a significant difference 
between the 2 methods. The PicoGreen method showed a much larger variation 
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in DNA concentration values with a standard deviation of 10.98 compared to 
2.312 for the Qubit. The maximum DNA concentration measured by the 
PicoGreen method was 30.53ng/µl and the maximum measured by the Qubit HS 
dsDNA assay was 10.30ng/µl. Based on the more consistent DNA concentration 
measurements, and the concentrations considered within normal range for this 
type of library preparation, the Qubit dsDNA HS assay was selected as the most 




Figure 3.5 Comparison of DNA Quantification Methods  
Comparison of Quant-iT PicoGreen and Qubit dsDNA HS assay. 3C DNA libraries were 
extracted from PBMCs and both methods were used to measure the DNA concentration 
of each sample. A) DNA concentrations (ng/ul) calculated via the 2 independent 
methods are plotted for comparison, data across 3 experimental repeats. Experiment 1 
and 2, n=7, experiment 3, n=4. Non-parametric T-test used to compare methods in one 
experiment. Wilcoxon test to compare between experiments. B) Combined DNA 
concentrations (ng/ul) from 3 experimental repeats, calculated via 2 independent 
methods - plotted for method comparison (N=18). Mann Whitney T test to compare 
methods. * P< 0.05. Data is shown as box and whisker plot showing the median and 
range. 
 
The 3C assay preparation continued with the optimisation of nested PCR and 
ultimate visualisation of the ligated DNA on an agarose gel, which is the 
surrogate for the presence of a loop in a sample. Establishment of a reliable 
detection method of DNA concentration (Qubit) enabled normalisation of sample 
DNA concentration prior to nested PCR. The first step in the PCR process was to 
test the variety of control primers that can aid the 3C assay (Table 3.1) to 




Table 3.1 Control Primers  
List of control primers tested for the 3C protocol.  




Table 3.2 Gel electrophoresis interpretation   





DNA loops from PBMCs (Figure 3.6A) and CD4+ T cells (Figure 3.6B) were used to 
test the control primers. Three primers were positive 3C controls, one was a PCR 
control and 1 was a negative control. 6 PBMC samples had bands present for the 
control primers MMP1 4/12, MMP1 9/12, ER 16/17, and RFA 17/19 at the 
expected size of 281bp or 556bp, 185bp, 246bp and 252bp, respectively 
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confirming successful 3C and loops present at these loop sites. It should be 
noted, however, that there was a level of variation in the RFA control. Across 
the 6 samples, some samples had the expected 252bp whilst other had a band 
that indicated a larger size product. The CD4+ T cells also had bands present at a 
variation of sizes using primers MMP1 4/12, MMP1 9/12 and RFA 17/19. These 
results suggested possible incomplete digestion of chromatin resulting in 
multiple ligation products. The ER primer consistently showed clear bands in 
each sample. This illustrated the PCR protocol was successfully executed. The 






Figure 3.6 Gel Electrophoresis of Control Primers  
Gel electrophoresis of nested PCR using DNA extracted from PBMCs and CD4+ T cells 
testing 5 3C controls. 3C DNA libraries were amplified using nested PCR and then loaded 
onto a 1.5% gel, N=3. L= 1kb+ ladder, 7 µl DNA ladder and 15 µl sample loaded. Samples 
loaded in 1 well each in duplicate. MMP1 4/12 and MMP1 9/12 = 3C controls, ER = PCR 
control, RFA = positive control and ERTM = negative control. Non-template control 
(NTC) used for each primer. A) DNA was extracted from PBMCs. B) DNA was extracted 
from CD4+ T cells 
	 94	
 
While the results presented in Figure 3.6 illustrated using the PCR method was 
successful in some samples for determining DNA loop presence, some consider it 
non-quantitative. Therefore, a semi-quantitative approach was attempted. After 
initial gel electrophoresis, MMP1 4/12 and MMP1 9/12 were considered the most 
robust 3C controls to use based on the most consistent presence of bands at the 
expected size. Additionally, after the initial gel electrophoresis, samples were 
loaded onto the gels in triplicate in line with the protocol used at OBD (Table 3.2). 
When carried out in triplicate, if a sample presents with 1 band or lower it can be 
stated that no loop is present at the locus of interest. However, if 2 or 3 bands 
are present at the predicted size, it can be stated that a loop is present at that 
locus. The samples for the semi-quantitative method were prepared by creating a 
1:2 serial dilution of samples. When carrying out this method it would be expected 
that 3C copy number would decrease as the DNA concentration decreased.  
 
The semi-quantitative method was tested with control primers and RA primers 
(Figure 3.7 and Figure 3.8). There was not a clear concentration dependent effect 
on loops using the control MMP 4/12 primer set. The neat sample had only 1 set 
of bands at expected size, however diluted samples of 0.25ng/ul and lower had 
multiple bands in some samples. Both samples used had instances with multiple 
bands. The images shown in Figure 3.8A reveal that only 1 patient, at 1 DNA 
concentration had bands present for the IL17A loop. The images in Figure 3.7B 
(CXCL13) demonstrate no bands were present. Due to the lack of bands in A + B, 
it was difficult to determine the effect of the varying DNA concentrations on 3C 
copy number. In contrast, Figure 3.8C (IL21R), D (IL23) and E (IFNAR1) highlight 
the semi-quantitative method well. Particularly in 3.8C, it was evident that the 
3C copy number decreased gradually with decreasing DNA concentration in sample 
1A1. This is also presented in 3.8D with sample 1A1. It is evident from this figure 
that the IL21R, IL23 and IFNAR1 loci had several loops in multiple samples. Overall, 
considering the unreliable semi-quantitative results in 3C controls, and the limited 
reliability in MTX CCS genes, the semi-quantitative method was not taken forward. 
However, based on the other data collected, it was confirmed that the 3C assay 




Figure 3.7 Gel Electrophoresis of 3C control loop using semi-quantitative method 
DNA was extracted from PBMCs of healthy donors, N=2, labelled A+B. 3C DNA libraries 
were amplified using nested PCR and then loaded onto a 1.5% gel. L= 1kb+ ladder, 7 µl 
DNA ladder and 13 µl of sample loaded in triplicate. Various concentrations of DNA 
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used: 1 ng/µl, 0.5 ng/µl, 0.25 ng/µl, 0.125 ng/µl, 0.06 ng/µl. Non-template control 













Figure 3.8 Gel Electrophoresis of MTX CCS Loops using Semi-quantitative Method  
DNA was extracted from PBMCs of healthy donors, N=3, labelledA1, A2 + 2A. 3C DNA 
libraries were amplified using nested PCR and then loaded onto a 1.5% gel. L= 1kb+ 
ladder, 7 µl DNA ladder and 13 µl of sample loaded in triplicate. Various concentrations 
of DNA used: 1 ng/µl, 0.5 ng/µl, 0.25 ng/µl, 0.125 ng/µl, 0.06 ng/µl. Non-template 
control (NTC) also used. A) RA1 (IL17A). B) RA2(CXCL13). C) RA3 (IL21R). D) RA4(IL23). 
E) RA5(IFNAR1). Patient sample annotation indicated above gel image, DNA library 
concentration shown below gel.  
 
3.2.3 Establishing use of quantitative PCR for MTX CCS 
 
Having verified that it was possible to run the original 3C method independently, 
but clearly demonstrating that the semi-quantitate method failed to produce 
robust results, I considered introducing a higher-throughput, more informative 
method of observing chromosomal loops. Moreover, OBD were in the process of 
transitioning to this methodology and therefore this work aligned with the 
direction of travel for EpiSwitchTM technology. A more informative method would 
be one which could successfully quantify the loops within a patient sample. A 
higher-throughput method would not only be of benefit in the short-term of the 
study, but also in the long-term if the signature was to be implemented 
clinically. Quantitative PCR (qPCR) would fill these criteria, however, the 
development and refinement of this process for chromosomal loops is complex 
and required a systematic approach. Various steps were carried out to determine 
if qPCR primers were suitable for detection of chromosomal loops of interest, 
and determine the optimal annealing temperature to use for the primers. This 
was carried out in accordance with the MIQE guidelines. Primers were designed 
to capture the 3C ligated DNA product which centred around a 4 base TCGA 
sequence (Figure 3.9A). Firstly, primers were designed (Section 2.2.7) and 
tested for the 3C control gene, MMP1 (Figure 3.10). For the process of 
determining the optimal primer annealing temperature, 3 primer versions for 




Figure 3.9 Primer Design for qPCR 
A) Ligated DNA region in which qPCR primers are designed around, full sequences found 
in Appendix. B) Expected sizes of qPCR products for all primers designed and tested  
 
The chromosomal loop, from pooled RA patient samples, was amplified at 6 
annealing temperatures and gave cycle threshold (Ct) values ranging from 31 to 
34 (Figure 3.10A). Melt curve analysis showed amplification of a single product 
(Figure 3.10B). This could be considered a successful qPCR amplification. The 
high Ct values for MMP1 may reflect weak ligation and the results were a 
possible indication that other loops from the MTX CCS may also amplify at a 
higher Ct value than expected for other qPCR reactions.  
   
 
Figure 3.10 Quantitative PCR with 3C control  
Quantitative PCR using pooled RA patient samples with MMP1 primers. A) Representative 
plot from 1 qPCR experiment of Ct values at 6 annealing temperatures with pooled RA 
patient samples, (N=8). B) Representative melt curve of from 1 qPCR experiment that 
was repeated twice with pooled patient samples (N=8): NF, non-fixtion, NTC, not-
template control; PH, pooled healthy, PP, pooled patient; TE, Tris-EDTA; NF= non-
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fixation - control generated by using nuclease-free water to fix the DNA, instead of 
formaldehyde.  
 
Once it was confirmed qPCR could be successful for amplifying chromosomal 
loops of interest, the next step was to determine the optimal annealing 
temperature of qPCR primers for all 5 loci in the MTX signature. This single step 
process used a temperature gradient to identify the optimum annealing 
temperature and overall primer efficiency. Amplification of only the product of 
interest (loop in pooled patient sample), without any product present in the 
negative controls (pooled healthy sample, Gen control, NF control, TE control, 
NTC) was the aim. The first primer set for IL17A amplified the product of 
interest at a Ct value of 9, at an annealing temperature of 68°C, alongside 
amplification of negative controls at higher Ct values (Figure 3.11A). Primer set 
B for IL17A could amplify the product of interest at all 6 annealing 
temperatures, however, there was also better amplification of negative controls 
at all 6 annealing temperatures (Figure 3.11B). Primer set 3 was also able to 
amplify the product of interest at all 6 temperatures at Ct values ranging from 
27 to 40. At 67.5°C only the product of interest was amplified (Figure 3.11G). 
The high Ct values of primer set B and C suggested presence of off-target 
products. Melt curve analysis was conducted alongside to confirm primer 
specificity. Many melt curves for IL17A primers, had multiple peaks (Figure 
3.11B,E,H) indicating the presence of off-target amplification products. The 
qPCR products were then purified using gel electrophoresis, which could also be 
used to check the amplified product was of the expected size. All 3 primer sets 
had products at the expected size (representative gel images can be found in 
Appendix). There was also the presence of multiple bands for all primers sets in 
pooled patient (PP) and pooled healthy (PH) samples at lower annealing 
temperatures. Primer set A and B did not meet requirements, however primer 
set C met requirements at 67.5°C only. As pooled heathy controls were amplified 
at neighbouring annealing temperatures, these results should be interpreted 









Figure 3.11 Temperature Gradient Quantitative PCR with IL17A primers  
3C DNA libraries were loaded in duplicate on 96-well reaction plate. qPCR analysis of 3 
versions of IL17A primers, Ct values shown as individual samples, and mean of 2. A) Ct 
values of version A primers, N=2. B) Representative melt curve at 68°C. C) 
Representative melt curve at 66.4°C. D) Ct values of version B primers, N=2. E) 
Representative melt curve at 62°C. F) Representative melt curve at 64.4°C. G) Ct values 
from version C primers, N=1 H) Representative melt curve at 68oC. I) Representative 
melt curve at 64.4°C. J) Summary of gel electrophoresis results from 3 primer versions. 
Numbers highlighted in red indicate one of the bands are at the expected size of 84bp 
for version A primers (2 technical repeats), 94bp for version B primers (2 technical 
repeats) and 104bp for version C primers.  
NF, non-fixation, NTC, not-template control; PH, pooled healthy, PP, pooled patient; 
TE, Tris-EDTA  
 
 
The first primer set tested for CXCL13 was unable to amplify the product of 
interest. At 68°C, 64.4°C, and 62°C the NTC control was amplified. Melt curves 
from 68°C (Figure 3.12B) and 66.4°C (Figure 3.12C) highlighted the presence of 
multiple products. The second primer set was also unable to amplify the product 
of interest (Figure 3.12D). At 62°C and 60°C there was amplification of the 
genomic control and TE control respectively. The melt curve from 64.4°C (Figure 
3.12F) suggested there was a single product. The melt curve from 60°C (Figure 
3.12E) also showed evidence that the product of interest was amplified. The 
product of interest was amplified with primer set C, at annealing temperatures 
of 64.4°C, 62°C and 60°C at Ct values of 33, 31 and 32, respectively. At each of 
those temperatures there was also amplification of negative controls. The melt 
curve at 60°C indicated that there was only a single product of interest amplified 
(Figure 3.12I). Gel electrophoresis of qPCR products for primer set B were 
reflective of amplification and melt curve results. A selection of products of 
interest at the expected size of 116 and 135bp were present on a gel for primer 








Figure 3.12 Temperature Gradient Quantitative PCR with CXCL13 Primers  
3C DNA libraries were loaded in duplicate on 96-well reaction plate. qPCR analysis of 3 
versions of CXCL13 primers, Ct values shown as individual samples, and mean. A) Ct 
values of version A primers, N=2. B) Representative melt curve at 68°C. C) 
Representative melt curve at 66.4°C. D) Ct values of version B primers, N=2. E) 
Representative melt curve at 60°C. F) Representative melt curve at 64.4°C. G) Ct values 
form version C primers, N=1. H) Representative melt curve at 68°C. I) Representative 
melt curve at 60°C. J) Summary of gel electrophoresis results from 3 primer versions. 
Numbers highlighted in red indicate one of the bands are at the expected size of 135bp 
for version A primers, 104bp for version B primers and 116bp for version C primers, 2 
technical repeats for all primer sets.   
NF, non-fixation, NTC, not-template control; PH, pooled healthy, PP, pooled patient; 
TE, Tris-EDTA 
 
IL21R primers could amplify the product of interest, but only alongside 
amplification of negative controls. Temperatures of 66.4°C to 60°C for primer set 
A had amplification of the pooled patient (PP) sample (Figure 3.13A). This was 
accompanied by amplification of negative controls. Melt curves from primer set 
A had multiple peaks indicating presence of off-target products (Figure 3.13B,C). 
Primer set B successfully amplified the product of interest at all 6 annealing 
temperatures (Figure 3.13D). Negative controls were also amplified at all 6 
temperatures. Melt curve from 64.4°C indicated peaks for only PP and PH. 
Primer set C also had amplification of PP at all annealing temperatures, as well 
as amplification of negative controls (Figure 3.13G). Gel electrophoresis of the 
qPCR results highlighted the presence of multiple bands at all temperatures in 
PP and PH samples (Figure 3.13J). Primer set A did not have any qPCR products 
at the expected size, however primer set B and C had bands at expected size. 
Primer set B and C met primer requirements at some temperatures. However, 
taken together, there is not enough evidence that any IL21R primer set could 







Figure 3.13 Temperature Gradient Quantitative PCR with IL21R Primers  
3C DNA libraries were loaded in duplicate on 96-well reaction plate. qPCR analysis of 3 
versions of IL21R primers, Ct values shown as individual samples, and mean. A) Ct values 
of version A primers, N=2. B) Representative melt curve at 66.4°C. C) Representative 
melt curve at 64.4°C. D) Ct values of version B primers, N=2. E) Representative melt 
curve at 64.4°C. F) Representative melt curve at 68°C. G) Ct values form version C 
primers, N=2. H) Representative melt curve at 68°C. I) Representative melt curve at 
64.4°C. J) Summary of gel electrophoresis results from 3 primer versions. Numbers 
highlighted in red indicate one of the bands are at the expected size of 110bp for 
version A primers, 119bp for version B primers and 119bp for version C primers 2 
technical repeats for all primer sets.   




Like IL21R, IL23 primer sets achieved amplification of the patient product of 
interest but not without amplification of control primers. Primer set A saw 
amplification at temperatures 64.4°C, 62°C and 60°C. Amplification of negative 
controls also occurred (Figure 3.14A). Primer set B also had amplification of the 
product of interest and negative controls at these temperatures, as well as 
66.4°C (Figure 3.14D). There was amplification of only the product of interest at 
annealing temperature of 66.4°C using primer set C (Figure 3.14G). Amplification 
also occurred at the 3 lower annealing temperatures along with negative 
controls. The melt curves for primer set A and B indicate the presence of non-
specific products (Figure 3.14B,C,E,F). At 62°C using Primer set C, the melt 
curves appeared to have less evidence of non-specific products (Figure 3.14I). 
Primer set A produced no products at the expected size when gel electrophoresis 
of qPCR products was conducted (Figure 3.14J). At temperatures from 64.4°C to 
60°C primers set B and C had bands at the expected sizes. Primer C met 
requirements at 66.4°C but again, annealing temperatures 2°C below had 








Figure 3.14 Temperature Gradient Quantitative PCR with IL23 Primers 
3C DNA libraries were loaded in duplicate on 96-well reaction plate. qPCR analysis of 3 
versions of IL23 primers, Ct values shown as individual samples, and mean. A) Ct values 
of version A primers, N=2. B) Representative melt curve at 62°C. C) Representative melt 
curve at 60°C. D) Ct values of version B primers, N=2. E) representative melt curve at 
66.4°C. F) Representative melt curve at 62°C. G) Ct values form version C primers, N=1. 
H) representative melt curve at 64.4°C, I) Representative melt curve at 60°C. J) 
summary of gel electrophoresis results from 3 primer versions. Numbers highlighted in 
red indicate one of the bands are at the expected size of 80bp for version A primers, 
81bp for version B primers and 85bp (2 technical repeats) for version C primers.   




qPCR using primer sets A, B and C for the IFNAR1 loop resulted in amplification 
of the product of interest, but not without amplification of negative controls. 
There was amplification of the patient product with annealing temperatures 
ranging from 67.5°C to 60°C using primer set A (Figure 3.15A). There was also 
amplification of negative controls at these temperatures. Primer set B achieved 
amplification of PP at temperatures from 66.4°C to 60°C (Figure 3.15D). Using 
primer set C, the product of interest was not amplified without negative controls 
(Figure 3.15G). Melt curves using primers set A produced varying results. At 
annealing temperature 66.4°C the melt curve shows evidence of multiple 
products (Figure 3.15B), but at 62°C the melt curve suggests only presence of a 
single product (Figure 3.15C). Melt curves using primer set B and C suggest 
presence of non-specific products (Figure 3.15E,F,H,I). There were bands at the 
expected sizes using all 3 primer sets, as well as multiple bands at all 
temperatures in many samples reflecting the melt curve results (Figure 3.15J). 








Figure 3.15 Temperature gradient quantitative PCR with IFNAR1 primers 
3C DNA libraries were loaded in duplicate on 96-well reaction plate. qPCR analysis of 3 
versions of IFNAR1 primers, Ct values shown as individual samples, and mean. A) Ct 
values of version A primers, N=1. B) Representative melt curve at 66.4°C. C) 
Representative melt curve at 62°C. D) Ct values of version B primers, N=2. E) 
Representative melt curve at 66.4°C. F) Representative melt curve at 64.4°C. G) Ct 
values from version C primers, N=1. H) Representative melt curve at 62°C. I) 
representative melt curve at 67.5°C. J) Summary of gel electrophoresis results from 3 
primer versions. Numbers highlighted in red indicate one of the bands are at the 
expected size of 117bp for version A primers, 117bp for version B primers and 149bp for 
version C primers.    




Overall, the qPCR protocol up to this point revealed some potentially useful 
primer candidates from successful amplification of the product of interest 
without parallel amplification of negative controls. Some annealing 
temperatures were emerging successful, but this could not be robustly 
replicated in multiple experiments. Despite the results not being conclusive, the 
gel products had to be purified before sending to Eurofins Genomics for 
sequencing (See section 2.2.11). This would be another measure to confirm 
amplification of the product of interest was successful, as the sequenced 
product could be checked against the known sequence (Appendix). The original 
gel purification protocol (as described in 2.2.9) was attempted but yielded little 
DNA, with concentrations ranging from 0.25ng/µl to 0.88ng/µl (Figure 3.16B). 
These concentrations were not sufficient for sequencing protocols, indicating 
optimisation of the gel purification process was needed. The first step to 
improve DNA yield was to add extra incubation steps at the buffer GQ stage and 
the elution stage of the protocol. This decreased DNA yield further to the lowest 
concentration of 0.106ng/µl (Figure 3.16B). The second optimisation step 
combined extra incubation stages (Section 2.2.9) with elution into heated 
elution buffer. This successfully increased yield to concentrations suitable for 
future sequencing. The minimum concentration from this attempt was 1.07 
ng/µl with a maximum of 2.8 ng/µl (Figure 3.16B). All protocols had significantly 
different DNA concentrations, with protocol 1.0 and 3.0 also having significantly 
different yields. We proceeded with protocol 3.0 based on the yield of DNA 
produced.  
     
	 119	
 
Figure 3.16 Optimisation of Gel Purification  
Optimisation of gel purification to increase DNA yield. A) Schematic representing 
optimisation steps used. Protocol 1.0: running qPCR products on 1.5% agarose gel, gel 
fragments of interest excised and dissolved using buffer GQ from QIAquick gel 
purification kit. Incubation with buffer GQ for 10 mins at 50°C. Incubation with elution 
buffer (1xTE) for 1 minute at RT. Protocol 2.0: As protocol 1.0 with buffer GQ 
incubation for 15 minutes with shaking every 2 minutes, incubation with elution buffer 
for 3 minutes. Protocol 3.0: as protocol 2.0, with heated (37oC water bath) elution 
buffer. B) Concentration of DNA ng/µl using each protocol version, protocol 1.0 N=7, 
protocol 2.0 N=2, protocol 3.0 N=6. 2 tailed Mann Whitney test used to compare DNA 
yield between protocols, Kruskal-Wallis test comparing variation between 3 groups as a 
whole. ** P< 0.01, **** P <0.0001.  
 
When the gel purification protocol was optimised to yield enough DNA for 
sequencing, the first sample to be sent was a product amplified by IFNAR1 
Version B primers at an annealing temperature of 62°C. This sequencing run 
proved unsuccessful. Images provided by Eurofins revealed the DNA was poor 
quality, as illustrated by the large proportion of black underneath each sequence 
row, representing DNA of 0-9% quality (Figure 3.17A). The alignment with the 
desired IFNAR1 loop sequence was 6.91% (Figure 3.17B), although as the 
sequencing was such low quality, this could not be interpreted with any 
certainty. The known sequence, based on DNA digestion and re-ligation, primer 
design, predicted amplicon size (Figure 3.9 and Appendix) facilitated the ability 
to determine alignment. The decision was made to implement cloning of the gel 
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purified qPCR product as a way to improve the quality of the sequencing product 
(Figure 3.17C). Plasmids produced from cloning steps would be expected to be of 
high quality and ideal for sequencing. After the cloning of the qPCR product into 
the Topo 2.1 cloning vector, a restriction digest using the EcoR1 enzyme using a 
standard protocol (Section 2.2.12), was conducted to confirm presence of the 
qPCR product. The first attempt based on the original cloning protocol (section 
2.2.12) did not yield the PCR product at expected size (Figure 3.17D). Version 
2.0 of the protocol added an polyA tail to the qPCR product with the aim of 
increasing product stability (Section 2.2.13). This also did not yield a product at 
the expected size (Figure 3.17E). Version 3.0 of the protocol combined a polyA 
tail addition with an optimised ratio of reagents for ligation. This was hoped to 
increase the chances of the product being successfully inserted into the plasmid 
and creating a positive clone. After restriction digest, this version of the 
protocol yielded a product at a size around 300bp, which was in the range to be 
expected. This product, which came from IL21R at 64.4°C, was sent for 
sequencing. This product was chosen as results appeared more robust than the 
IFNAR1 product used previously. Images from Eurofins were provided to illustrate 
sequencing quality. The quality of the sequencing was better than the first 
sample sent, highlighted by the large proportion of green, representing DNA of 
>30% quality. (Figure 3.17G). However, alignment with the desired sequence was 









Figure 3.17 Optimisation of Sequencing of Quantitative PCR Products  
Optimisation of qPCR product cloning to increase sequencing quality. Eurofins Tubeseq 
service was used for sequencing. A) Sequencing of product from IFNAR1 primer version 
B, at annealing temperature of 62°C, image provided by Eurofins. B) Alignment of 
sequenced product with expected IFNAR1 loop sequence, image provided by Eurofins. C) 
Schematic representing optimisation of the cloning method to generate plasmids 
containing loop products. Protocol 1.0: Topo 2.1 cloning vector used. Plasmid isolated 
using purelink miniprep kit. Restriction digest with EcoR1. Protocol 2.0: as protocol 1.0 
with addition of PolyA tail to qPCR product before insertion to cloning plasmid. Protocol 
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3.0: as protocol 2.0 with ligation ratio optimised for 1.5ug DNA insert. D) Gel image of 
restriction digestion of cloned qPCR product using protocol 1.0. E) Gel image of 
restriction digestion of cloned qPCR product using protocol 2.0. F) Gel image of 
restriction digestion of cloned qPCR product using protocol 3.0. G) Sequencing of 
product from IL21R primer version C, at annealing temperature of 66.4°C, image 
provided by Eurofins. H) Alignment of IL21R sequenced product with IL21R expected 
loop sequence, image provided by Eurofins. 
 
In summation, reviewing the collection of data from the qPCR optimisation 
(Figure 3.10 to Figure 3.17), I concluded that it was not possible for me to 
translate the nested PCR-based method previously used to evaluate our 
chromosomal loops of interest into a qPCR-based method. Whilst some primers 
showed some evidence that they could successfully amplify the loop of interest 
in the absence of negative control amplification at some temperatures, 
sequencing revealed they were not the expected loop product. After discussions 
with OBD, after they acquired additional propriety information about the 
translatability of the 5 markers to the qPCR platform, it was agreed that it was 
not appropriate to invest more time into the translation of these particular 
loops. Notably, since that point, the platform at OBD has been optimised and 
markers are now more easily translated from the nested to the qPCR platform.  
 
Overall, based on minimal evidence that loops from the MTX signature could 
successfully be detected with qPCR following MIQE guidelines, the decision was 
taken to revert to nested PCR to amplify our 3C libraries. Based on this decision, 
an alternative method of gel visualisation was sourced. The decision to use the 
Lab Chip GX provided results quicker than a traditional gel electrophoresis 
protocol and results that were easily interpreted, highlighted by a clear band in 
combination with clear peaks at the expected size (Figure 3.18). These features 
allow high-throughput, more informative analysis than the original gel 




Figure 3.18 LabChip GX platform 
Representative images from LabChipGX Touch imaging platform of IL23 loci. 3C from 
SSZ treated RA patient. A) 1kb+ DNA ladder highlighting a band at 171bp. B) Peaks 
highlighting the lower (LM) and upper (UM) of the 1kb+ ladder and band at 171bp.  
 
 
3.2.4 Understanding the stability of the MTX CCS 
 
Having determined that it was not possible to translate the assay into a qPCR-
based platform, I decided to go back to the nested PCR-based assay and 
evaluate the stability of the MTX CCS signature over time. To achieve this, 
baseline and 6 month samples from the original SERA cohort (R and NR groups 
used to discover the MTX signature) were used. It is important to note that 
patients in the R group at 6 months had reduced clinical disease activity index 
(CDAI) scores compared to baseline. All R had CDAI of less than 7.7, meaning all 
had low disease activity (LDA) or were in remission (Figure 3.19). NR had little or 
no improvement in CDAI scores by 6 months. All samples were investigated to 
find the presence or absence of each of the 5 loops of the MTX CCS at 6 months. 
Across all 5 loci, there were several samples that had a loop at both time points 
(labelled stable), a number that had no loop at baseline and one at 6 months, 
and another group that had a loop at baseline, but no loop at 6 months. These 
three categories of loop dynamics were present in both R and NR. The genomic 
locations with the most stable loops were IL17A NR, with 21 patients (72.4%) 
having loops present at both time points (Figure 3.19C). The least stable loop 
was IL21R from R, with 3 patients (10.7%) having loops at 6 months who had 
them at baseline (Figure 3.19E). 13.8% of NR had the CXCL13 loop still present at 
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6 months (Figure 3.19D). 35.7% and 46.4% of R had IL23 (Figure 3.19F) and 
IFNAR1 loops present at 6 months, respectively (Figure 3.19G). 
 
 
Figure 3.19 MTX CCS stability at 6 months 
Analysis of presence of MTX CCS loops at 6 months in MTX R and NR from SERA cohort. 
A) CDAI of R at baseline (BL) and 6 months (6m), N=28. B) CDAI of NR at BL and 6m, 
N=29. C) Loop status of IL17A loop at BL and 6m. D) Loop status of CXCL13 loop at BL 
and 6m. E) Loop status of IL21R loop at BL and 6m. F) Loop status of IL23 loop at BL and 
6m. G) Loop status of IFNAR1 loop at BL and 6m. R shown in green and NR shown in red.  
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6m, 6 months; BL, baseline; CDAI, clinical disease activity index; m, month;  





Statistical tests were carried out on this data to gain further insight into the 
stability of the MTX CCS. The Boschloo independence tests were employed to 
measure the change in the signature at both time points for both groups, as well 
as measure the ability to stratify the two groups at each time point. This test 
was chosen based on the sample number available. The score of 0.48 for IL17A 
showed that is the only loop in R to not significantly change between baseline 
and 6 months, i.e., partly stable. In NR, IL17A, CXCL13 and IL21R significantly 
changed between time points (Figure 3.20A). The score of 1 for IL23 suggested 
the loop does not change between time points and suggests stability of that loop 
in NR. With a score of 0.69 in IFNAR1, the loop in NR could be considered partly 
stable. The test of how the CCS could stratify between R and NR to MTX at both 
time points confirmed, at baseline only, all loci of the signature could 
successfully stratify, with significant scores of 0.1 and below for all gene loops 
(Figure 3.20B). This was expected as it was based on the original MTX CCS study 
data and illustrates the 5 loci required for the signature. At 6 months, the score 
of 1 for IL17A suggests the loss of significant stratification ability to differentiate 
MTX R and NR for that loop. Other scores ranging from 0.19 to 0.76 implies 
limited stratification ability for the 4 remaining CCS loops at 6 months. 
Ultimately the data showed that the signature is not stable and would only be 




Figure 3.20 Statistical analysis for identification of stable markers and markers with 
stable stratification ability  
Analysis conducted by Ewan Hunter (OBD). Boschloo independence test carried out using 
binary data from MTX 6m stability analysis at baseline (BL) and 6 months (6m). Green 
for significant, red for insignificant and black for limited significance. A) Test analysing 
difference between time points, significant ≤0.4. B) Test analysing difference 
stratification ability of R and at BL and 6m, significant ≤ 0.1.  




With the results indicating a largely instable CCS, an initial investigation was 
carried out using clinical scores to determine whether disease severity played a 
role in this variability between time points. As such, the correlation between CDAI 
(Figure 3.21) and DAS28 (Figure 3.22) scores with number of stable loops was 
examined. The results showed no clear correlation between chromatin stability 
and disease activity state. The numbers of stable loops are similar between R and 
NR. Furthermore, individual patient scores are widely distributed within each 
stable loop category, from as low as CDAI 10 to 49.5 (Figure 3.21C). This showed 






Figure 3.21 CDAI Correlation with Loop Stability 
The CDAI scores for each patient sample at BL and 6m was plotted against the no of 
stable loops. A) baseline CDAI in R. B) 6m CDAI in R. C) baseline CDAI in NR. D) 6m CDAI 
in NR. The linear regression of the data was plotted. R, N=27, NR, N=28.  
6m, 6 months; CDAI, clinical disease activity index 
 
 
Figure 3.22 DAS28 correlation with loop stability  
The DAS28 scores for each patient sample at BL and 6m was plotted against the no. of 
stable loops. A) Baseline DAS28 ESR in R, N=18. B) 6m DAS28 ESR in R N=17. C) Baseline 
DAS28 ESR in NR, N=18. D) 6m DAS28 ESR in NR, N=18. E) Baseline DAS28 CRP in R, N=27. 
F) 6m DAS28 CRP in R, N= 27. G) baseline DAS28 CRP in NR, N=27. H) 6m DAS28 CRP in 
NR, N=28. The linear regression of the data was plotted.  
CDAI, clinical disease activity index; CRP, C-reactive protein;  
DAS, disease activity score; ESR, erythrocyte sedimentation rate 
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3.2.5 Ability of the MTX CCS to predict response csDMARD 
treatment 
 
While a biomarker for MTX is beneficial, there would be value in identifying if 
the MTX CCS biomarker could predict response to baseline treatment, regardless 
of which csDMARD or csDMARDs were given to a patient. We wanted to assess 
whether the MTX CCS 5-loop signature for MTX would be applicable for 
determining response to patients treated with a combination of csDMARD 
treatment.  
 
To evaluate the suitability of this, the disease activity at baseline, 6 months and 
12 months was assessed in the SERA cohort. Patients were assigned a R or NR 
status based on the disease activity scores at 6 months and 12 months (Figure 
3.23). To differ from the cohort used previously, patients were identified that 
had been treated with HCQ or SSZ, which may have been in addition to MTX. 35 
patients treated with HCQ or SSZ, with or without MTX, were selected that had 
strong R or NR status (Table 3.3). A strong status was defined as a R remaining in 
remission or low disease activity at 12-months, or a NR with a high disease 
activity score at that time point. Patient baseline demographics revealed a 
similar profile between groups (Table 3.4 and 3.5). The presence/absence of 
MTX CCS loops was assessed in patients from these groups.  
  
Table 3.3 Chosen SERA Patient Treatment Assignment 
csDMARDs received in first 12 months of treatment 






Figure 3.23 Disease activity in responders and non-responders to HCQ and SSZ  
CDAI scores at baseline and 6 months (shown on left and right within each responder 
type, respectively) in SERA patients treated with HCQ or SSZ with or without MTX. CDAI 
represented as individual scores. A) R (N=9) and NR (N=12) to HCQ. B) R (N=11) and NR 
(N=8) to SSZ. T test to compare CDAI between time points, *P< 0.05.  
CDAI, clinical disease activity index; HCQ, hydroxychloroquine; NR, non-responder; 
R, responder; SSZ, sulphasalzine 
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Table 3.4 HCQ +/- MTX-treated Patient Demographics  
 
 




3C analysis was used to examine the presence of loops belonging to the MTX 
signature in HCQ and SSZ (with or without MTX) treated patients at baseline. 
Patients had a variety of loop combinations, however there was no clear 
difference between R or NR in most treatment subgroups (Figure 3.24). 
Monotherapy HCQ was the only treatment subgroup that showed a 
differentiation in signature loci between R and NR (Figure 3.24A). However, this 
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was also the smallest treatment group, and not large enough for robust 
interpretation. Loops were only present at IL17A, CXCL13 and IL23 loci. There 
were no loops detected at IL21R and IFNAR1 loci in any response group which 
meant these loci always clustered together within the heat map. The MTX CCS 
NR signature was observed 5 times (Figure 3.24B, C), but was only once observed 
in a patient with a clinical NR status (Figure 3.24C). The HCQ combination 
therapy group had most variation in loop presence of all subgroups, but no clear 
differentiation between R and NR could be observed. All subgroups were very 
low in number, therefore solid conclusions cannot be drawn from the data.  
 
 
Figure 3.24 Heat map of MTX CCS loop presence in R and NR 
3C carried out on baseline samples from patients treated with HCQ or SSZ, with or 
without MTX. Heat map indicating binary presence or absence of 5 MTX CCS loci loops. 
A) Patients treated with monotherapy HCQ. B) Patients treated with combination HCQ + 
MTX. C) Patients treated with monotherapy SSZ. D) Patients treated with combination 
SSZ +MTX. Blue = loop, Red = no loop. Yellow box indicates NR signature in a clinical 
response, green box indicates NR signature in clinical NR  
NR, non-responder; R, responder 
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Based on the MTX signature, HCQ and SSZ +/- MTX treated patients were 
assigned a predicted response. The correct response status was only assigned in 
1 patient (Figure 3.25B). This patient received monotherapy. Several patients, 
also monotherapy SSZ-treated, had a NR signature present, but were clinically 
responders to therapy. The remaining patients had a combination of loops out-
with the MTX signature conformation and therefore their response could not be 
predicted. These values were used to employ ROC analysis to determine 
specificity and sensitivity of the signature in this group. The ROC curve for HCQ 
monotherapy treated patients had a sensitivity of 50% and a specificity of 33.3% 
(Figure 3.26A) and combination treated ROC curve had a sensitivity of 33.3% and 
a specificity of 50%. ROC analysis of monotherapy SSZ treated patients revealed 
a sensitivity of 0% and a specificity of 25% (Figure 3.26D). Combination treated 
SSZ patients had sensitivity of 0% and specificity of 100%. The highest accuracy 
value was 50%, which confirms that there is no predictive potential for the MTX 




Figure 3.25 Binary classifier and ROC curve analysis of MTX signature for csDMARD 
response prediction 
Assessment of the predictive ability of the MTX CCS to stratify HCQ and SSZ +/- MTX 
treated patients. Classifier of observed and predicted response status for A) 
Monotherapy HCQ and B) SSZ + MTX. C) Monotherapy SSZ. D) SSZ + MTX. E) ROC curve 
for monotherapy HCQ. F) ROC curve for HCQ + SSZ. G) ROC curve for monotherapy SSZ. 
H) ROX curve for SSZ and MTX. ROC curves generated using web-based calculator which 
utilises JROCFIT program.  
 
 
To understand why the CCS could successfully predict response in only 1 patient, 
and other patients had a mostly undefined signature, demographic and disease 
activity was measured in each category (Figure 3.26). The patients were split 
into 4 categories: 1) responders who were predicted to be non-responders (R-NR, 
2) non-responder predicted to be non-responder (NR-NR), 3) responders who 
could not be given a prediction response (R-un-defined (UD) and 4) non-
responders that could not be given a prediction (NR-UD). The NR that had the NR 
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signature had an age within the range of ages in the other 3 categories of 
patients. Unlike the other 3 categories, the successfully predicted NR was 
neither a current smoker, or had an ex-smoker status. In the other categories, 
there was at least 1 current smoker and ex-smoker. The alcohol intake in the NR 
was within the range of the other categories. When considering the baseline 
disease activity of the NR, it was within the CDAI and DAS28 CRP upper range 
with the other categories. The CDAI and DAS28 CRP of the NR were 39.1 ad 5.7 
respectively. The other interesting group to consider was the 4 R who had the 
NR signature. While the prediction was wrong, the MTX CCS was present. This R 
group had the largest age range from a minimum of 28 to a maximum of 88. The 
number of current smokers was the same as the R-UD group and ex-smoker 
number half of the UD groups. Alcohol intake, CDAI and DAS28 CRP scores were 
in similar range with the UD groups. As already discussed, the sample number for 
this part of the stud were very low and higher numbers in every subgroup would 




Figure 3.26 Demography and disease activity relationship with csDMARDs response 
prediction 
BL demographic factors and disease activity was measured in all HCQ/SSZ +/- MTX-
treated patients. A) Age. B) Number of patients who currently smoke. C) Number of 
patients who smoked previously. D) Units of alcohol consumed weekly. E) CDAI at BL. F) 
DAS28CRP at BL. 
CDAI, clinical disease activity index; CRP, C-reactive protein; NR, non-responder;  
R, responder; UD, undefined 
 
 
As well as exploring the relationship between demographic factors and the 
ability of the MTX CCS to predict response correctly, it was important to 
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understand if mono or combination therapy had an influence. Most patients with 
the presence of the MTX NR signature were SSZ monotherapy treated. There was 
1 patient in this group that was treated with a combination of HCQ and MTX 
(Figure 2.27). The R and NR group that had an UD signature had a combination of 
the 4 treatment options of monotherapy HCQ or SSZ, or combination therapy 
with MTX. 35.7% of R with the UD signature had most patients treated with the 
HCQ and MTX combination. 26.6% had combination SSZ and MTX, followed by 
21.4% with monotherapy SSZ and 14.3% with HCQ. 31% of NR with UD signature 
were monotherapy HCQ treated. The remaining 3 combinations made up 23% 
each of this group. R with UD signature had over 60% using combination therapy, 
however the R with NR signature have 75% on monotherapy. Overall, most 
patients that had loci in a conformation from the MTX CCS were monotherapy 
treated. This could be expected as the signature was developed in a 





Figure 3.27 Relationship of mono and combination therapy with csDMARD response 
prediction  
BL treatment was recorded and split into 4 groups: HCQ monotherapy, SSZ 
monotherapy, HCQ+MTX combination therapy and SSZ+MTX combination therapy. R 
predicted to be NR = R-NR, NR correctly predicted as NR=NR-NR, R without prediction= 
R-UD, NR without prediction = NR-UD 
HCQ, hydroxychloroquine; MTX, methotrexate; NR, non-responder; R, responder;  
SSZ, sulphsalazine; UD, undefined 
 
 
3.2.6 Validation of MTX CCS in new clinical cohort 
 
With a robust PCR protocol established for assessing the 3C epigenome in RA 
patients, the decision was made to validate the MTX CCS in another RA cohort. A 
group of early RA samples from the Towards A Cure for Early Rheumatoid 
Arthritis (TACERA) cohort were selected based on the assignment of 
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monotherapy MTX at baseline. The TACERA cohort replicates the SERA cohort 
based on collection of samples from early RA patients who were treatment naïve 
at baseline. Peripheral blood samples were retrieved from these patients. At 
selection for our study, patient characteristic information was not retrieved as it 
was to be conducted blinded. Nested PCR was carried out at OBD and statistical 
analysis was used to understand if the MTX CCS could predict MTX response in an 
independent clinical cohort. 2 models were used to assess the predictive ability 
and plots can be used to visualise the loops in the CCS with the best predictive 
potential (Figure 3.28). These models have been developed since the discovery 
of the MTX CCS and are sophisticated, boosted machine learning models. 
Compared to the Weka model used to develop the original MTX CCS, the newer 
models are better at classification. The other advantage is the ability to see use 
these models directly in R Studio, as opposed to using externally with the Weka 
model. Weka could be used within R, but functionality is limited. Dilutions of 
primers to detect each loop were also used to help assess the influence of each 
loop on the model. The plot for one of the models, named XGBoost, shows 
SHapley Additive exPlanations (SHAP) scores which best represent results from 
tree-based algorithms. The plot shown highlights that IL17A provided the most 
stratification potential to the model with a score of 0.705 (Figure 3.28). Many 
patient samples with a low abundance of this loop had good prediction of a 
producing a negative in the model, and another group of patient samples with a 
high abundance of this loop contributed to a positive predictive score. Overall, 
this contributes to the highest ranking of this loop in the model. IL21R did not 
add any value to the model with all dilutions of the sample producing a score of 
zero. The plot indicates that most dilutions over 2-fold did not add anything to 




Figure 3.28 Identification of MTX CCS Loops that add value to Model in New RA 
Cohort  
Data from XGBoost training model to plot contribution of each MTX CCS to new 
prediction model using the SHapley Additive exPlanations (SHAP) values. Each dot 
represents patient sample. Positive and negative values on x-axis indicate whether the 
loop is associated with a positive or negative prediction. Colour indicates whether loop 
abundance is high or low. Loops are ranked from top to bottom (from best to worst), 
based on the contribution to model. EpiSwitchTM loop detecting primers diluted used 
neat, or diluted 2, 4 or 8 fold; ‘_1’, neat; ‘_2’, 2-fold; ‘_4’, 4 fold; ‘_8’ 8 fold.  
 
 
2 training models were built using 2 methods, XGBoost and Light GBM (Figure 
3.29). For the purposes of prediction, these patients had to be unblinded. The 
first model, XGBoost, identified 20 R successfully and 15 NR successfully (Figure 
3.29A). 9 NR were incorrectly identified as R, and 3 R wrongly assigned a NR 
status. With the Light GBM model, 12 R were correctly identified and 20 NR 
successfully identified (Figure 3.29B). 11 NR were predicted to be a R and 6 R 
predicted to be NR. The XGBoost model revealed a sensitivity of 0.833 and 
specificity of 0.69 (Figure 3.29C). The Light GBM model revealed a sensitivity of 
0.62 and specificity of 0.67 (Figure 3.29D). The XGboost model had 74.5% [95% CI 






Figure 3.29 Binary classifier and ROC curve analysis of Training Models of MTX CCS 
for MTX Response prediction 
Assessment of the predictive ability of the training models on 47 RA patients. Classifier 
of observed and predicted response status for A) XGBoost model and B) Light GBM model 
C) ROC curve for XGBoost. D) ROC curve for LightGBM. ROC curves generated using web-
based calculator which utilises JROCFIT program. 
 
Once the training sets had been generated, they were tested on 23 blinded 
patients (Figure 3.30). The XGBoost identified 6 R successfully and 8 NR 
successfully (Figure 3.30A). 5 NR were incorrectly identified as R, and 4 R 
wrongly assigned a NR status. With the Light GBM model, 7 R were correctly 
identified and 8 NR successfully identified (Figure 3.30B). 4 NR were predicted 
to be R and 4 R predicted to be NR. The XGBoost model revealed a sensitivity of 
0.62 and specificity of 0.6 (Figure 3.30C). The Light GBM model revealed a 
sensitivity of 0.67 and specificity of 0.64 (Figure 3.30D). The XGBoost model had 
65.2% [95% CI (0.39, 0.8)] accuracy and the Light GBM an accuracy of 63.8% [95% 
CI (0.49, 0.77)]. Overall, I can’t conclusively say that the signature was 
successfully validated in another cohort. There is some evidence that some loci 
hold their predictive capacity, but ultimately, the signature was not validated. 
Based on the recognition of the models used and their predictive power, 
evidence suggests that the signature should be improved, as the sophistication of 
the models used would have likely extracted the results of stratification if it was 





Figure 3.30 Binary classifier and ROC curve analysis of testing models of MTX CCS for 
MTX Response Prediction 
Assessment of the predictive ability of the testing models on 23 blinded RA patients. 
Classifier of observed and predicted response status for A) XGBoost model and B) Light 
GBM model C) ROC curve for XGBoost. D) ROC curve for LightGBM. ROC curves 







The discovery that chromosome conformation signatures had the ability to 
successfully predict MTX response in treatment naive RA patients at baseline was 
a promising finding, but validation was needed. The work in this chapter 
explores the validation of this biomarker using bioinformatics techniques and 
experimentally using an independent clinical cohort. It also explores the 
transition of the 3C technique from OBD to the lab in house and the attempt to 
transition to alternative protocols. Further measurements to define the 
stratification potential by measuring stability of the MTX CCS at 6 months, and 
ability to predict response to treatment, regardless of csDMARD(s) assigned at 
baseline was also explored. 
 
The first step in the in-silico validation process was to assess the quality of the 
data. It is recognised that pre-processing and appropriate normalisation steps 
are crucial to produce robust results that lead to reliable biological 
interpretation273. Limma was chosen as the software to validate the results due 
to its features to analyse data quality and normalisation, and for its linear 
modelling potential. Multiple studies have demonstrated that dye bias exists in 
dual colour microarray experiments, so this was one of the first steps to assess 
quality in our dataset274. This dye bias can contribute to the inaccurate 
interpretation of the expression intensities of the material being measured. 
There is debate in the literature about the methods that should be used to 
combat dye bias. Some researchers believe that dye swaps should be used, 
however, others believe that it is not essential, and the latter was the approach 
in this study274,275. The red-green dye densities shown did not highlight any 
arrays with a dye bias and the distribution of both colours was comparable 
(Figure 3.1A). MA plots were also used to visualise the red-green intensity log 
ratio (M) and mean signal intensities of each of spot on the array (A). With our 
dataset, it was assumed that most loops captured on the array were unlikely to 
change, meaning the plots should have most spots centred around the middle 0 
line. The results in Figure 3.1C show a curved line, highlighting that pre-
normalisation, there were more spots than expected with a positive or negative 
fold change representing loop abundance. There was also substantial variability 
at the low intensities, shown by the V shape on the left side to the middle of the 
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plot. This shape of plot has been shown in the literature273 and suggests a low 
intensity bias for large fold changes. Despite the indication that there may be 
some bias at certain intensities for large fold changes, this analysis highlights 
that the most loops do not change between samples, but that there were enough 
to warrant further investigation.  
 
After this first visualisation step of the array parameters, normalisation of the 
data was required. Loess normalisation is considered an appropriate 
normalisation approach for datasets where most measured elements are unlikely 
to change. Loess normalisation successfully reduced variability between the dyes 
in each array, indicated by more uniform histogram distributions (Figure 3.1B). 
In the MA plots (Figure 3.1D), it is evident that Loess normalisation reduces the 
curvature of the middle of the plot, highlighting the reduction in the number of 
loops with differential fold change. The last QC assessment shown is the boxplot 
(Figure 3.1E). This represents normalisation of signal intensities across 8 the 
arrays, and similar to other plots, indicated normalisation was successful and 
there were no problematic arrays that should be removed from the analysis.  
 
The second stage of the validation process was to confirm the stratification 
potential of the MTX CCS loci. Analysis confirmed the potential for stratification 
using the MTX CCS loops. Contrast models in Limma, contrasting NR and R 
revealed the association of IL17A and CXCL13 with NR and IL21R, IL23 and 
INFAR1 with R, as is present in the signature (Figure 3.2A). Next, the 5 loci had 
to be tested on a set of patient samples. Using a Random Forest classification 
method, the model revealed an accuracy of 87%, shown visually with a ROC 
curve, which can be considered in alignment with the original model. Overall 
these tests indicated that the signature could be validated and there was a basis 
to explore this signature further throughout this study.  
 
The first stage in establishing that I could carry out the 3C independently was to 
obtain samples to work with. These samples were generated from healthy BC 
donors. A purity check was carried out to ensure successful isolation of the 
intended cell type (Figure 3.3). These checks illustrated that the isolation was 
effective. The population of CD4+ T cells were within the expected range of 20-
60% of the total PBMC population276.  
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The generation of the first 3C libraries using these cells was successful, as 
demonstrated by the Quant-iT PicoGreen method of DNA quantification (Figure 
3.4). After measuring the first samples using the PicoGreen assay, it was 
considered that there may be a higher-throughput method of quantification for 
the 3C libraries, which would be more suited to the number of samples in our 
study. The Qubit platform has been shown to be a reliable method of choice to 
calculate DNA concentration when carrying out next-generation sequencing 
(NGS) or microarray methods277. Compared to other DNA quantification methods, 
the Qubit is rapid, precise and sensitive278. As such, this was the alternative 
method to PicoGreen that was chosen. A direct comparison was carried out 
between PicoGreen and the Qubit dsDNA HS assay (Figure 3.5). The results 
revealed a statistically significant difference in the yield of DNA measured. This 
experiment was repeated and there continued to be a disparity in results 
between the two quantification methods, with the Qubit consistently calculating 
lower concentrations. Exploration of these methods has also been shown in the 
literature279. Like the results described, the Qubit measured lower DNA yields 
than an alternative method, specifically, the Taqman RNAse assay. This could be 
considered surprising as the Qubit should capture all dsDNA. However, since the 
Qubit only measures dsDNA and not any single stranded (ssDNA) or other 
contaminants which may be present in the sample, that could be a contributor 
to the disparity in this example. Interrogation of the data showed that the Qubit 
results were the most consistent over the 3 experiments. These results, coupled 
with the reliability of this assay in the literature meant the Qubit was the 
method chosen to continue the study with. Moreover, the Qubit system has 
various kits that can be tailored to the yield of DNA expected from a sample, 
which could be useful in the future278.   
 
Another essential check that had to be carried out was nested PCR and gel 
electrophoresis using the control primers for EpiSwitchTM 3C before future work 
could commence. Figure 3.6 illustrates these results and highlights that the 
control primers perform as expected. MMP1 4/12 and MMP1 9/12 are positive 3C 
controls as there is a stable copy number in normal blood. Both controls were 
consistently present at the expected size. The primers designed to capture the 
loops in the MTX signature were also tested in healthy BC before being used on 
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patient samples (Figure 3.7 and Figure 3.8). This employed a semi-quantitative 
method, which was used in the seminal 3C paper by Dekker et al. The analysis of 
gel electrophoresis from healthy donors displayed a wide variation between 
samples. The higher copy number of loops in the IL21R and IL23 loci compared to 
the other 3 loci was interesting. It could suggest that these genes are more 
active genes in the general population or could mean the alternative if the 
looping of the gene causes inactivation. Until the function of the loops within 
the signature is investigated, it cannot be fully understood why there are a 
higher number of loops at these loci in healthy donors over IL17A and CXCL13. 
There is the likelihood that absence of loops in these loci could mean that IL17A 
and CXCL13 are more associated with disease phenotype and pathogenesis 
compared to the other genes in the signature. Marwa et al have suggested a 
polymorphism in IL17A has been associated with response to MTX280. As our 
signature has the predictive power in only RA patients, it is not unsurprising that 
the healthy donors used for the 3C assays thus far would have a low number of 
individuals presenting with loops in our genomic regions of interest. It should be 
noted that the results shown are from a limited number of healthy donors 
therefore it is difficult to draw conclusions from this data. In summary, the 
results presented thus far demonstrate that I was able to successfully execute 
the 3C assay and analysis using patient samples from the SERA biobank could 
commence. 
 
In my hands, I considered whether we could transition to a high-throughput 
method of biomarker detection. Work in this chapter details the attempt to 
optimise a qPCR assay for this purpose. This aligned with the work being carried 
out at OBD, as they were translating other signatures to the higher throughput 
qPCR platform. qPCR has been described widely in the literature, but it is 
recognised that there are challenges in achieving a robust assay for 3C 
templates. A high DNA template concentration and primer-dimers can result in 
non-specific fluorescence281. As such, it was important that the MIQE guidelines 
were followed which state the minimum requirements for publication of PCR 
results272. qPCR MMP control primers were obtained from OBD and tested in RA 
patient samples (Figure 3.10). The results for qPCR with the MMP primer 
indicated that generally there is a low level of 3C template, indicated by the 
high Ct value. This has been consistently shown with work since carried out at 
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OBD where the MMP positive control primer has a low Ct value indicating very 
low DNA template. (Figure 3.31). This gave an indication of what could be 
expected from the MTX CCS loci.  
 
Figure 3.31 qPCR Positive Control Analysis 
Concentration of DNA of 3C products using positive 3C controls from recent qPCR 
microarray data generated at OBD. Data is shown as box and whisker plot showing the 
median and standard deviation, N=1.  
 
 
One of the first stages in the optimisation process was primer design. 3C regions 
are non-germline and low complexity which makes them prone to hairpin loops 
and primer dimers, therefore making primer design challenging. A low 
complexity sequence will reduce the primers discriminatory power on the 
sequence of interest and result in nonspecific binding282,283. This challenge is 
reflected in the results shown in this chapter. To be taken forward, primers had 
to demonstrate evidence of efficiency and specificity. Efficiency was measured 
by temperature gradient qPCR, with the aim of identifying the optimal 
temperature that a single product could be amplified. Specificity is shown by the 
existence of a single product, which can be evidenced through the melt curve 
and gel electrophoresis analysis. Three separate primer sets were tested for all 5 
loci from the MTX signature, and results indicated that most primer sets were 
marginally improved on the set before, i.e. A better than B, and B better than C. 
This can be seen from primer set A having the most amplification of negative 
controls and primer set C, designed last, having the least amplification of 
negative controls. However, this was not the case for IL21R. Moreover, it was 
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evident that primers for CXCL13 were not efficient or specific with any set 
(Figure 3.12). The three primer sets tested were unable to amplify the patient 
product of interest at most annealing temperatures. Any occurrence of the loop 
of interest was accompanied by amplification of negative controls. In general, 
the lower the annealing temperature, the lower the Ct of the patient loop of 
interest. However, it is at temperatures of 66.4°C and above that appear to be 
most optimal to amplify only the patient loop of interest without negative 
controls. Based on analysis of the Ct values, primer set C for IL17A and IL23 
appeared good candidates for 3C qPCR (Figure 3.11 and Figure 3.14). However, 
when gel electrophoresis was carried out on the qPCR products, a band could not 
be found at the temperatures that resulted in single product amplification. 
Manual gel loading could be considered a reason for this. Additionally, gel and 
melt curve analysis taken together suggest the presence of non-specific 
amplification. The mean Ct values for IL21R and IFNAR1 suggest that no primer 
set was suitable for amplifying the patient loop of interest. However, limited 
individual experiments provided evidence that the primers may be good 
candidates for 3C qPCR. 68°C was an optimal temperature for primer set B and C 
to amplify the patient IL21R loop of interest without amplification of negative 
controls. For primer set B, the qPCR product of interest did not appear at the 
expected size, however it did appear at the expected size for primer set C. The 
optimal annealing temperatures for amplification of only the IFNAR1 loop were 
66.4°C and 64.4°C. This only occurred with primer set B, and this was in 
conjunction with a gel band at the expected size. Based on the limited primer 
success there were several candidates that were chosen for sequencing: IL21R 
version C and IFNAR1 version B. 
 
Sequencing was used to confirm if the amplified qPCR product was correct. The 
known sequence of the ligated 3C product with the characteristic TCGA 
sequence in the centre was used as the reference. This, combined with the 
predicted product size based on the specific primer design facilitated this 
prediction. In order to send a qPCR product for sequencing, the band from gel 
electrophoresis had to be purified and the yield of DNA established. As 
documented in Figure 3.16, this process required optimisation as the original 
protocol yielded only 0.88ng/µl which was not sufficient for sequencing 
protocols. The first attempt to improve the yield added additional incubation 
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steps to the protocol. The kit used for this purification is based on the 
centrifugal filtration method. This method has been shown to have a normal 
recovery rate of between 60%284. This was chosen as the first factor to modify, 
based on evidence from the literature that states increased incubation 
temperature or incubation time could improve yield in cross-linked DNA285. This 
proved unsuccessful, yielding less DNA than the first attempt. A possible cause 
could be degradation of the DNA. Alternatively, since the sizes of DNA fragments 
are not considerably large, this alteration of the protocol may not have had 
much influence. The third attempt to increase the DNA yield comprised of 
additional incubation steps in addition to elution in heated buffer with the aim 
that this would allow more DNA to be released from the membrane. This 
optimisation step resulted in a statistically significant increase in DNA yield from 
the first attempt (Figure 3.16) and provided sufficient DNA concentrations to 
facilitate sequencing steps. 
 
As discussed, the first product sent for sequencing was a product from an IFNAR1 
reaction; annealing temperature 62°C. This resulted in sequencing that was low 
quality and had a very low alignment with the known IFNAR1 loop sequence 
based on only a small number bases of the known sequence aligning with the 
sequencing product (Figure 3.17). This meant optimisation was required to 
ensure a good quality DNA product was sent for sequencing. Cloning of the gel-
purified qPCR product was chosen as a method of increasing DNA quality. This 
would allow amplification of only the single qPCR product. After cloning, a 
restriction digest was conducted to cleave the cloned qPCR product. The results 
from the first cloning attempt did not yield the product with restriction digest 
(Figure 3.17D). This revealed that optimisation of the cloning protocol would be 
necessary. The addition of a PolyA tail to the qPCR product was not enough, and 
an optimised ligation ratio to facilitate increased chance of clone insert was 
needed. With the protocol optimised, another qPCR product was sent for 
sequencing. Despite the quality improvement on the first sequencing attempt, 
the alignment with the loop sequence was too low. The resulting high quality 
product, with similarly low alignment to the first sequencing attempt which 
suggested the primers were not amplifying the correct product.  
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Combined, the data generated suggested that the translation of this assay to a 
qPCR-based platform was not easily achievable. This could be due to a multitude 
of reasons, but it is conceivable that the qPCR assay could be less sensitive due 
to low ligation frequency in 3C loops in our signature of interest. As mentioned 
above, 3C ligated sequences produce low-complexity templates, and it has been 
documented that in some circumstances, low complexity sequences are 
excluded from primer design processes286. Furthermore, these low-complexity 
templates have been explored and shown to contribute to the formation of 
pathological ribonucleoprotein assemblies287. Taken together, this evidence 
illustrates the challenge of designing qPCR primers for these loop regions and 
why it is plausible that optimisation would be ineffective. However, with the 
addition of a more easily interpreted, high-throughput gel electrophoresis 
technology (Figure 3.18), I was confident that I could move forward with nested 
PCR.  
 
We also wanted to understand if the biomarker was stable after 6 months on 
treatment. The literature describes chromosome conformation as both stable 
and dynamic185, so it was important to establish chromatin dynamics in the 
context of RA. Establishing the time frame within which this biomarker can 
successfully stratify R and NR to MTX is of great importance. It has been 
recognised that the timing of biomarker detection is critical and that plasticity 
of the epigenome is a complex factor to consider in such studies288,289. If the 
biomarker is to measure disease progression, biomarkers that fluctuate with 
disease progression is desirable, as demonstrated by Selaas et al290. They found 
that IL-6 and VEGF-A could be promising candidate disease biomarkers due to 
their reduction over the disease course. However, as the MTX CCS has the aim of 
establishing treatment response, and MTX can be given at any time throughout 
the RA treatment regimen, stability would be considered beneficial. Results 
illustrated that the signature was not stable in the majority of the patients. All 5 
loops from the signature, had variability between time points in both R and NR. 
The loop dynamics came in the form of loops being lost and gained over the 6 
months on treatment. It is highly plausible that MTX treatment can influence the 
structural epigenome. Studies of the transmembrane receptor tyrosine kinase, 
HER2, have illustrated the influence of treatment on the epigenetic landscape. 
In two breast cancer cell lines, there was genome-wide reprogramming of HER2 
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binding sites after treatment with the growth factor EGF291. Molecular changes 
caused by treatment have also been shown in RA studies. A study by Tasaki et al 
investigated the levels of multiple serum proteome signatures associated with 
RA, such as serum CRP and ESR over time. They found that treatment with 
Infliximab and Tocilizumab reduced proteome signatures, as did MTX to a lesser 
extent292. While this study did not monitor the molecular features of the MTX 
signature, it does highlight the ability of MTX to modify other markers and 
highlights that loops would be likely to alter conformation as a result of 
treatment. The Boschloo test was used to statistically test the degree of change 
in the signature loops between baseline and 6 months in each responder group. 
Only IL23 was considered statistically stable as the confirmation in most patients 
remained the same at both time points. Boschloo independence tests were also 
used to determine the predictive ability of differentiating R and NR to MTX at 6 
months (Figure 3.20B). The tests clearly confirmed the ability of the signature to 
differentiate between R and NR at baseline, as expected, but by 6 months this 
capability is lost. It must be considered how the underlying disease has changed 
in this time, and may be the reason why the signature no longer has predicative 
capacity.  
 
To try and understand if there was a relationship between the stability of the 
biomarker, and demographic factors, correlations were carried out between 
CDAI and DAS28 scores and the number of stable loops (Figure 3.21 and 3.22). 
There was a minimal positive correlation between CDAI at baseline and the 
number of stable loops. Those with a lower CDAI at baseline have marginally 
lower chance of having more stable loops. This relationship is also observed with 
DAS28 ESR and CRP scores at baseline in R (Figure 3.22A and E). In all NR, there 
is the indication that there is a negative correlation that exists between 
increased disease activity and number of stable loops. However, collectively, the 
results suggest there is no relationship between disease activity and the number 
of loops in the signature that are present at both time points. Several R had all 5 
loops in the MTX CCS at baseline and 6 months, whereas there were no NR with 
all 5 loops present at both time points. This may allude to a stable epigenetic 
set point that facilities a good response to MTX. However, the distribution of 
stable loop number is otherwise similar between these 2 groups. Due to the lack 
of interim time point to test the presence of the biomarker loops in all patients 
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we are unable to conclude if the chromatin loops change immediately after 
treatment, or at some point in between. Many studies in the field of oncology 
have illustrated the ability of drug treatment to alter chromatin architecture. 
Using histone modification enzymes, Gerrard et al illustrated that structural 
epigenome changes occurred within days of drug treatment293. Based on those 
findings, it would be reasonable to consider an earlier time point after MTX 
administration to test the presence of MTX CCS loops. 
 
Another important question to explore for the MTX CCS was the ability to use it 
to predict response to csDMARD treatment as a whole. The results demonstrated 
that the signature was not able to predict response to treatment, whether it be 
monotherapy or combination therapy. The results shown in Figure 3.24 
illustrated that there was no difference in signature loci conformation between 
R and NR. Only monotherapy HCQ showed a clear differentiation between R and 
NR based on loop confirmation. However, 5 patients is not enough to draw a 
robust conclusion. Moreover, in the HCQ +/- MTX R group, there was a marked 
age difference between patients receiving monotherapy and those receiving 
combination therapy. Specifically, monotherapy patients had an average age of 
47, and combination therapy patients, an average of age 70. Due to the low 
numbers of patients already in each responder, and therapy, subgroup, 
unfortunately, the groups could not be stratified further to account for age. This 
is something that should be considered in the future, and enough samples should 
be obtained to ensure subgroups are comparable in age, or numbers are 
sufficient to stratify by age group. In contrast to the MTX signature that groups 
IL17A and CXCL13 together, and IL21R, IL23 and IFNAR1 together, all heat maps 
appear to group IL23 with IL17A and CXCL13. However, a new signature involving 
these new groupings would not be possible, as this grouping is the same in R and 
NR.  
 
Based on the binary results, a predicted response type was assigned to each 
patient. The results shown in Figure 3.25 show that most predictions could not 
be made and were labelled undefined (UD). No patient sample had an R 
signature, but 5 patients in total had an NR signature. However, of those, only 1 
patient was a clinical NR. The ROC analysis conducted from this data highlighted 
the specificity and sensitivity of the signature in these patients. All ROC analyses 
	 153	
had poor sensitivity and specificity results. The predictive ability of the MTX CCS 
for these combination of therapies is poor, at no more than 50% accuracy. This is 
greatly reduced from the predicative capacity of the CCS for MTX R and NR of 
87% and 90%. The findings of the monotherapy HCQ group highlight, on a small 
scale, the importance of a large patient group for biomarker testing. Recent CCS 
discovery studies have used 74, 59 and 116 patients in their cohorts to define 
their signature216,218,217. The MTX CCS was systematically developed with a group 
of treatment naive samples that were given MTX monotherapy. Due to this 
systematic approach, it is not surprising there is little capacity for the same 
signature to stratify patient treated with a combination of other csDMARDs.  
 
In general, there was no obvious demographic or clinical characteristic which 
defined why some patients had the MTX CCS present, and others didn’t (Figure 
3.26). The successfully predicted NR had no history of smoking, while patients in 
the other 3 groups had a combination of current and ex-smokers. It could be 
disputed that as smoking is well recognised influence on the RA epigenome, that 
this may play a role. However, in the patient groups used to identify the original 
MTX CCS, there were current and previous smokers. The same numbers of 
current and previous smokers were present in from the HCQ and SSZ treated 
patient groups, as well as no smoking history. Therefore, it is unlikely that 
smoking plays a significant role in the efficacy of the biomarker. The 
successfully predicted NR was in the middle of the age range of all other groups, 
suggesting this is not an influential factor either. Baseline disease activity 
measurements were in the upper range of values. CDAI and DAS28 CRP for this 
patient were close to the maximum values of the response groups with an 
undefined signature. The other group of responders that had a signature, 
although unsuccessfully predicted, also had patients with high baseline disease 
activity. This may suggest that the presence of the MTX CCS is more likely in 
those with worse disease at baseline.    
 
When investigating the potential influence of treatment option on the ability of 
the MTX CCS to successfully predict response, results in Figure 2.27 suggest 
treatment has little influence. Observing these results from the perspective of 
treatment option on response, suggests monotherapy or combination therapy has 
around equal chance of being successful. The clear majority of patients with the 
	 154	
presence of a MTX signature were monotherapy treated. However, there was 1 
combination DMARD treated patient. R and NR with UD signatures have patients 
representing all 4 treatment options. R with UD signatures have marginally more 
combination treated patients, however, non-responders have marginally more 
monotherapy treated patients. However, with the MTX CCS loci in the ‘correct’ 
conformation in only 5 patients, the influence of therapy is difficult to 
comprehend fully. Looking at this data with a view of understanding if DMARD 
treatment option had an influence on response, once again, overall monotherapy 
and combination therapy both appear to work just as well as each other in this 
patients group. This work is very limited by patient number and if this was to be 
explored further, a much larger patient group would be needed. This data 
confirms that it is not a csDMARD biomarker that was found, but a biomarker 
specifically for MTX response and highlights the need to explore other options 
for a CCS for baseline csDMARD treatment. The 5 genetic loci for the MTX CCS 
began with a list of RA associated loci, so it is plausible to consider that a pan-
DMARD CCS could be generated from this list. Similar questions of CCS extending 
to other therapy areas have been discussed, but not fully explored in the 
literature. Work by Rousseau et al, identified a CCS could be used to classify a 
subtype of leukaemia. They acknowledged that it was likely other genes would 
have to be consulted to find a signature able to identify other subtypes294. 
Similarly, in another study by Rousseau, they found evidence that distinct 
cellular states in macrophages had distinct chromatin conformations295. This 
means with further investigation, different cellular states, captured by 3C, may 
shed more light on the MTX CCS and biological consequences.  
 
Overall, while the data has been interpreted with a lot of caution based on 
limitations described, these findings suggest that the patient cohorts used to 
test the stratification potential of the signature were comparable, and the 
difference in sensitivity and specificity measures were unlikely to be caused by 
patient demographics or disease activity measures. This experiment was very 
limited by available patient samples and the fact that many patients were on 
combination therapy makes it difficult to interpret where the clinical response is 
arising from and therefore the meaning of the stratification using the chromatin 
signature. Based on the data gathered, it is evident that the MTX CCS is not 
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capable of stratifying patients who are on a different csDMARDs and a new 
signature would be required to stratify RA patients at baseline.  
 
Another clinically important question that had to be asked was if the MTX CCS 
could also be validated in an independent clinical cohort. The results from this 
investigation indicated that the CCS could not differentiate R and NR to MTX as 
well as in the SERA cohort. Despite both experiments using different models 
(Weka vs XGBoost and Light GBM), evidence has shown that the newer models 
used to assess the signature in the TACERA cohort are statistically superior, and 
if the signature could differentiate R and NR, these models would have most 
likely identified this. Only 3 of the 5 loops from the MTX CCS were shown to have 
albeit limited, stratification potential with the newer models. A dilution series 
was used as a semi-quantitative method that was described previously (Figure 
3.7, 3.8). Only the neat primer cocktail and the 2-fold dilution produced results 
that added any value to the predictive model. It must be considered that the 
sample collection processes of the SERA samples and TACERA samples were 
different and that could impact the ability of the signature to perform as well. It 
is known that nucleic acids are susceptible to oxidative damage after blood 
collection296. One study compared blood extraction protocol for whole blood 
gene expression profiling experiments using mRNA. They revealed that there 
were substantial differences in the transcriptomic profiles of PBMCs that had 
gone through three different blood collection processes297. However, it is largely 
understood that DNA is more stable than RNA and therefore, for our signature, 
differences in blood collection should not have as much of an effect. 
Interestingly, the 3 loci with promising predictive potential were IL17A, IL23 and 
IFNAR1. The results from the qPCR optimisation revealed IL21R and to a lesser 
extent, IFNAR1, as better candidates than other loci for an effective qPCR assay, 
while CXCL13 showed little evidence of success. This may be due to the 
advantage of the updated extraction protocol (Protocol 2, Section 2.2.3) that 
has been implemented by OBD, supporting the idea that the extraction protocol 
favours loops in some genes over others. This could be attributed to the 
variation of copy number of each library that is evidenced with the 3C control 
primers (Figure 3.31). In contrast, these 3 loops suggesting some of their 
predictive potential was retained across cohorts may suggest that the regulation 
of these three genes is more important in RA pathogenesis, or in response to 
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MTX. The IL17A/IL23 axis and its role in driving chronicity in autoimmunity has 
been widely explored248. Moreover, this axis is heavily implicated in PsA. Based 
on that evidence, it could be possible that the CCS may hold some predictive 
potential in patients with PsA. However, as has been suggested by our data, 
heterogeneity and protocol variances may play a large role in the stratification 
potential of the biomarker and therefore, a tailored biomarker for PsA would 
most likely need to be specifically found. The role of this axis in response to MTX 
has been investigated in murine models of psoriasis298. One human study with 
etanercept plus MTX revealed higher levels of IL17A and IL23 in PBMCs in 
psoriasis patients299. The combination therapy significantly reduced cytokine 
levels and the addition of MTX improved therapeutic response. Another study in 
humans, with RA, explored the effect of anti-TNFα on levels of IL17A and IL23 
among other pro-inflammatory cytokines. At the beginning of the study there 
were increased level of cytokines in the sera of patients. After 24 weeks of 
treatment this was reduced300. Loops form in IL17A and IL23 loci in NR and R, 
respectively, therefore it is important to establish the biological impact of loop 
formation to understand gene expression and it’s relation to drug response. This 
will be explored later in this thesis. However, there are multiple studies that 
have explored the involvement of IFNAR1 and CXCL13 in RA pathogenesis, and 
therefore it can’t be said with certainty that the biomarker translates better for 
some loci than other due to underlying pathogenesis.  
 
Of the 2 models tested, the XGBoost model had better capacity to differentiate 
R and NR. The sensitivity was much higher than Light GBM in the training set and 
comparable with Light GBM in the testing cohort (Figure 3.29 and 3.30). The 
literature supports use of both models and each have their own advantages and 
disadvantages. While Light GBM can find results faster in some cases, in some 
experiments, while slower, XGBoost has been shown to find the more accurate 
answer301. Moreover, compared to Light GBM, XGboost has been found to require 
less training time to produce an accurate model. While not impacted by our 
dataset, studies have shown LightGBM to be superior for large datasets due to 
memory limitations for XGBoost and this should be considered going forward.  
 
One of the limitations of this part of the study was the difference in blood 
collection protocols and difference in DNA extraction method. Both differences 
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could contribute to the reduced predictive capacity of the signature and 
reduction of statistically significant loops. Furthermore, a blinded cohort of 23 is 
not large, and a larger cohort may reveal more about the predictive potential of 
the CCS in this cohort. However, as the aim would be to have this work at the 
individual level, it must be considered if a larger cohort size would be of 
relevance.  
 
The selection process for sample collection for this validation was based only on 
csDMARD assignment at baseline, as it was the important to carry out the testing 
blinded. Therefore, disease activity information was only retrieved once the 
testing had been carried out. This meant that the heterogeneity that is present 
in RA could not be fully interrogated and shed light on the clinical information 
which may impact the stratification ability. Moreover, of the work documented 
in this thesis, this validation experiment was the most recently conducted and 
therefore there was not sufficient time to investigate correlations between 
demographic factors and predictive ability of the signature as was done with the 
cohort for testing broad csDMARD stratification potential. With more time, this 
would be useful to understand if differences in demographics or disease activity 
contributed to the decreased sensitivity and specificity of the signature in this 
cohort. Furthermore, additional work is planned to test the TACERA samples 
with additional markers that have been found through other studies (which will 
be described in Chapter 5) to identify the best stratification marker.  
 
A significant caveat to the work described in this chapter from an exploratory 
perspective is the heterogeneity of PBMCs. Studies have successfully illustrated 
the differences in the epigenome between subsets of cells within PBMCs209,302 
and therefore it is important to consider that the CCS will likely be structurally 
different in the cell subsets. The aim would be to identify the loops that are 
relevant in one state but not in other states. For successful assessment of the 
subsets within PBMCs, they would have to be isolated before freezing. The 
biobank samples used in this study did not have cell subsets prepared in this way 
and therefore this question could not be easily addressed. Despite this, 
EpiSwitchTM is a technique developed to work in a mixed population of cells and 
is sensitive enough to detect loops even if they were present in only in a certain 
subtype. Future work examining CCS in patient groups would benefit from bio 
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banking cell subsets separately in order to fully understand the heterogeneity of 






In summation, this chapter details the complexity of investigating the structural 
epigenome in RA. It was ascertained that assessment of the MTX CCS should be 
carried out with nested PCR methodology and the Qubit dsDNA HS assay and 
LabChip GX technology could facilitate a high-throughput protocol for the 
number of samples normally processed. It was also established that the MTX CCS 
was not stable, but largely dynamic. Additionally, we ascertained that some loci 
of the MTX signature had some predictive capacity in an independent clinical 
cohort, but the full signature had limited capacity. Further work should be done 
to find a more powerful signature suitable to a range of sample collection 
protocols. Furthermore, results confirmed the CCS was specific to MTX response 
prediction and not suitable to simply predict response regardless of baseline 
treatment.  
 
Further work is warranted to understand the consequence of MTX CCS loop 
formation on the underlying RA cellular biology. Moreover, ways to interrogate 
the data in cell subtypes should be explored.  
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Chapter 4 Exploration of the Possible Functional 
Implications of Methotrexate Chromosome Confirmation 




The work in Chapter 3 explored the stratification potential of the methotrexate 
(MTX) chromosome conformation signature (CCS). Following on from these 
findings, it was important to begin to understand the potential biological 
consequences of loop formation in MTX responders (R) and non-responders (NR). 
It is known that chromosome looping has a role in the regulation of 
transcription, by bringing regulatory regions such as enhancers and promotors 
together288. As epigenetic features of the genome are subject to changes 
through exposure to medication, understanding the epigenetic landscape in CCS 
genes pre-treatment may help to understand the differences in R and NR to MTX 
288. The work by Carini et al highlighted that expression quantitative trait loci 
(eQTL), identified from work by Walsh et al, were present at R loop sites but 
absent at NR loop sites, which provides a foundation for the suggestion of 
regulatory differences between response types209,219.  
 
Some epigenetic features that could help elucidate the function of the MTX CCS 
loops are methylation, histone modifications, DNase hypersensitive sites (DHSs), 
and their relationship with transcription factors (TF). When hypermethylation of 
a promotor occurs, this results in gene repression due to the inability of TF to 
bind to the promoter region. However, hypomethylation, largely characterised in 
cancer, often occurs in heterochromatin and can aid in upregulation of gene 
expression303. Hyper and hypomethylation have been previously explored in RA T 
cells and monocytes in the context of MTX treatment. Andres et al found that RA 
patients had global hypomethylation before initiation of MTX treatment, and 
treatment appeared to reverse this. However, this study did not incorporate the 
influence of the chromatin conformation, which may impact the methylation 
effects304. Multiple histone modifications have been characterised, with some 
associated with increased transcription, and others with transcriptional 
repression. The work in this chapter focuses on 6 histone modifications, chosen 
based on availability of data and their representation of various transcriptional 
consequences. H3K4me1, H3K4me3, H3K27ac and H3K36me3 represent 
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transcriptional activation marks and H3K27me3 and H3K9me3 represent 
transcriptional repression marks. Furthermore, DNase hypersensitivity can 
provide an additional layer to the understanding of the 3D epigenetic landscape. 
DNase I is a DNA sequence non-specific endonuclease. This enzyme at open 
chromatin sites and collocated with transcriptionally active genes. As such, 
these areas are termed DHSs305,306. These sites are often located at 
transcriptionally active genes and are susceptible to multiple regulatory 
elements.   
 
As research into the genome, and epigenome, has grown over the last decade, 
there are multiple online databases where data can be downloaded and analysed 
for other research interests. Numerous datasets from peripheral blood 
monocular cells (PBMCs), and derivatives are available. Two such databases are 
the encyclopedia of DNA elements (ENCODE), and the BLUEPRINT epigenomics 
consortium, both of which have previously yielded informative results in 
Rheumatology307,308,309. However, utilising this information for an extension of an 
epigenetic biomarker has yet to be done. It has been recognised that combining 
this data is ultimately what will result in a clinically useful biomarker310.  
 
Based on the loci within the MTX signature, multiple cell types could be explored 
to provide insight into the potential biological impact of loop formation. 
However, to ensure a comprehensive analysis of multiple epigenetic features in 
the context of this study, PBMCs, CD4+T cells and CD14+CD16- monocytes were 
chosen as a focus.   
 
The aim of this chapter was to elucidate potential regulatory differences 
between R and NR, which may indicate the relationship between the MTX CCS 
and underlying pathogenesis. To accomplish this, the aims were:    
 
1) Utilise publicly available online datasets from healthy cells to extract 
information about epigenetic regulatory features present at the MTX loop sites in 
PBMCs, CD4+T cells and CD14+CD16- monocytes 
 
2) Where possible, use RA datasets to build on findings from healthy data. 
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4.2 Results  
 
4.2.1 Identification of publicly available data available to explore 
3D epigenetic environment at MTX CCS loop sites 
 
The first step in exploring the 3D epigenomic landscape was to identify the data 
that was publicly available. Through a search of the literature, the DeepBlue 
Epigenomic Data Server (https://deepblue.mpi-inf.mpg.de) was found. This 
database collates the findings from several large-scale epigenome studies. 
Numerous studies are included, namely the BLUEPRINT Epigenome, ChIP-Atlas, 
ENCODE and Roadmap Epigenomics (Figure 4.1A). Once this data source was 
found, it was important to establish the experiments that would yield data that 
was of interest in our study. As such, the techniques, biosources and epigenetic 
marks from the database were explored, and biologically relevant sources 
quantified. Many experiments were available for interrogation. Analysis of the 
experimental techniques included in the database highlighted the epigenetic 
motifs that had the most interest from researchers. There were significantly 
more ChIP-Seq experiments than any other methodology, with 31,922 
experiments included in the database (Figure 4.1B). As such, this technique was 
removed and a second graph plotted to clearly identify the distribution of other 
techniques (Figure 4.1C). The next technique with the most data available was 
DNAse-Seq, used to identify DHSs throughout the genome, with 3,855 
experiments available. The next stage in the process was to ascertain the 
biosources available. Blood, with 3,817, was the biosource with the most 
experiments accessible (Figure 4.1D). Multiple experiments from cells types of 
interest were found, namely PBMCs and derivatives including CD14+CD16- 
classical monocytes and CD4+ T cells with 46,287 and 1,171 experiments 
available, respectively. Lastly, the epigenetic marks of interest were quantified 
(Figure 4.1E). In line with the techniques available, histone modifications were 
the highest epigenetic mark represented, with 3,635 experiments available 






Figure 4.1 Quantification of DeepBlue Epigenomic Server Data  
Identification and quantification of epigenetic data available for our study. A) 
Schematic of relevant studies collated within DeepBlue Epigenomic Data Server. B) 
Quantification of techniques from server. C) Quantification of techniques, with ChIP-Seq 
excluded. C) Quantification of Biosources from server. D) Quantification of Epigenetic 
marks available from server. Data includes experiments using both Hg38 and Hg19 
genomes.  
CTCF, CCCTC-binding factor 
 
Once appropriate biosources and epigenetic marks were identified, the next step 
was to extract the relevant information for the MTX CCS sites. A custom script 
(Appendix) was used to pull out any epigenetic marks that were found in and 
around the signature anchor sites (Figure 4.2). As well as the coordinates of the 
loop anchor sites (Figure 4.2A,B), coordinates 500 kilobases (kb) up stream of 
anchor point a and downstream of anchor point b (Figure 4.2C,D) were included 
in the analysis, as epigenetic marks from that distance can be brought into close 
proximity with the formation of a chromosomal loop. Data from between the 
loop anchor sites was also captured (Figure 4.2E), which could include up to 
91,723 base pairs (bp) of the genome (Table 1).  
 
 
Figure 40 Sites Included in In-silico Analysis Methodology  
Schematic illustrating sites included in custom script to map epigenetic marks to CCS 
loop sites. Site a = first EpiSwitchTM anchor point in CCS loop, site b= second EpiSwitchTM 
anchor point in CCS loop. A) EpiSwitch Site a = IL17A (Site 3), CXCL13 (Site 1), IL21R Site 
5), IL23 (Site 4), IFNAR1 (Site 2). B) EpiSwitch site b = IL17A (Site1), CXCL13 (Site 3), 
IL21R (Site 2), IL23 (Site 5), IFNAR1 (Site 4). C) 500kb upstream of EpiSwitch Site a. D) 
500kb downstream of EpiSwitch Site b. E) Distance between site a and site b. 
Coordinates used to capture epigenetic marks at EpiSwitch sites, the distance 500kb 








 4.2.2 Exploration of epigenetic landscape in PBMCs 
 
In the first instance, as the biomarker was found in the PBMC population, broad 
analysis of epigenetic marks in PBMCs was explored (Figure 4.3). Firstly, ranges 
of the genome within which histone peaks were found were mapped around MTX 
CCS loop anchor sites. All loop sites had the presence of at least one histone 
modification. At the IL17A site there was the presence of H3K4me1 at site a and 
H3K9me3 and H3K27me3 at site b (Figure 4.3A). At the CXCL13 site there was 
the presence of only H3K27me3 (Figure 4.3B). There were H3K4me1, H3K4me3, 
H3K27ac, H3K36me3 and H3K27me3 ranges at the IL-12R loop sites (Figure 4.3C). 
Both IL23 and IFNAR1 had H3K4me1, H3K4me3 and H3K27ac histone peaks at 
loop sites, with a maximum of 2 ranges quantified (Figure 4.3D,E).Between loop 
anchor sites, the histone profile was similar to that of anchor sites at the IL17A 
locus and IL23 locus. However, at the other 3 signature loci, histones with both 
enhancer and repression transcriptional consequences were captured. 
Methylation was also explored in PBMCs. At all loop sites hypermethylation was 
present at the minimum of one anchor site. Most ranges, maximum of 3, were 
present at site a for IL17A. At site b, IL21R had most (2) hypermethylation 
ranges (Figure 4.3F). Hypomethylation was less present than hypermethylation, 
with only ranges present at IL21R and IFNAR1 loop sites (Figure 4.3G). Between 
anchor sites, IL21R has the most hyper and hypomethylation ranges (20 and 24, 
respectively), with CXCL13 having a similar number of hypermethylation ranges 
(23). DHSs represent accessible areas of the genome, and as such, these sites 
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were mapped at loop regions and could be layered above other epigenetic marks 
to understand how likely the other modifications may impact gene expression. 
IFNAR1 had the most ranges, with an average of 7.5 at site a (Figure 4.3H). IL21R 
had the most ranges at site b, and between anchor sites, with an average of 5 
and 20, respectively. CXCL13 was the only loop site not to have any DNase I sites 
present. Overall, the data suggest that there is the potential for a more 
repressive transcriptional environment at IL17A and CXCL13 loci, than at IL21R, 
IL23 and IFNAR1 loci. Moreover, based on the DNAse I sites mapped, IL21R may 
be the loci with the potential to be most accessible and could aid in enhancing 






Figure 4.3 Mapping of Epigenetic Marks at MTX CCS Loop Anchor Sites in PBMCs 
Mapping of histones, methylation and DHSs in PBMCs from healthy samples, extracted 
from DeepBlue Epigenomic Server. Data from hg38 genome. Histone data from ChIP-Seq 
technique (N=2), methylation data from Bisulphite-Seq (N=1) and DNase data from 
DNase-Seq (N=1). Ranges = regions of the genome within which peaks were recorded 
from ChIP-seq, Bisulphite-seq or Dnase-seq experiments. Site a = first EpiSwitchTM 
anchor point in CCS loop, site b= second EpiSwitchTM anchor point in CCS loop. In-
between = stretch of DNA between CCS sites. Coordinates (See Appendix). A) Histones 
from IL17A. B) Histones from CXCL13. C) Histones from IL21R. D) Histones from IL23. E) 
Histones from IFNAR1. F) Hypermethylation at EpiSwitchTM sites for all MTX CCS loops. 
G) Hypomethylation at EpiSwitchTM sites for all MTX CCS loops. H) DHSs at MTX CCS loop 
sites. Data is presented as mean with range. 1-way ANOVA with Tukey’s multiple 
comparisons. *p<0.05, **p< 0.01, ***p < 0.005, ***p<0.0001  
 
 
Taking the association of regions of DNA with an epigenetic mark further, the 
Integrated Genome Browser (IGV) was used to visualise how the epigenetic 
marks may overlap at the loop anchor sites. The IL21R site is shown as a 
representative of this visualisation in PBMCs (Figure 4.4). Data representing 
eQTLs were also overlaid in this data. The IL21R loop site 5 can be visualised 
overlapping with H3K36me3. At IL21R loop site 2, there is overlap between 
multiple eQTLs, H3K4me1, H3K27me3, and multiple DNase I sites. These data 
further suggest that enhanced gene transcription at this locus is possible. 
Moreover, the anchor sites coming together would bring the DNase I sites closer 
to H3K36me3, potentially making this a highly active transcription site.  
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Figure 4.4 Environment Surrounding IL21R MTX CCS Loop Anchor Sites in PBMCs 
Images generated in IGV. Representative image of IL21R MTX CCS sites. hg38 genome 
used. Histone and DNase I data from DeepBlue Epigenomic server. eQTL data from 
Walsh et al. 209. CCS sites boxed in red encompassing epigenetic marks that lie within 
that region. Tracks shown in collapsed format. Track marks in green represent 
epigenetic marks that are likely to increase transcription, and track marks in red 
representative of epigenetic marks with potential repressive transcriptional impact. Site 
5 is CCS site on left, Site 2 is CCS site on right.  
CCS, chromosome conformation signature; eQTLs, expression quantitative trait loci;  
kb, kilobase; RR, reverse-reverse orientation 
 
Following on from the association analysis of epigenetic marks at the loop 
anchor sites, the number of histones were quantified 500kb up and downstream 
of the loop anchor sites (Figure 4.5). At 500kb upstream, IL17A appears most 
distinct from the other 4 loci in the signature (Figure 4.5A). This is based on the 
higher number of H3K27me3 histone marks and low number of other histone 
marks. All other signature loci have many ranges of H3K4me1 and H3K27ac 500kb 
upstream. 500kb downstream from the CCS sites, the distribution of histones 
appears different. All loci have the presence of H3K4me1, H3K36me3 and 
H3K27ac (Figure 4.5B). IL17A has the highest presence of H3K4me1, IL21R the 
highest for H3K36me3 and CXCL13, IL23 and IFNAR1 highest for H3K27ac. There 
were low numbers of H3K9me3 and H3K27me3 captured across all loci. 
Upstream, this data somewhat reflects the data at the anchor sites at the IL17A 
loci, as it suggests a largely repressive environment. Yet downstream, there is 
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little differentiation between IL17A and CXCL13 from IL21R, IL23 and INFAR1, as 
there was at the anchor sites themselves. This indicates the importance of 
considering the whole stretch of DNA to provide a more thorough picture of the 
potential effect on transcription with the formation of a loop.  
 
Moving on, using the online datasets offered the opportunity to explore cell 
types within the PBMC population and shed further light on regulatory 
differences between loci. As such, CD4+ T cells were analysed next. 
 
 
Figure 4.5 Histone Enrichment Up and Downstream of MTX CCS Loop sites in PBMCs 
Plots generated in JMP. Heat map representing number of ranges within which histones 
500kb up and downstream of MTX CCS sites in PBMCs were mapped. Data from DeepBlue 
Epigenomic Server. Number of ranges were unique for each locus and each histone mark 
(See Appendix). A) Enrichment of histones mark 500kb upstream of MTX CCS site a. B) 
Enrichment of histone marks 500kb downstream of MTX CCS site b. Coordinates used to 
capture epigenetic marks at EpiSwitch sites, the distance 500kb upstream and 
downstream and in-between (See Appendix).  
 
 4.2.3 Exploration of epigenetic landscape in CD4+ T cells 
 
CD4+ T cells were chosen as one of the cell types relevant for our loci of interest. 
These were chosen as CD4+ T cells are known producers of IL17A, CXCL13, and 
express IL21R and IFNAR1222,231,238. As before, histone and methylation 
enrichment were mapped, in addition to DHSs (Figure 4.6). Site b for both IL17A 
and CXCL13 loci had no histone marks recorded. H3K27me3 was only recorded at 
IL17A and CXCL13 site a and between CXCL13 and IFNAR1 anchor sites (Figure 
4.6A,B,E). The CXCL13 site also had the presence of H3K27ac captured (Figure 
4.6B). H3K4me1 marks were present at IL17A, IL21R, IL23 and IFNAR1 sites. 
H3K27ac had more ranges than the other histone marks and these were found at 
the IL21R site. Between anchor sites IL21R had considerably more, with one 
experiment finding 79 H3K27ac peaks. H3K36me3 marks were also present at 
IL21R and IFNAR1 sites. There were statistically significant differences between 
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the histones across the IL21R and IFNAR1 loci, and site a and in-between on the 
IL23 loci. At the CXCL13 in-between site, there was also a statistically significant 
different between the histones. Overall, the most statically significant 
differences appeared to be at site a or b of the loci. Similarly, when quantifying 
DNase ranges, there was statistical significant differences between the loci at 
site a and b, but not in-between.  Ranges with hypermethylation and 
hypomethylation were recorded at both sites in at least 1 loci. Hypermethylation 
was present in more abundance than hypomethylation (Figure 4.6E,F). IL17A site 
a had the most hypermethylation recorded with 4 ranges in 2 experiments. Other 
genes had similar levels of hypermethylation, between 1 and 3 ranges. 
Hypomethylation marks were only found at IFNAR1 and IL21R at site a and b 
respectively. Hypomethylation was more represented in between anchor points, 
but only at IL21R, IL23 and IFNAR1 loci only. At anchor sites, IL17A, CXCL13 and 
IFNAR1 sites had DHSs present (Figure 4.6G). IL17A had a large variation of 
ranges between samples, from 1 to 6. CXCL13 had DNase I marks only at 1 
anchor point (Figure 4.6H). Yet, between sites, IL21R is clearly the locus with 
the most DNase I sites, and no sites are recorded at the IL17A loci. This data 
suggests that a stable gene repression state may exist in CD4+ T cells at the 
IL17A locus and an enhanced transcription state may be possible at the IL21R 
site. Interestingly, this would be on contrast to the known expression of IL17A in 







Figure 4.6 Mapping of Epigenetic Marks at MTX CCS Loop Anchor Sites in CD4+ T cells 
Mapping of histones, methylation and DHSs in CD4+ T cells from healthy samples, 
extracted from DeepBlue Epigenomic Server. Data from hg38 and hg19 genome. Histone 
data from ChIP-Seq technique (N=9), methylation data from Bisulphite-Seq (N=34) and 
DNase data from DNase-Seq (N=12). Ranges = regions of the genome within which peaks 
were recorded from ChIP-seq, Bisulphite-seq or Dnase-seq experiments. Site a = first 
EpiSwitchTM anchor point in CCS loop, site b= second EpiSwitchTM anchor point in CCS 
loop. In-between = stretch of DNA between CCS sites. Coordinates used to capture 
epigenetic marks at EpiSwitch sites, the distance 500 kb upstream and downstream and 
in-between (See Appendix). A) Histones from IL17A. B) Histones from CXCL13, site, in-
between,. C) Histones from IL21R. D) Histones from IL23. E) Histones from IFNAR1. F) 
Hypermethylation at EpiSwitch sites for CCS loops. G) Hypomethylation at EpiSwitch 
sites for CCS loops. H) DHSs MTX CCS loop sites. Data is presented as mean with range. 
1-way ANOVA with Tukey’s multiple comparisons. *p<0.05, **p< 0.01, ***p < 0.005, 
***p<0.0001 
 
As with PBMCs, IGV software was used to image the relationship between 
epigenetic marks. IGV demonstrated the location of histone marks at IL17A loop 
anchor site 3 (Figure 4.7). The site is dominated by the repressive marks 
H3K9me3 and H3K27me3. However, overall there is no overlap of histone marks 
at the same genomic locations. This suggests that both enhancing/repressive 
marks could have an influence on the gene transcription as they are unlikely to 
be in direct contact with each other, and there are no marks at anchor site b to 






Figure 4.7 Environment Surrounding IL17A MTX CCS Loop Anchor Sites in CD4+ T 
Cells 
Image generated in IGV. Representative image of IL17A MTX CCS sites in CD4+ T cells. 
Histone data from DeepBlue Epigenomic server. CCS sites boxed in red encompassing 
histone marks that lie within that region. Tracks shown in collapsed format. Track 
marks in green represent epigenetic marks that have a positive effect on transcription, 
and track marks in red are representative of a potential repressive transcriptional 
histone modifications. Site 3 is CCS site on left and Site 1 is CCS site on right.  
CCS, chromosome conformation signature; kb, kilobase; RR, reverse-reverse orientation 
 
At the anchor sites, there was little evidence which indicated that the 
regulatory environment differed between loci that are known to be expressed by 
CD4+T cells, and those that are not. Therefore, at this stage of the analysis, I 
chose to focus on genes known to be expressed by CD4+ T cells, thus the 
presence of histones 500kb up and downstream of more biologically relevant CCS 
sites in CD4+T cells was determined (Figure 4.8). At the region 500kb upstream, 
IL17A appears more distinct from CXCL13, IL21R and IFNAR1 (Figure 4.8A). IL17A 
had most H3K27me3 ranges, followed by H3K9me3, suggestive of an environment 
that could supress gene expression. Conversely, CXCL13, IL21R and IFNAR1 have 
most ranges of H3K4me1 and H3K27ac, with less of the other histone marks. At 
500kb downstream of the CCS anchor sites, IL21R appeared most distinct with 
high enrichment of H3K36me3 only (Figure 4.8B). IL17A most H3K4me1 ranges, 
with many ranges of H3K27ac also quantified. CXCL13 and IFNAR1 appear to 
share similar enrichment of H3K36me3 ranges with IL21R. The number of 
repressive histone marks quantified at IL17A build on earlier evidence which 
suggests a highly repressive environment which extends upstream. However, the 
data downstream suggest a largely gene enhancing environment which, if coming 
into contact with the region upstream, may create something of a more poised, 





Figure 4.8 Histone Enrichment Up and Downstream of MTX CCS Loop Sites in CD4+ T 
cells 
Plots generated in JMP. Heat map representing enrichment of histones 500kb up and 
downstream of biologically relevant MTX CCS sites in CD4+ T cells. Data from DeepBlue 
Epigenomic Server. Enrichment values were unique to each locus and each histone mark 
(See Appendix). A) Enrichment of histone marks 500kb upstream of MTX CCS site a. B) 
Enrichment of histone marks 500kb downstream of MTX CCS site b. Coordinates (See 
Appendix). 
 
 4.2.4 Exploration of epigenetic landscape in CD14+ CD16- 
Monocytes  
 
CD14+CD16- monocytes were determined another appropriate cell type to allude 
to the potential functional impact of loop formation. This was decided due to 
the known expression of CXCL13 and IL23, as well as IFNAR1311-313. As before, 
histone marks, methylation and DHSs were mapped at all CCS sites (Figure 4.9). 
Both IL17A and CXCL13 sites had only few histones ranges associated, with 
H3K27me3 and H3K9me3 being the dominant marks, with 4 samples with 4 
ranges of H3K9me3 in the stretch between CXCL13 anchor sites (Figure 4.9A,B). 
Across it’s anchor sites, the IL21R locus had ranges with all histone marks apart 
from H3K4me3 (Figure 4.9C). Between anchor sites, ranges with all histone 
marks were found. IL23 had the presence of H3K27ac and H3K36me3 at both 
loop anchor points, as well as H3K4me1 and H3K4me3 at site b (Figure 4.9D). 
This distribution was also found in the region in-between. At the IFNAR1 site, 
both anchor points had ranges of H3K4me1, H3K4me3, H3K27ac and H3K36me3 
(Figure 4.9E). H3K4me3 and H3K27ac had the most variation in ranges, between 
1 and 3. At all points across the IL21R, IL23 and IFNAR1 loci measure, there was 
a statistically significant difference between the number of histone ranges. 
Hypermethylation ranges were found at all site b anchor points. (Figure 4.9F). 
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Hypomethylation was only found in the anchor regions of IL17A, IL21R and 
IFNAR1 (Figure 4.9G). Ranges with DNase I were not found at the IL17A or 
CXCL13 loop anchor sites. However, they were present at IL23 and IFNAR1 sites 
(Figure 4.9G). IFNAR1 site b had the most hypersensitive ranges, with a 
maximum of 9 and average of 5 between experiments. This observation was also 
similar in the region between IFNAR1 anchor sites, with many more DNase I 
ranges than the other loci. There was a statistically significant difference 
between the loci at all methylation sites and DNase sites measured. Taken 
together, these data suggest that there is a similar regulatory environment at 
IL17A and CXCL13, which differs to IL21R, IL23 and IFNAR1; with epigenetic 
marks indicating is a repressive environment, and an environment that would 






Figure 4.9 Mapping of Epigenetic Marks at MTX CCS Loop Anchor Sites in CD14+CD16- 
monocytes 
Mapping of histones, methylation and DHSs in CD14+CD16- from healthy samples, 
extracted from DeepBlue Epigenomic Server. Data from hg38 and hg19 genome. Histone 
data from ChIP-Seq technique, methylation data from Bisulphite-Seq and DNase data 
from DNase-Seq. Ranges = regions of the genome within which peaks were recorded 
from ChIP-seq, Bisulphite-seq or Dnase-seq experiments. Site a = first EpiSwitchTM 
anchor point in CCS loop, site b= second EpiSwitchTM anchor point in CCS loop. In-
between = stretch of DNA between CCS anchor sites. Coordinates used to capture 
epigenetic marks at EpiSwitch sites, the distance 500kb upstream and downstream and 
in-between (See Appendix). A) Histones from IL17A. B) Histones from CXCL13. C) 
Histones at IL21R. D) Histones from IL-23. E) Histones from IFNAR1. F) Hypermethylation 
CCS sites. G) Hypomethylation at CCS sites. H) DNaseI hypersensitive sites at CCS loop 
sites. Data is presented with range. 1-way ANOVA with Tukey’s multiple comparisons. 
***p < 0.005, ***p<0.0001 
 
Once again, IGV was used to better visualise the epigenetic landscape at the CCS 
sites. As multiple histone marks were associated with the loop sites of IFNAR1, 
this was a useful region to visualise. There is enrichment of enhancer associated 
histones (Figure 4.10A). Each loop anchor point clearly overlaps with multiple 
histone marks. These marks also overlap with DHSs. The transcription associated 
histone, H3K36me3, is also evident at this loop site. The DeepBlue epigenomic 
server also provided data on transcription factors at this site of interest. IGV 
demonstrated that DHSs at the CCS anchor points intersect with several TF 
(Figure 4.10B). IFNAR1 loop site 2 is branched by CCCTC-binding factor (CTCF) 
and Signal transducer and activator of transcription 1 (STAT1). The IFNAR1 loop 
site 4 overlaps with CTCF, interferon regulatory factor (IRF) and STAT1. As 
demonstrated previously, multiple eQTLs are present at this site and as such, 
overlap with the epigenetic marks described. Despite represented separately, it 
is evident that TF would also be present at the site of histone marks. Taken 
together, this data suggests that there is likely to be enhanced gene expression 







Figure 4.10 Environment Surrounding IFNAR1 MTX CCS Loop Anchor Sites in 
CD14+CD16- monocytes 
IGV used to generate image of area surrounding IFNAR1 MTX CCS sites in CD14+CD16- 
monocytes. CCS sites boxed in red encompassing epigenetic marks that lie within that 
region. Histone and DNase I data from DeepBlue Epigenomic server. eQTL data from 
Walsh et al.,2016. Tracks shown in collapsed format. Track marks in green represent 
epigenetic marks that have a positive effect on transcription, and track marks in red are 
representative of potential negative transcriptional epigenetic marks. A) Histones at 
IFNAR1 CCS sites. B) DHSs and transcription factors at IFNAR1 CCS sites.  
CCS, chromosome conformation signature; CTCF, CCCTC-binding factor;  
eQTLs, expression quantitative trait loci; IRF, interferon-regulatory factors;  
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kb, kilobase; RR, reverse-reverse orientation; STAT1, 1 Signal transducer and activator 




Again, presence of histone marks 500kb up and downstream of sites in 
monocytes were mapped (Figure 4.11). As with CD4+ T cells, I chose the most 
biologically relevant loci to focus analysis on at this stage. Upstream, in the 
region of CXCL13, H3K4me1 was the mark with most ranges (Figure 4.11A). 
H3K27ac was the most enriched mark in the region of IL23 and IFNAR1. The 
lowest number of H3K27me3 ranges were found at the CXCL13 region, closely 
followed by IL23. H3K36me3 was the histone with least ranges at the IFNAR1 
region. Enrichment of histones 500kb downstream was similar to upstream 
(Figure 4.11B). Broadly, the histone profile for all 3 loci appear similar and 
suggest an enhanced gene expression environment which would be in line with 




Figure 4.11 Histone Enrichment Up and Downstream of MTX CCS Loop Sites in 
CD14+CD16-monocytes 
Plots generated in JMP. Heat map representing enrichment of histones 500kb up and 
downstream of biologically relevant MTX CCS sites in CD14+CD16-monocytes. Data from 
DeepBlue Epigenomic Server. Enrichment values unique to each histone modification 
(See Appendix). A) Enrichment of histone marks 500kb upstream of MTX CCS site a. B) 
Enrichment of histone marks 500kb downstream of MTX CCS site b.  Coordinates used to 
capture epigenetic marks at EpiSwitch sites, the distance 500kb upstream and 
downstream and in-between (See Appendix) 
 
 4.2.5 Exploration of markers of chromatin stability 
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As explored in earlier work detailed in this thesis (Chapter 3, Section 3.2.4), 
data suggest the MTX CCS biomarker cannot be considered stable. There are 
known markers of stability that can be found throughout the genome, therefore 
it was decided that it would be of interest to identify if these markers could be 
found at loop anchor sites. Once only known for their function in holding sister 
chromatids together, cohesin proteins, and co-localisation to CTCF, have now 
been implicated in loop stability and gene regulation. As such, cohesin protein 
and CTCF interaction was quantified at MTX CCS loop sites (Figure 4.12). To 
determine interaction, a function of the Bedtools program in R software was 
used. This program determines overlap between genomic elements and provides 
an output of interactions, which can then be quantified. Only data from the 
GM12878 cell line was available in the server, which is representative of B cells. 
Whilst not a focus in this chapter, B cells are very much a biologically relevant 
cell type and suitable for this part of the study. Based on available data, RAD21 
and SMC3 proteins (which are part of the cohesin complex) were quantified. At 
site a, the IL17A loop had a maximum of 43 interactions between RAD21 and 
CTCF, and at site b, a maximum of 26 interactions between SMC3 and CTCF 
(Figure 4.12A). The difference between the number of these proteins was 
statistically significant. These interactions were visualised in IGV software 
(Figure 4.12B). This visualisation helps visualise that a loop would be required to 
form, to bring the cohesin complex into contact with the IL17A gene. At the 
IL21R loop site a, there were 3 interactions between CTCF and SMC3 (Figure 
4.12C). At the IFNAR1 loop site a, there were a maximum of 10 interactions 
between SMC3 and CTCF, and maximum of 27 with SMC3 and CTCF at site b 
(Figure 4.12E). The difference between the number of these proteins was 
statistically significant. Interactions were visualised with IGV (Figure 
4.12E,F).  These data indicate that there is the potential for a stable loop 
formation at these loci, but since data of all cohesin proteins was not available, 






Figure 4.12 CTCF and Cohesin Protein Overlap at CCS MTX Loop Anchor Sites  
Quantification of interactions between CTCF sites and cohesin proteins from the 
GM12878 cell line, extracted from DeepBlue Epigenomic Server. Data from hg19 
genome. Number of samples variable for each loci. Site a = first EpiSwitchTM anchor 
point in CCS loop, site b= second EpiSwitchTM anchor point in CCS loop. Coordinates used 
to capture epigenetic marks at EpiSwitch sites, the distance 500kb upstream and 
downstream and in-between (See Appendix). A) Intersections from IL17A, site a – 
RAD21, N=40, SMC3, N=21. B) IGV visualisation of intersections from IL17A. C) 
Intersections from IL21R, site 6 – SMC3, N=4. D) IGV visualisation of intersections from 
IL21R. E) Intersections from IFNAR1, site a – SMC3, N=4, site b – SMC3, N=28. F) IGV 
visualisation of intersections from IFNAR1. Data is presented as mean ± SD. Mann 
whitney test. ****p<0.0001 
CCS, chromosome conformation signature; CTCF, CCCTC-binding factor;  
kb, kilobase; RR, reverse-reverse orientation; SMC3, structural maintenance of 
chromosomes protein 3 
 
 
 4.2.6 Exploration of promotor sites at MTX CCS sites 
 
Another technique that we thought could be informative and enable 
interpretation of the interactions was Promotor Capture HiC (PCHiC). This 
technique aims to capture loops from the genome that occur at the promotor 
site. Javierre et al conducted a study in 17 human primary blood cell types to 
determine the relationship between 3D architecture and gene regulation using 
promotor capture HiC 260. Data from the MTX CCS loop sites was extracted from 
their dataset and significant interactions were quantified (Figure 4.13). IL17A 
understandably had significant interactions in the lymphoid compartment. IL21R, 
IL23 and IFNAR1 had significant interactions in myeloid and lymphoid cells. 
There were no peaks at the CXCL13 site. Most significant interactions for IL17A 
were in non–activated (na) CD4 cells. All lymphoid cells had 3 significant 
interactions in the IL21R loop region. naCD4 cells also had the most significant 
interactions at the IL23 loop site, and (total B) tB cells had the most significant 
interactions for IFNAR1 loop site. This data shows that at the MTX signature loci, 
there is the potential for a loop to cause the activation of the gene, and suggests 
this is most likely in lymphoid cells. As with all data explored to this point, it 
was found in healthy cell populations, therefore finding an inflammatory cell 





Figure 4.13 Mapping of Promotor Loops at MTX CCS Loop Anchor Sites 
Mapping of number of significant interactions defined by CHiCAGO score >5 (Appendix). 
Data from Promotor Capture HiC (PCHiC) study by Javierre et al., 2016. A) Part 1 of 
PCHiC protocol, generation of libraries for capture. Briefly, DNA is formaldehyde 
crosslinked, restriction digested and labelled with biotin. This is followed by ligation. 
Next, sonication and streptavidin pull down is used to shear ligated fragments and 
enrich the HiC library for ligation products, alongside A-tailing to repair the sheared 
ends. Adapters are then ligated to the ends of each fragment ahead of sequencing. B) 
Part 2 of PCHiC protocol, bait capture. C) Quantification of significant interactions at 
IL17A loop site. D) Quantification of significant interactions at IL21R loop site. E) 
Quantification of significant interactions at IL23 loop site. F) Quantification of 
significant interactions at IFNAR1 loop site. Monocytes (Mon), Naïve Macrophages (M0), 
Type 1 Macrophages (M1), Type 2 Macrophages (M2), Neutrophils (Neutrophils), 
Megacaryocytes (MK), Erythrocytes (Ery), Fetal Thymus FeT), Naïve CD4+ T cells (NCD4), 
Total CD4+ T cells (tCD4), non-activated CD4+ T cells (naCD4), activated total CD4+ T 
cells, naïve CD8+ T cells (nCD8) total CD8+ T cells (tCD8), naïve B cells (nB), total B cells 
(tB).  
 
 4.2.7 Exploration of epigenetic landscape in Inflammatory 
Macrophages 
 
As most of the data was obtained from healthy cells, data from inflammatory 
samples was sourced as a way of understanding the epigenome in the 
inflammatory environment more clearly. Data from inflammatory macrophages 
was obtained from the DeepBlue server. These were derived from healthy 
primary cells cultured with beta glucan to induce an inflammatory phenotype. 
Data from macrophages was also mapped to allow comparison of the 
inflammatory and non-inflammatory state and allude the influence of an 
inflammatory environment (Figure 4.14). In both cell types, only inhibitory 
histone marks were present at the IL17A locus (Figure 4.14A). At the CXCL13 
locus, only H3K4me3 and H3K36me3 marks were not present, across both sites 
and in-between (Figure 14.4B). Across both anchor sites, all 6 histone marks 
were found at the IL21R, IL23 and IFNAR1 loci in both cell types (Figure 
4.14C,D,E). As before, methylation marks were also mapped. Across all 5 loci, 
hypermethylation was more present than hypomethylation (Figure 4.14F,G). At 
anchor site a, IL17A had the most hypermethylation ranges, at site b, IL21R, and 
in-between sites, CXCL13 has the highest number of ranges, closely followed by 
IL21R. Hypomethylation ranges were only found at the IFNAR1 locus at anchor 
site a. IL17A had no hypomethylation marks at any site. Ranges with DNase I 
sites were present at IL17A and IFNAR1 loci at anchor site a, IL21R, IL23 and 
IFNAR1 at anchor site b, and across all loci in between sites (Figure 4.14H). In 
general, macrophages and inflammatory macrophages had similar epigenetic 
landscapes at the 5 CCS loci. DNase I was the only epigenetic mark to indicate 
any difference between macrophages and inflammatory macrophages, however 
this profile differed between the anchor sites and the region in-between. 
Specifically, at anchor sites of IFNAR1, macrophages had more DNase I ranges 
than inflammatory macrophages. Yet, in between anchor sites, inflammatory 
macrophages had more ranges. Therefore, taking this region as one, the 
difference is minimal and conclusions cannot be drawn. Taken together, this 
data broadly reflects earlier data from PBMCs, CD4+ T cells and monocytes, and 
shows that repressive epigenetic marks are more present at IL17A and CXCL13 
sites, and more enhancing epigenetic marks at the other CCS loci. However, as 
this dataset was gathered to understand the influence of an inflammatory 
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setting and overall, macrophage and inflammatory macrophage as largely 
comparable this did not further that understanding. However, it is important to 
note that the length of activation time of macrophage in an in-vitro setting is 
considerably different than the chronic activation that is present in RA. 
Ultimately these data highlight that to ascertain the difference in epigenetic 
marks between inflammatory and non-inflammatory environments, more 
datasets need to be used. It was considered that data from disease and healthy 







Figure 4.14 Mapping of Epigenetic Marks at MTX CCS Loop Anchor Sites in 
Inflammatory Macrophages 
Mapping of histones and methylation in inflammatory macrophages from healthy 
samples, extracted from DeepBlue Epigenomic Server. Data from hg38 genome. Histone 
data from ChIP-Seq technique (N=14), methylation data from Bisulphite-Seq (N=14) and 
DNase data from DNase-Seq (N=14). Ranges = regions of the genome within which peaks 
were recorded from ChIP-seq, Bisulphite-seq or Dnase-seq experiments. Site a = first 
EpiSwitchTM anchor point in CCS loop, site b= second EpiSwitchTM anchor point in CCS 
loop. In-between = stretch of DNA between CCS anchor sites. Coordinates used to 
capture epigenetic marks at EpiSwitch sites, the distance 500kb upstream and 
downstream and in-between (See Appendix). A) Histones from IL17A. B) Histones from 
CXCL13. C) Histones from IL-21R. D) Histones from IL-23. E) Histones from IFNAR1. F) 
Hypermethylation at EpiSwitchTM sites. G) Hypomethylation at EpiSwitchTM sites. Data is 
presented as mean. H) DNaseI hypersensitive sites at CCS loop sites. 2-way ANOVA with 
Tukey’s multiple comparisons. **p< 0.01, ***p < 0.005, ***p<0.0001 
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 4.2.8 Exploration of epigenetic landscape in RA CD14+CD16- 
Monocytes 
 
While data collected in healthy subjects could provide some insight, data from 
RA samples offered the opportunity to improve understanding of the epigenetic 
landscape and the potential functional consequences in disease. Other lab 
colleagues, namely John Cole and Cecilia Ansalone, conducted a ChIP-Seq 
experiment on RA CD14+ monocytes to understand the H3K4me3 profile in those 
cells. From the data, the same approach employed with the DeepBlue data was 
used to extract the MTX CCS relevant information. All patients were comparable 
in age, but there was a large variation on clinical disease activity index (CDAI) at 
the time the sample was taken (Table 4.2). Broadly, at sites of interest, RA and 
HC samples had similar H3K4me3 profiles (Figure 4.15). At Site a, IFNAR1 was 
the only locus to have any H3K4me3 peaks, both RA and HC had 1 peak present 
(Figure 4.15A). At Site b CCS loci, IL21R, IL23 and IFNAR1 had H3K4me3 peaks, 
with a maximum of 3 recorded in 1 RA patient (Figure 4.15B). In-between CCS 
sites, only IL17A (RA + HC) and CXCL13 (HC) had no peaks (Figure 4.15C). The 
IL21R site had most peaks, with a maximum of 16 recorded in 1 RA patient. 
These in-between data highlight the largest difference between RA and HC 
samples; at the IL21R site, RA samples have more peaks, but at the IFNAR1 site, 
HC have more peaks. Considering H3K4me3 is associated with enhancer activity, 
these data replicate earlier findings, that loop sites associated with R have 




Table 4.2 Characteristics of RA Patients used for ChIP-Seq 
Demographic and clinical information of 9 RA patients at the time peripheral blood 




Figure 4.15 Mapping of H3K4me3 at MTX CCS Loop Anchor Sites in RA CD14+ 
Monocytes 
Data from ChIP-Seq experiment in CD14+CD16- monocytes from RA peripheral blood, N=9 
and peripheral blood from HC, N=5. A) Number of peaks of H3K4me3 at Site a at all CCS 
loop sites. B) Number of peaks of H3K4me3 at Site b at all CCS loop sites. C) Number of 
peaks of H3K4me3 in-between all CCS loop sites. Coordinates used to capture epigenetic 
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marks at EpiSwitch sites, the distance 500kb upstream and downstream and in-between 






The work in this chapter aimed at identifying possible functional implications of 
the loop formation in the MTX CCS genes. Previous data indicated there may be 
a functional difference between R and NR loops, and epigenetic marks were used 
to investigate this further. Publicly available datasets were utilised to identify 
these epigenetic marks at the sites of interest. In the search for appropriate 
datasets to use, the DeepBlue Epigenomic Data Server was identified. Within this 
server were hundreds of datasets that could be mined for relevant information 
in this study. Included in the server were data on histone modifications, DNA 
methylation, DNA accessibility and markers of chromatin stability. Taken 
together the work explored in this chapter suggests the loops in NR may be more 
inhibitory for gene expression, and the R loops may be causing enhanced gene 
expression.  
 
The datasets available within the DeepBlue Epigenomic server reflect the 
literature. Most experiments were from blood, a part of which (PBMC) would be 
relevant in our work. The availability of data from various cell types also offered 
the opportunity to breakdown the potential impact of loops forming in each cell 
type. ChIP-Seq experiments were the most represented in the DeepBlue 
database. This is expected based on the discovery of ChIP-Seq in 2007, providing 
12 years to gather data using this methodology. Furthermore, ChIP-Seq is a 
relatively low complexity analysis and offers the ability to increase sensitivity by 
increasing sequencing depth314. DNase-Seq was another technique with abundant 
experiments available. This may be based on this technique being the hallmark 
for the identification of epigenetic modifications of the genome, and many other 
techniques have been adapted from that315. DNase-Seq is a versatile technique 
that can identify open chromatin, leading to identification of many regulatory 
features from enhancers and promotor regions to silencer regions. Moreover, it 
can often be applied to any cell type and applied genome-wide316. Other 
techniques, including ATAC-Seq, are in their relative infancy and therefore it 
was not expected that there would be an abundance of data for these 
techniques317. Data for multiple histone modifications also had thousands of 
experiments. Less data was available for cohesin proteins, but there was a 
minimal set of data that could be applied to this study. Ultimately, there was 
enough data to interrogate regions of interest for the MTX CCS.  
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With the datasets identified, data specific for our study could be extracted. We 
were interested in quantifying the epigenetic marks at the EpiSwitchTM anchor 
sites, including regions up to 500kb up and downstream. This was important as 
loops have been shown to range in size, comprising a large genomic area and 
bringing large stretches of DNA into close-proximity. Mamberti and Cardaso have 
shown loops to range from 30-90kb in size318 and loops in a study by Zhao et al 
were a median of 16kb in size319. Some other studies have suggested a region of 
~500kb to 2mb could be possible for a loop, and could even reach over 
7mb141,320. Notably, this variation in sizes will depend of sequencing depth used, 
and larger loops may be less regulatory dense. Moreover, the EpiSwitchTM 
algorithm identifies loops, which may differ in size, but that are reproducibly 
detected. Loop formation can have a variety of consequences, dependent on the 
other epigenetic features in the 3D genomic area. Including the larger region in 
our analysis provided a more detailed, informative picture of the possible 
functional consequences of loop formation. This also extends on previous studies 
that have chosen to include regions 5kb up and downstream of genes of 
interest321.  
 
With the availability of data on epigenetic marks with differing regulatory 
consequences, the potential functional implications of loop formation could be 
explored. Firstly, data was studied from experiments using healthy PBMC 
samples. IL17A and CXCL13 loop sites (associated with NR) had predominantly 
the presence of known inhibitory histone modifications, H3K9me3 and 
H3K27me3. IL21R, IL23 and IFNAR1 loop sites (associated with R) had the 
majority known to be associated with increased transcription (Figure 4.3). The 
disparity between activation and repression marks were not as clear with 
methylation. At the EpiSwitchTM loop anchor sites, hypermethylation was 
marginally more present than hypomethylation, suggesting the potential for 
transcriptional inhibition. DHSs at loop anchor points were also measured. The 
IFNAR1 loop was the most accessible, based on DHSs, while CXCL13 had no 
presence of any hypersensitive sites. This suggests the CXCL13 locus may be less 
accessible for other epigenetic modifications to have a regulatory impact. 
Mapping the data between the anchor sites showed the disparities at the anchor 
sites were not replicated, which makes the potential functional impact of loop 
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formation less clear. IGV was used to visualise how these epigenetic marks may 
interact with each other (Figure 4.4). The representative image of the IL21R 
EpiSwitchTM site illustrates that DHSs interact with several histone marks. The 
overlap of enhancer marks H3K27ac and H3K4me1 suggest the site is an active 
enhancer site. However, these marks also overlap with the known repressor 
mark, H2K27me3, suggesting the potential for a more poised state of this gene. 
Identifying transcription factor binding sites would be helpful to further 
understand the enhancer potential of this loop and others in the signature322. 
The enrichment of histone marks up and downstream of the site also alluded to 
the potential function of signature loops (Figure 4.5). Results revealed the IL17A 
locus to be most distinct based on enrichment. Similar to results at the 
EpiSwitchTM anchor points, data suggests that the IL17A loop may be inhibitory in 
nature. This may result in the downregulation of other proinflammatory 
cytokines. Secukinumab, an IL17A inhibitor has been shown to be effective in 
the reduction of RA disease activity323. Based on the efficacy of this therapy, it 
may suggest if IL17A activity in RA is already reduced, MTX or other 
pharmacological interventions may be less effective.  
 
The data from CD4+ T cells appeared to replicate the findings from PBMCs 
(Figure 4.6). IL17A and CXCL13 had mostly inhibitory histone marks while IL21R, 
IL23 and IFNAR1 regions were absent of inhibitory histone marks. Similarly, 
hypermethylation was highest in IL17A at site a, and highest in IL21R at site b, as 
with PBMCs. Again, hypomethylation levels were lower than hypermethylation. 
As with PBMCs, IFNAR1 and IL21R were the only loci to have ranges of 
hypomethylation in their region. There were many more DHSs recorded in CD4+ T 
cells than in PBMCs. Most loci, at both loop anchor sites, and in-between anchor 
sites, had considerably large variation in the number of DHSs recorded between 
experiments, which serves as a reminder that the results should be interpreted 
with care. IGV visualisation suggests IL17A is in a poised state, based on the co-
localisation of histone modifications with opposite regulatory functions (Figure 
4.7)324. Considering the histone enrichment 500kb upstream, CD4+ T cells are 
comparable to PBMCs and illustrate IL17A is the most distinct gene (Figure 4.8). 
The enrichment of H3K27me3 continues the suggestion that IL17A loop may be 
inhibitory in nature. IL21R and IFNAR1, are almost identical in enrichment of all 
histones measured. This splitting of enrichment, grouping IL21R and IFNAR1 
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together follows the hypothesis that R and NR loops have functional differences. 
The profile associated with particular loops is lost when monitoring the 
enrichment of histones 500kb downstream of loop anchor sites. In this region, 
IL21R appears most distinct, with high enrichment of only H3K36me3. Compared 
to upstream, the enrichment of histones at the region around IL17A implies an 
environment likely to enhance transcription. Overall, this suggests the formation 
of a loop would create more of a poised environment. 
 
CD14+CD16- monocyte data suggests histone enrichment at loop sites to be 
similar to previous data from PBMCs and CD4+ T cells (Figure 4.9). There were no 
histone marks mapped to CXCL13 sites and no inhibitory histone marks mapped 
to IL23 and IFNAR1 anchor sites. At IFNAR1 anchor site b, there was a substantial 
degree of variation between ranges recorded between samples, particularly at 
H3K4me3 and H3K27ac, which highlights the importance of interpreting the data 
with caution. As with previous data, there were more ranges of 
hypermethylation than hypomethylation recorded across all loci. The DNase 
hypersensitivity profile was different to CD4+ T cells with the absence of DHSs at 
the CXCL13 loci. IFNAR1 had considerably more DHSs then IL23. IGV visualisation 
showed crossover of multiple histone marks at both loop anchor sites in IFNAR1 
(Figure 4.10). However, in the absence of inhibitory histone marks, unlike the 
suggested poised state of genes shown in PBMCs and CD4+ T cells, this data here 
suggests IFNAR1 is an active enhancer site. This data was also supported by the 
availability of transcription factor data from the DeepBlue Epigenomic server. 
DHSs sites overlap with CTCF, STAT1 and IRF at site a and b, respectively. This 
further supports the suggestion of likelihood that there could be enhanced 
transcription of this gene. This is supported by previous work in mice and 
humans, particularly in the locus control region (LCR). In transgenic mice, in a 
1.9kb region with a DHS, the human beta-globin gene expression was increased 
100-fold325. Previous work has implicated the role for DHSs in protein 
interactions at the LCR. Data suggests that DHS properties are more responsible 
for protein interactions than to other LCR regulatory features326. In the region 
500kb upstream, all 3 loci appear to have similar enrichment of all histones 
(Figure 4.11). IL23 differs with the higher enrichment of H3K4me3 and 
H3K36me3. Based on the low enrichment of H3K9me3 and H3K27me3, all three 
loci in this region appear to be in an environment which would support active 
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transcription. This environment appears to be similar 500kb downstream, based 
on higher enrichment of the same histones as upstream. The data suggests 
active transcription would be more likely in the downstream region based on the 
higher enrichment of H3K36me3.  
 
Exploring data in the differing cell types gave the opportunity to observe if the 
epigenetic environment may be different between them, a question that could 
not be answered from data explored in Chapter 3. Overall, the data suggests 
that the environments at CCS loci are similar in CD4+ T cells, CD14+CD16- 
monocytes and PBMCs. Similar regulatory profiles between CD14+ monocytes and 
CD4+ T cells alludes to their interaction in vivo327. However, as this data is for 
healthy cells, samples from RA are very likely to differ. In RA, elevated IFNAR1 
expression is known, which would parallel our data328. However, it could be 
hypothesised that there may be more enrichment of enhancer marks at the 
IFNAR1 locus in an inflammatory cell than found in healthy populations studied 
here. Moreover, a study has shown that the whole blood IFNAR1 signature is 
mostly contributed to by peripheral granulocytes, such as neutrophils. This is an 
indication of another cell type of interest for future work257. While our data 
suggest that CXCL13 expression could be repressed, CXCL13 levels have been 
suggested to be a potential candidate for measuring RA disease severity234. 
Furthermore, while IL21R expression is known to contribute to osteoclast 
formation in multiple myeloma, its expression in RA is less understood. Our data 
from healthy subjects would indicate the potential for increased expression of 
this gene, which exemplifies the need for caution when interrogating the data 
and the importance of exploring these results in RA patients329.  
 
The overlap of CTCF and cohesin has been widely discussed in the literature and 
has been found to be indicative of stable chromatin loop formation330. From the 
datasets available, interactions between CTCF sites and cohesin proteins were 
discovered. Most interactions were found at the IL17A loop site, which was the 
only loop site to have both RAD21 and SMC3 cohesin complex proteins (Figure 
4.12). The IL21R loop site had least CTCF cohesin protein overlap, with only 
SMC3 presence at one anchor point on the loop. Li et al carried out a study to 
demonstrate constitutive CTCF and cohesin interaction in the human genome. 
Using multiple cell lines they illustrated that RAD21 and SMC3 overlap in 90% of 
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cases331. This may suggest the CTCF-cohesin interaction at the MTX CCS loop 
sites are not constitutive, which would relate to the findings that the loops are 
largely dynamic (Section 3.2.4).  The CTCF and cohesin proteins are not close to 
promotors of transcription start sites (TSS) in the IL17A loop region, suggesting a 
structural role. The interactions at IL21R and IFNAR1 loop sites may play more of 
a transcriptional role based on the localisation to the gene itself. If this co-
localization was indicative of enhancer transcription, and results could be 
translated from cell line to B cells in the context of RA, this may suggest 
contribution to B cell dysregulation in those who respond to MTX239 332. B cells 
would be of interest to explore further as they have been heavily implicated in 
RA pathogenesis. Specifically, they can act as antigen-presenting cells leading to 
the activation of autoreactive T cells, and can also contribute to the production 
of autoantibodies333,334. Contrastingly, some studies report that peripheral B cell 
level in RA blood is comparable to healthy blood. Moreover, some new roles for 
B cells in RA have been found which suggest B cells within bone marrow 
aggregates contribute to the upregulation of bone-resorbing osteoblasts, and 
thus restore bone homeostasis335. Preferably, exploration of these concepts 
would be done in primarily cells, although data from a B cell representative cell 
line, GM12878 would be an appropriate surrogate. 
 
Further research has shown that CTCF-cohesin protein interactions are highly 
cell specific. Cohesin was found to co-localize with master regulators such as ER 
in breast cancer cell lines and HNF4A in liver cell lines336, which suggests their 
role in transcription. As our data was taken from the GM12878 cell line, it would 
be of interest to understand if any of the cohesin proteins at the loop sites were 
also in proximity to master regulators for B cells, such as Pax5337. There was not 
sufficient time to identify publicly available datasets for this information, but it 
should be done going forward to build on the data already found. Moreover, the 
interpretation of these results is limited by the lack of datasets available to 
explore the presence of other cohesin proteins such as SMC1 and STAG. Research 
should be done to ascertain if other online datasets exist obtain this 
information.  
 
Data shown in Figure 4.13 revealed that significant interactions at promotor sites 
are present within the regions of the MTX CCS loci. These results indicate that 
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the formation of signature loops in R and NR to MTX are potentially playing a 
vital role in transcriptional regulation. IL23 and IFNAR1 have most interactions, 
and the biggest range across the 17 cell types tested. These findings closely 
relate to the findings from mapping of other epigenetic marks at MTX CCS sites 
and further support the hypothesis that the loops in IL21R, IL23 and IFNAR1 are 
acting to enhance gene expression. Lymphoid subsets have more interactions 
than the myeloid subset, which would correspond to the cytokines and receptors 
being investigated. CD4+ T cells had high numbers of significant interactions in 
all loci. Earlier data shown in this chapter suggests that some loci may be in a 
poised state based on the co-localisation of certain histone marks. Interestingly, 
a study has linked the formation of new promotor-enhancer loops, identified by 
PCHiC, with activation of poised genes338. Moreover, a recent study has shown an 
adapted 3C method has facilitated identification of over 7000 active 
promotors339. Specifically, by removing the noise created by some 3C 
methodologies, it has allowed the capture of more information, such as hubs. 
Another newly developed enhancer exploratory network, HACER, allows 
exploration of cell-specific enhancers at loci of interest340. Association analysis 
with these datasets would be useful to compliment the work described in this 
chapter. Our work shows where possible poised genes were identified is also 
where promotor loop interactions were found. No interactions were captured at 
the CXCL13 locus in our area of interest, however, other datasets may exist to 
find out information about the epigenetic marks in this region. In future studies, 
it will be important to explore this dataset further and capture the relationship 
between promotor sites and eQTLs. Notably, a recent study has explored this 
concept in heart disease and was able identify new candidate genes in heart 
disease through exploration of the promotor interactome and eQTLs in 
embryonic stem cell-derived cardiomyocytes341. Out with the scope of this 
chapter was exploration of the possible orientation of transcription. This may be 
an appropriate follow up experiment.  
 
So far, based on availability, only data from healthy cells had been analysed. To 
translate these findings to further understand disease, data from cells in an 
inflammatory environment was considered beneficial. Data from inflammatory 
macrophages was of interest in the exploration of possible loop function. 
Mapping of epigenetic marks in macrophages, allowed direct comparison 
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between a non-inflammatory and inflammatory environment. Like PBMCs, the 
histone enrichment at loop sites suggests the region surrounding the CXCL13 
locus is more inhibitory, and the region around IL23 and IFNAR1 may be more 
likely to enhance transcription (Figure 4.14). However, there was only 1 
H3K237ac protein identified at the CXCL13 loop site, therefore it is difficult to 
be conclusive. Multiple experiments identified a peak of H3K36me3 at the IL23 
loop site, indicating potential for transcription. Regulation of transcription in 
macrophages can be largely attributed to enhancers342. The H3K4me3hiH3K27achi 
status of site a in IFNAR1 indicates enhancer presence. An enhancer at this site 
would result in the downstream increase of inflammatory cytokines343. There 
was no methylation data extracted at the IL23 site, while CXCL13 loop site was 
more enriched for hypermethylation, than IFNAR1. In this case, the histone data 
and methylation data are partially aligned with each other in terms of functional 
implications. Once more, further data on other inflammatory cell types would 
provide more insight.  
 
In summation, the high-throughput mapping of histone marks, methylation and 
DNA hypersensitive sites consistently suggests that NR loops are more likely to 
have an inhibitory function, while R loops are more likely to enhance 
transcription. This is consistent with the eQTL presence at only R loops, which 
show where single nucleotide polymorphisms (SNPs) are likely to have a 
functional impact. It is important to note that variation in results and the 
variation between samples in each cell type may not be due to biological 
reasons, but down to differing experimental protocols. As mentioned previously, 
ChIP-Seq experiments are easily adaptable and vary in sequencing depth. As 
such, a peak measured in one region in one experiment and not another, may be 
due to sequencing depth344. Moreover, variability with methylation 
quantification can arise from the incomplete bisulphite conversion resulting in a 
hyper methylated region being interpreted as a hypo methylated region345.  
 
Further to the analysis described, interpretation of the data could be enhanced 
by quantifying the signal of each peak, mapping the coverage of each epigenetic 
mark, quantifying the distance to nearest to TSS and finding more TF data. 
Previous research has identified that signal quantification is more applicable to 
transcription factor binding as there is a large peak over a small range, as 
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opposed to a histone modification which may span a large region, as this data 
has shown (Figure 4.10)346. HACER, as mentioned above, would be an 
appropriate tool to explore this concept further. HACER could facilitate 
association analysis with functional SNPs and TF binding sites. Moreover, going 
forward it would be useful to look at B cells and DCs. Work by Karlic et al 
demonstrated that gene expression predictions based on the predictions of 
certain histone modifications could be translated successfully from one cell type 
to another347.  
 
Although data from inflammatory macrophages may be more easily applied to 
RA, the data was still from healthy donors. Data from RA patients would be 
extremely valuable to understand the epigenetic landscape in RA and observe if 
there were similarities or differences with the data gathered from healthy 
datasets. Thus, data from a previous experiment carried out in the lab on CD14+ 
monocytes was used. It was found that H3K4me3 peaks had similar profiles in 
both RA and healthy samples (Figure 4.15). Across IL17A and CXCL13 loci, there 
were few H3K4me3 peaks, in comparison to the IL21R, IL23 and IFNAR1 loci. 
Whilst this data did not provide much insight into the influence of RA on this 
histone profile, the data did align with other findings discussed earlier in this 
chapter (Figure 4.6, 4.9, 4.12) and suggest at some loci where loops are 
associated with R (IL21R and IFNAR1), there is an environment that could 
enhance gene expression activity. A recent study demonstrated that increased 
IFNAR1 expression could be associated with patients less likely to respond to 
TNFα inhibitor treatment348. Most of these patients were also being treated with 
MTX, so it is interesting to consider the influence of increased IFNAR1 expression 
and contribution to treatment response from MTX. As IL21R is not expressed on 
classical monocytes, the result of increased expression in RA in this cell type is 
less understood. However, increased expression in monocyte derived 
macrophages and Th1 cells, is known to contribute to osteoclastogenesis and 
cytokine production, respectively, which ultimately contributes to RA disease 
progression if not controlled349,350. The caveat to this section of the study is that 
only the H3K4me3 histone modification was explored, and therefore, it is very 
likely there are other epigenetic marks at these sites in RA patients would 
provide more insight into the pathogenic consequences of loop formation in R 
and NR.  
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One of the significant limitations of this chapter is the varied availability of data 
for each epigenetic mark and cell type. As mentioned above, data from DCs, B 
cells, and regulatory T cells, from both health and disease would of benefit to 
provide a more informed picture on RA pathogenesis implications. Not all cell 
types had data available for every epigenetic mark of interest. Moreover, most 
data came from healthy samples, therefore the implications of disease have yet 
to be fully understood. There was also differing number of samples and 
experiments between each locus and epigenetic mark, which limited statistical 
analysis capabilities. Other datasets that would strengthen interpretation of 
functional implication of loop formation may be those that identify the function 
of SNPs which co-localise with loop anchor points and epigenetic marks. Further 
work in-silico to gain more of an understanding may lead to useful in-vitro 





The work in this chapter builds on the findings of the MTX CCS and has shed light 
on the possible functional implications of loop formation in RA patients pre-MTX 
treatment. As with the previous chapter, this work demonstrates the complexity 
of investigating the 3D epigenetic environment in disease. The breadth of 
publicly available data analysed in this work suggests that R and NR loops are 
present in contrasting epigenetic environments, that may contribute the ability 
to respond to MTX. Data from RA patients implied that the findings from healthy 
data collected could be applicable in disease, however this is likely to change 
with analysis of more RA datasets.  
 
In future studies, the work in this chapter should be extended to further publicly 
available datasets, or the generation of new bespoke data, to assess the 
epigenetic environment in other disease relevant cell types such as B cells and 
DCs, as well as RA T cells and monocytes. Ultimately this work should be 
translated in-vitro to validate the findings found in-silico. Overall, this work has 
shown the potential to gather a more informed picture of CCS loops and their 
functional potential, which may ultimately provide insight into disease 
pathogenesis and MTX response.   
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The work in previous chapters explored the stratification potential of the 
methotrexate (MTX) chromatin conformation signature (CCS) in more detail and 
attempted to understand the functional consequences of loop formation and its 
relation to disease pathogenesis. Whilst exploring stratification around MTX 
response is vital, further baseline stratification signatures would be beneficial 
and may provide useful insight into the 3D architecture underpinning different 
responses to rheumatoid arthritis (RA) therapy.  
 
There has been a regulatory role suggested for genome-wide association study 
(GWAS) loci, which has been strengthened by the observation that single 
nucleotide polymorphisms (SNPs) found through GWAS are abundant at DNA 
variants associated with gene expression alterations209. These are known as 
expression quantitative trait loci (eQTL) and have been found in the loci of 
people with autoimmune diseases, including RA. These eQTLs could provide the 
link between suggested causal SNPs and the consequent abnormal gene 
expression which can lead to disease.  
 
By most, RA is now considered a heterogeneous syndrome, based on molecular 
and clinical endotypes351. With the development of new technologies, identifying 
endotypes in RA has attracted growing research interest. Various methods have 
been used to define RA endotypes, such as identification of serum biomarkers351, 
as well as RNA-seq of blood and synovial tissue from RA patients352. Given that a 
prior proof-of-principle study in leukaemia patients provided evidence that 
chromosome conformation could classify leukaemia subtypes294,353, we 
hypothesised that using 3D chromosomal conformation could be a way to define 
endotypes in RA. 
 
For the work in this chapter, custom microarrays were designed based on 
findings by Walsh et al 209, with the aim of capturing the differences in the 3D 
epigenetic environment underpinning different response states in RA. This 
chapter explores the process of identifying appropriate longitudinal early RA 
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clinical samples for use on the custom microarrays and determining the most 
informative analysis methods.  
 
To achieve this the aims were:  
 
1) Identify patients from Scottish Early Rheumatoid Arthritis (SERA) cohort with 
varying 12-month response trajectories 
 
2) Use samples on custom microarrays to identify stratifying EpiSwitchTM loops 
between groups 
 
3) Statistically refine microarray data to find informative stratifying loops and 
use these to shed light on underlying pathogenesis between endotypes 
 
4) Identify potential candidates for a new CCS that could predict response 





5.2.1 Distinct trajectories of early RA exist in SERA cohort  
 
In addition to identifying prediction signatures for response to specific therapies, 
being able to identify if someone will follow a certain response trajectory is 
valuable. The SERA cohort was interrogated to identify the 12-month response 
trajectories of early RA patients (Figure 5.1). Three main trajectories were 
observed over this time-period. The first of these are the ‘responders’ (R) 
(Figure 5.1A). These are patients who achieve clinical remission or low disease 
activity (LDA), CDAI <2.8, by 6 months and maintain this state by 12 months. The 
second common group are the ‘non-responders’ (NR). These are patients who are 
do not reach LDA (CDAI 2.8>10) or remission, regardless of therapy (Figure 5.1B). 
The third group identified in this cohort are the ‘initial responders’ (IR) (Figure 
8.1C). These are patients who achieve remission by 6 months, however by 12 
months, these patients have increased disease activity that varies from low to 
high (HDA). By examining the epigenome from patients from these three groups, 
we hypothesised that there may be a differing 3D chromatin profile, which could 
allude to differing underlying pathogenesis. To do this, the ‘extremes’ from the 
3 trajectories were chosen (Figure 5.1D-F), and the demographics of these 
patients were assessed to determine if there was indication of which trajectory 
a patient would follow (Table 5.1). Of the chosen ‘extreme’ patients, the R 
group were made of patients who all had HDA at baseline, reached remission and 
remained there for the period of observation. Those in the NR group all had HDA 
over the 12-month period. In the IR group, 4 patients had HDA at baseline, of 
which 2 achieved LDA and 2 achieved remission by 6 months. The 2 patients in 
remission had moderate disease activity by 12 months and the 2 with LDA at 6 
months, had HDA at 12 months. The other 2 patients in this group began with 
moderate CDAI at baseline, reached low CDAI at 6 months and returned to HDA 





Figure 5.1 Identification of Different Response Trajectories in SERA cohort 
Trajectory of patient response over 12 months. CDAI defined as (TJC28/10)+(SJC28/10)+ 
patient global assessment + physician global assessment. A) Responders. B) Non-
responders. C) Initial responders. D-F) Trajectory of patients selected for use on arrays 
(N=6 for each group, each time point =54 samples in total). DAS28 scores were also used 
to confirm disease activity; data not shown  
BL, baseline; CDAI, clinical disease activity index; DAS, disease activity score; N, 
number of samples; TJC, tender joint count; SJC, swollen joint count 
 
Most baseline characteristics of chosen SERA patients were similar between the 3 
groups, with the biggest difference between groups observed with clinical 
disease activity scores (Table 5.1). NR and IR had very comparable average ages 
(54.6 and 57.6, respectively), with R having the highest average age (61.3). Sex, 
race and BMI were very comparable between groups. NR and IR had the same 
percentage of rheumatoid factor (RF) positive patients; and R and IR had the 
same percentage of anti-citrullinated protein antibodies (ACPA) positive 
patients. Overall, there was no baseline demographic, serum protein or disease 
activity score that could successfully predict what trajectory someone would 
follow from baseline. The baseline characteristics between groups were tested 
for statistical significant differences. DAS28 CRP was the only characteristic to 
show statistically significant differences between the 3 responder groups. As 
there was no statistically significant differences between the groups for CDAI 
score, this meant that the groups were comparable in terms of baseline disease 
activity. This warranted the investigation via custom microarrays to identity the 





Table 5.1 Baseline Characteristics of RA Patients used for Custom Microarray  
ACPA, anti-citrullinated protein antibodies; CDAI, clinical disease activity index; CRP, C-




There was an effort to select patients for the microarray that had the same 
treatment regimens. However, the priority was the availability of patients with 
‘extreme’ trajectories that had samples from all three time points available 
from the SERA biobank. As such, chosen patients had a variety treatments over 
the 12-month trajectory (Figure 5.2). All patients were treated with at least 1 
conventional synthetic disease modifying anti rheumatic drug (csDMARD) over 
the 12 months and only 1 patient did not start treatment on MTX. 4 of 6 R were 
treated with monotherapy MTX for the year, with 1 other on combination MTX 
and HCQ therapy and the other combination MTX and SSZ. Four NR were also 
only treated with monotherapy MTX over 12 months. One patient was treated 
with triple csDMARD therapy. The other NR was treated with MTX for 3 months 
before switching to SSZ monotherapy, then SSZ and HCQ in combination. Most IR 




Figure 5.2 Treatment Timeline of Chosen RA Patients for Microarray Patient 
Treatment Timeline 
Treatment trajectories shown for patients selected for endotype microarray analysis. 
Patient treatment information from SERA cohort. Trajectory represents csDMARD 
therapy over 12 months from baseline. R shown in green, NR shown in red, IR shown in 
orange. Black arrows represent MTX, blue for HCQ and green for SSZ.  
csDMARDs, conventional synthetic disease modifying anti-rheumatic drug;  
HCQ, hydroxychloroquine; NR, non- responder; m, month; MTX methotrexate;  
R, responder SERA, Scottish Early rheumatoid arthritis cohort; SSZ, sulphasalazine  
 
5.2.2 Microarray quality control  
 
The custom microarrays were designed by Oxford BioDynamics Plc (OBD), based 
on results from the study by Walsh et al. In brief, EpiSwitchTM loops in proximity 
to eQTLs identified by Walsh et al209, which were biologically relevant for RA, 
were chosen for the array (Appendix). After clinical samples were chosen, they 
were subsequently sent to the facilities at OBD to be run on the microarrays. 
The first step in the microarray analysis process was to measure the quality of 
the data. Firstly, this involved observing the red / green dye distribution of the 
data. Preliminary analysis before all batches of the array had been run, revealed 
that 1 array was an outlier, as the dye distribution was not in-line with the other 
arrays (data not shown). This resulted in that array being included in the 4th 
batch where the error was rectified, and all densities were uniform (Figure 
5.3A). Loess normalisation was successful, as shown in Figure 5.3B. Another 
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quality control (QC) measure was to plot slide number on a PCA plot. To reduce 
batch effects, samples of different time points and different response 
trajectories were spread across slides, therefore slides would not be expected to 
cluster on the PCA. Samples from slide 14 are highlighted as a representative of 




Figure 5.3 Quality Control Assessment of Microarray Data  
Series of plots demonstrating quality of raw microarray data and the influence of 
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normalisation. 4 dual-colour arrays in total, 4 slides per array, 4 samples per slide. Each 
slide had samples of different responder types and time points. A) Red-green density 
histogram before normalisation. B) Red-green density histogram after within array 
locally weighted polynomial regression (Loess) normalisation. C) PCA plot with numbers 
of slides labelled, and samples from slide 14 circled in orange. Plots created using 
Limma package on R studio. 
 
Based on the success of the quality control, it was deemed appropriate to 
continue with further analysis. In the first instance this involved the use of 
Limma software (Section 2.5.3). Clustering through PCA plotting was performed 
as a global level analysis of the data (Figure 5.4). At baseline, R appeared to 
cluster together in PC1, with some more overlap between NR and IR (Figure 
5.4A). At 6m, NR and IR more closely clustered together and R did not cluster as 
1 group, but 2 groups (Figure 5.4B). At the 12-month time point all groups were 
clustered together, with only 3 IR samples shown in proximity to each other 





Figure 5.4 Global Analysis of Microarray Data  
Pre-linear model analysis of microarray data. 4 dual-colour arrays in total, 4 slides per 
array, 4 samples per slide. N=6 for each responder group at each time point. A) PCA 
labelled by responder type at baseline. B) PCA labelled by responder type at 6m. C) PCA 




5.2.3 Limma linear modelling 
 
After global level analysis, a linear model within Limma was used to extract 
informative contrasts between endotype groups, as well as between disease and 
pooled healthy controls (HC) (Table 5.2). An informative contrast was one that 
adj.P.Val <=0.05 and abundance score (AS) -1.1<= or >=1.1. More details on this 
analysis are found in Section 2.5.3. Disease-HC contrasts produced more 
informative loops than endotype comparisons at all time points. All disease-HC 
contrasts had over 10,000 informative loops. The maximum number of 
informative loops was found from the R-HC contrast (23131); R in the R-IR 




Table 5.2 Informative loops from Limma contrasts  
Data generated from contrasts made in the Limma linear model. Informative loops 
defined as a statistically significant difference from 0 on a log 2 scale with adj.P.Val 
≤0.05 and abundance score (AS) -1.1≤ or ≥1. Positive (+) AS associated with sample on 
left of the contrast model and negative (-) AS associated with sample on right of the 
contrast model.   
6m, 6 months; 12m, 12 months; HC, healthy control; IR, initial responder;  




Reflecting on the data from the Limma contrasts, I debated whether the model 
was extracting many more ‘meaningful’ loops than expected. This led me to 
consider that the model may not be stringent enough to find true stratifying, 
and disease-informing loops. With some comparisons extracting over 20,000 
‘informative’ loops, approximately 10% of the total loops captured on the array, 
it was decided that a more stringent method of identifying stratifying loops was 
needed. The hope with a new model is that we would find true biologically 
meaningful results, and it would also reduce the number of loops to take 
forward for further analysis.  
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5.2.4 RankProd analysis of microarray data - Responders 
 
To overcome the possible issues of statistical filtering with the linear parametric 
testing using Limma, an alternative analysis method was chosen. Namely, 
RankProd 2.0, a Bioconductor package used to find differentially expressed 
molecular profiles based on two non-parametric statistics (rank product and rank 
sum). This method has been widely used to detect variables consistently 
upregulated (or downregulated) in replicate experiments and developed with 
gene expression microarrays in mind. As such, RankProd 2.0 was chosen as the 
analysis method going forward.  
The RankProd approach produced many significant loops, but considerably less 
than the Limma method, with a maximum number of statistically significant 
loops of 4765 in the R-HC contrast at 6m (Table 5.3). Disease-HC contrasts were 
most significant at 6m for R and NR groups, and at 12m for IR. 
 
Table 5.3 Informative Loops from RankProd Contrasts 
Analysis conducted under supervision of Dr Ewan Hunter and Christina Koutsothanasi 
(OBD). Significant loops defined as loops adj P value ≤0.05 and AS -1.1≤or ≥1.1 For each 
patient group at each time point, N=6, pooled HC, N=20  
6m, 6 months; 12m, 12 months; HC, healthy control; IR, initial responder;  





The significant loops that had the potential to stratify disease and pooled HC 
samples were taken for further analysis. Initially, a Venn diagram was generated 
from the significant loops at baseline, 6m and 12m in R (Figure 5.5A). This 
allowed the visualisation of stratifying loops common between pairs of time 
points, and importantly loops that were common to all time points. 319 
significant loops were common to all time points, and could be considered the 
‘stable’ loops. 6m had the highest number of time-point unique loops (4175), 
followed by 12m (48) and baseline (16). Using analysis software on the 
EpiSwitchTM data portal, a new interactive interface 
(https://episwitch3dgenomicsportal.com) to interrogate EpiSwitchTM analysis 
data, the closest 3 genes to the 319 ‘stable’ loops were identified (Figure 
5.5B)(Section 2.5.10). This list of genes was then entered into the Gene 
Analytics platform to understand the most significant pathways enriched based 
on these genes (Figure 5.5C). All pathways had medium score matches for the 
genes in each pathway which indicated a corrected P-value of 0.05 to 1. The 
‘phagosome’ pathway was the most significant of this group, with 16 genes 
matching this pathway. Gene Ontology (GO) terms were also explored (Figure 
5.5D). In contrast to the pathways, all GO terms had a high score match for the 
genes associated with each term, suggesting better ontologies with defined 
genes, in addition to a corrected P value of <0.05. The ‘ER to golgi transport 
vesical membrane’ had the highest match score in this group. This may suggest 
that the effective transport of intracellular proteins is important in responding 




Figure 5.5 Pathway Enrichment of Significant Stable Loops in R    
List of loops generated from RankProd analysis. A) Venny 2.1 used to generate Venn 
diagram of significant loops in the R group at all time points, significant ≤0.05 and AS -
1.1≤ or ≥1.1. B) Schematic representing how EpiSwitchTM data portal captures 3 closest 
genes to an anchor site, IL17A locus used as a representative image. Gene Analytics 
then used to generate list of significant pathways based on matched genes. Scores are 
given to each pathway to reflect their matching quality to the set of genes entered to 
the analysis platform. An algorithm is used to determine the threshold for high, medium 
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and low scores in each dataset. Cells in green = high score match, corrected P-value of 
<0.05, cells in orange = med score match, corrected P-value of 0.05-≥1. Tables 
generated for C) Top pathways, D) Top GO terms.   
6m, 6 months; 12m, 12 months; BL, baseline, kb, kilobase;  
RR, reverse-reverse orientation 
 
The gene list used for Gene Analytics analysis was then used to make a protein 
network to understand the relationship between the genes found in the region of 
stable loops in the R group (Figure 5.6). The online STRING platform 
(https://string-db.org/) was used to generate this network (Appendix). which 
could subsequently be transferred to a programme called Cytoscape for further 
analysis (Section 2.5.7, 2.5.8). Network analysis tools (topology statistics) were 
then employed on Cytoscape to find the most connected genes, represented by 
network ‘nodes’ and ‘edges’. This was carried out with a view of considering the 
more connected nodes, the most contributing loci in the pathways associated 
with R. The top 9 nodes were noted (Figure 5.6A). The most connected node for 
the R network, with 23 connections to other genes from the whole Gene 
Analytics list, was BRCA1. Finally, the EpiSwitchTM data portal was used to 
visualise the genomic environment around this locus, an approach shown in 
Chapter 4 (Figure 5.6B). Two loops could be visualised in this region; the anchor 
point of the loop with statistical significance in R is highlighted. For closer 
characterisation, specifically to visualise the other epigenetic marks that 
surround this locus, a circos plot was generated (Figure 5.6C). The ability to 
generate circos plot within the EpiSwitchTM data portal was extremely useful, as 
this platform contained data from other experiments which investigated histone 
modifications in immune cells. The anchor point that resides within the BRCA1 
gene overlapped with H3K27ac, (found in CD8, CD4 cells) as well as multiple 
clinically important SNPs. The other anchor point that is part of this loop lies 
within G6PC locus. At this site, there is also the presence of H3K27ac from CD8 
and CD19 cells. These epigenetic marks illustrate an environment that may 





Figure 5.6 Environment Surrounding Central Enriched R Loop 
Network analysis used to understand central players in significant pathways. A) Top 
most connected nodes determined by most directed edges of a node in Cytoscape. Gene 
with most connections highlighted in red. B) Genome browser view from EpiSwitchTM 
data portal showing BRCA1 gene genomic environment. Genes in dark blue, loops in pink 
and EpiSwitchTM anchor points in orange. Red boxes illustrate anchor points statistically 
significant loops in this group. 1 anchor point present behind ‘EpiSwitchTM Anchors’ 
label. C) Circos plot with the addition of ClinVar representing disease associated SNPs, 
and H3K27ac marks from publicly available datasets. Red box indicates gene of interest 
and gene which other loop anchor point lies within and where anchor points of interest 
interact with other epigenetic features.  
 
5.2.5 Rank Prod analysis of microarray data – Non-Responders 
 
The same approach used for significant R loops was used for NR loops (Figure 
5.7). 625 loops significantly differentiated disease and HC at all 3 time points 
(Figure 5.7A). 825, 70 and 25 loops significantly differentiated between disease 
and HC at 6m, 12m and baseline, respectively. The 625 ‘stable’ loop list was 
entered into GeneAnalytics software. All pathways had a med match gene score 
(Figure 5.7B). The top scoring pathway was the ‘Phagosome’ pathway. There 
were 2 high score matching GO terms, namely ‘Interferon-gamma-mediated 
signalling pathway’ and ‘ER to golgi transport vesical membrane’ with 13 and 14 
matched genes, respectively (Figure 5.7C). This data suggests regulation of 
interferon gamma signalling may be important to NR, and the enrichment of 
genes in the ‘ER to golgi transport vesical membrane’ pathways may suggest that 





Figure 5.7 Pathway Enrichment of Significant Stable Loops in NR 
List of loops generated from RankProd analysis. A) Venny 2.1 used to generate Venn 
diagram of significant loops at all time points, significant adj. P value ≤0.05 and AS -
1.1≤ or ≥1.1. Gene Analytics then used generated list of significant pathways based on 
matched genes. Scores are given to each pathway to reflect their matching quality to 
the set of genes entered to the analysis platform. An algorithm is used to determine the 
threshold for high, medium and low scores in each dataset. Cells in green = high score 
match, corrected P-value <0.05, cells in orange = med score match. P-value 0.05-≥1. 
Tables generated for B) Top pathways and C) Top GO terms.   
6m, 6 months; 12m, 12 months; BL, baseline, kb, kilobase;  
RR, reverse-reverse orientation  
 
Once again, the gene list generated from stable loops was used for network 
analysis to further characterise the significant pathways differentiating NR and 
pooled HC (Figure 5.8). The top 10 nodes had at least 25 connections in the 
network, with the top a total of 34 (Figure 5.8A). The most connected node 
represented the TLR4 gene. This was an interesting find based on it’s 
implications in RA pathogenesis. TLR4 is expressed on a number of immune cells 
involved in RA pathogenesis, including peripheral monocytes and synovial 
macrophages. Activation of TLR4 can lead to down-stream production of 
interferons, cytokines and chemokines. As such, the EpiSwitchTM data portal was 
used to visualise the genomic area around this gene. The genome browser view 
clearly demonstrated this gene was enriched with many EpiSwitchTM anchor 
points, hinting that it is a highly-regulated region (Figure 5.8B). Of note, not all 
loops in this region are associated with the NR endotype. The largest central 
anchor point, connecting several of these loops, was the EpiSwitchTM loop with 
significance in this NR group. To look at this area in more detail, a circos plot 
was used (Figure 5.8C). The second anchor point of this loop does not lie within 
another locus, but does overlap with H3K27ac, recorded in CD19 cells. 
Visualising in this way showed that the anchor point within the TLR4 locus can 
overlap with H3K27ac marks which have been found in CD4, CD8, CD19 and CD56 
cells. Interestingly, there are no clinically relevant SNPs residing in this area. 
The histone marks present at this locus suggest the potential for enhanced 







Figure 5.8 Environment Surrounding Central Enriched NR loop 
Network analysis used to understand central players in significant pathways. A) Top 
most connected nodes determined by most directed edges of a node in Cytoscape. Gene 
with most connections highlighted in red. B) Genome browser view from EpiSwitchTM 
Data Portal showing TLR4 gene genomic environment. Genes in dark blue, loops in pink 
and EpiSwitchTM anchor points in orange. Red boxes illustrate anchor points statistically 
significant loops in this group. C) Circos plot generated from genome browser with the 
addition of ClinVar representing disease associated SNPs and H3K27ac marks from 
publicly available datasets. Red box indicates gene of interest and region which other 




5.2.6 RankProd analysis of microarray data – Initial Responders 
 
As with the other endotype groups, multiple analysis tools were employed to 
understand the highly-regulated areas the genome unique to the IR disease 
group (Figure 5.9). 279 loops could stratify disease and pooled HC at all time 
points (Figure 5.9A). 4, 392 and 447 were unique to baseline, 6m and 12m, 
respectively. As with the other endotype groups, the closest 3 genes to each of 
the stable loops were carried forward for gene enrichment analysis. The 
pathways enriched had a mix of high scoring and med scoring enrichment scores 
(Figure 5.9B). The high scoring pathways were ‘translocation of ZAP-70 to 
immunological synapse’, and ‘TCR signalling’. There were 8 GO terms scoring a 
high match score (Figure 5.9C). The pathway with the most matched genes was 
the ‘T cell receptor signalling pathway’. Deficient TCR signalling has been shown 
to contribute to RA pathogenesis and it is interesting that this pathway was 
enriched in the IR group. Exploring the genomic region of genes in this pathway 





Figure 5.9 Pathway Enrichment of Significant Stable loops in IR    
List of loops generated from RankProd analysis. A) Venny 2.1 used to generate Venn 
diagram of significant loops at all time points, significant adj P value ≤0.05 and AS -1.1≤ 
or ≥1.1. Gene Analytics then used generated list of significant pathways based on 
matched genes. Scores are given to each pathway to reflect their matching quality to 
the set of genes entered to the analysis platform. An algorithm is used to determine the 
threshold for high, medium and low scores in each dataset. Cells in green = high score 
match, P-value <0.05 cells in orange = med score match, P-value 0.05-≥1. Tables 
generated for B) Top pathways and C) Top GO terms.   
6m, 6 months; 12m, 12 months; BL, baseline, kb, kilobase;  
RR, reverse-reverse orientation;  
 
As with previous analysis approaches, network analysis tools were used to 
further characterise genes from significant pathways (Figure 5.10). Once again, 
in Cytoscape, network analysis was used to identify the most connected nodes. 
The most connected nodes ranged from 14 to 18 connections, with HLA-DRB1 
having the most connections (18) (Figure 5.10A). Again, this is a gene with 
known implications in RA pathology. Specifically, this allele is associated with 
susceptibility to the development of RA. This gene was explored further using 
the EpiSwitchTM data portal. Exploration of the surrounding genomic area 
revealed that 5 loops resided in this region (Figure 5.10B). All loops were 
statistically significant in the IR group. A circos plot was used again to visualise 
the epigenomic environment in more depth (Figure 5.10C). The area was clearly 
enriched with H3K27ac marks which can be found in CD4, CD8, CD19 and CD56 
cells. This data illustrates the capacity for enhanced gene transcription at this 
site. Of note, 4 loops stem from 1 anchor point in this region, which appears to 
lie within the HLA-DRB5 locus, hinting at the significant regulatory role of this 
gene. Interestingly, this allele has been shown to be play a protective role in RA. 
Anchor sites residing within loci with differing functional consequences in RA is 





Figure 5.10 Environment Surrounding Central Enriched IR Loop 
Network analysis used to understand central players in significant pathways. A) Top 
most connected nodes determined by most directed edges of a node in Cytoscape. Gene 
with most connections highlighted in red. B) Genome browser view from EpiSwitchTM 
Data Portal showing HLA-DRB1 gene genomic environment. Genes in dark blue, loops in 
pink and EpiSwitchTM anchor points in orange. Red boxes illustrate anchor points 
statistically significant loops in this group.  C) Circos plot generated from genome 
browser with the addition of ClinVar representing disease associated SNPs and H3K27ac 
marks from publicly available datasets. Red box indicates gene of interest and gene 
which other loop anchor point lies within and where anchor points of interest interact 
with other epigenetic features. 
 
5.2.7 RankProd analysis of microarray data – RA 
 
While it was of interest to understand the pathways enriched in each endotype 
group, it was also of interest to determine the loops common to all endotypes 
that could stratify disease and HC at all time points. As such, all the stable loops 
from each endotype group were used to generate a fourth Venn diagram (Figure 
5.11A). One hundred and eighty-three loops were common to all groups, and 
collectively made an RA-specific loop signature group. Forty-three, 23 and 297 
loops were unique to R, IR and NR, respectively. The closest 3 genes to the 183 
RA loops were analysed further using GeneAnalytics as before. This produced a 
set of pathways all with a med gene match score (Figure 5.11B). The most 
significant enriched pathway was the pathway of the ‘regulation of apoptosis by 
parathyroid hormone related protein’. Once again, GO terms were also 
interrogated. Seven GO terms in total had high gene match scores (Figure 
5.11C). The ‘cytosol’, ‘nucleus’ and ‘cytoplasm’ were GO terms with many 
matched genes. This alludes to the highly-regulated environment of an RA 





Figure 5.11 Pathway Enrichment of Significant Stable Loops in Disease 
A) Venny 2.1 used to generate venn diagram of significant loops at all time points, 
significant ≤0.05 and AS -1.1≤ or ≥1.1. Gene Analytics then used generated list of 
significant pathways based on matched genes. Scores are given to each pathway to 
reflect their matching quality to the set of genes entered to the analysis platform. An 
algorithm is used to determine the threshold for high, medium and low scores in each 
dataset. Cells in green = high score match, corrected P-value <0.05 cells in orange = 
med score match, P-value 0.05 ≤ 1.Tables generated for B) Top pathways and C) Top GO 
terms.   
6m, 6 months; 12m, 12 months; BL, baseline, kb, kilobase;  
RR, reverse-reverse orientation; 
     
As before, network analysis was used to further interpret the data (Figure 5.12). 
Using network tools, the most connected nodes were identified, with the top 
nodes having 13 or more connections. The most connected node was shown to be 
PSMC6 with 18 connections (Figure 5.12A). Using the EpiSwitchTM data portal, the 
genomic environment around the PSMC6 gene was revealed (Figure 5.12B). Two 
loops were found to be in this region. For increased characterisation, a circos 
plot was used (Figure 5.12C). H3K27ac marks found in CD4, CD8, CD19 and CD56 
cells were found at all anchor points, once again suggesting that this region of 
the genome may be subject to enhanced transcription in T cells, B cells and NK 
cells. This enhanced transcription in RA could lead to increased immune 
pathology and exacerbation in disease. The circos plot also illustrates that the 
second anchor point of the significant loop lies in proximity to the GRP137C 





Figure 5.12 Environment Central Enriched Disease Loop 
Network analysis used to understand central players in significant pathways. A) Top 
most connected nodes determined by most directed edges of a node. Gene with most 
connections highlighted in red. B) Genome browser view from EpiSwitchTM Data Portal 
showing PSMC6 gene genomic environment. Genes in dark blue, loops in pink and 
EpiSwitchTM anchor points in orange. Red boxes illustrate anchor points of statistically 
significant loops in this group. C) Circos plot generated from genome browser with the 
addition of ClinVar representing disease associated SNPs and H3K27ac marks. Red box 
indicates gene of interest and where anchor point of interest interacts with other 
epigenetic features. 
 
Whilst the network analysis data extracted genes that did appear to heavily be 
regulated, many of the pathways from GeneAnalytics analysis had limited 
significance with corrected P-values between 0.05 and 1, suggesting there may 
be more significant pathways to find. With this in mind, it was of interest to 
employ a second analysis method, as a way to compare evidence and observe if 
similar pathways were found in both methods. 
 
5.2.8 SearchLight as second approach to analysis of microarray 
data 
 
To potentially identify other important loops that could be used to stratify RA 
patients at baseline, and to possibly strengthen our confidence in the findings 
from the RankProd method, it was decided that another method could be used 
to validate and further explore findings. A computational analysis method, 
Searchlight, primarily used for RNA-seq data, was adapted to analyse our 
microarray data. While analysis with RankProd focused on contrasts between 
disease and HC, Searchlight was used to focus on contrasts between pairs of 
endotype groups. Using linear modelling, differences between endotype groups 
at all 3 time points were extracted using the contrasts from the model within 
Limma. A 1 to 1 comparison between pairs of endotypes was done to attempt to 
understand the degree of difference between each group. This pairwise 
comparison was done first as a thorough approach to find regulatory differences 
and hopefully capture the nuances between groups, that may not be captured if 
a three-way analysis was done in the first instance. This would be carried out 
later in the analysis pipeline. Firstly, the stratification of NR and R was assessed 
(Figure 5.13). PCA plots were generated to assess differences between groups at 
each time point (Figure 5.13A-C). The largest separation between NR and R was 
seen at baseline (Figure 5.13A). Observing the plots, the least separation seems 
to appear at 12 months (Figure 5.13C). The reduction in difference between 
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baseline and 12m may be due to the effect of treatment on individuals. The next 
step was to evaluate whether there were any loops that were significantly 
different at the various time points, and observe if any signatures emerged from 
the data. Notably, there were no significant differentiating loops at 12m, 
however, at both baseline and 6 months, differences were observed (Figure 
5.13D-E). At both the baseline and 6m time points, there were 2 loops which had 
differential fold change in abundance between NR and R. One loop had higher 
fold change in NR and the other in R. Both loops at 6m also had differential fold 
change. At 6m, all 6 individual patients appeared to have more varied fold 
change values that the 6 patients at baseline. Collectively these data suggested 







Figure 5.13 Differential Loops Between R and NR at Each Time-point  
Data analysis was performed by John Cole, University of Glasgow. Principal component 
analysis (PCA) of microarray data at (A) M0 (baseline), (B) 6 months, (C) 12 months. 
Data scaled by Z-score transformation. Each dot represents 1 patient sample. Pink = NR, 
blue =R. N=12. (D&E) un-clustered heat map representing significantly different loops 
between NR and R at (D) baseline and (E) 6 months. Log2 fold > 1, adj. P value ≤ 0.05. 
Expression levels of loops represented as z-scores, -1 -1 = loop abundance fold change 
 
Whilst analysis did not identify stratification signatures at each time point, the 
most differential individual loops, based on fold change in abundance, were 
identified to discover if any individual loops had differences at the patient level 
(Figure 5.14). The 10 most up and down regulated loops were plotted and those 
loops were then mapped to the closest gene, with a view to understand possible 
functional consequences of loop formation. To investigate the extent of change 
in each loop across samples, we evaluated the loops that were most up or down 
regulated in R compared to NR. The loops that appeared to be most upregulated 
in R were Loop_41682 (KIAA1468), Loop_79207 (RP11-500G9.1) and Loop_38167 
(GBP3)(Figure 5.14A). Two other loops in this set also mapped to KIAA1468 and 
GUCYGP2, implying that expression of these genes has implications for the R 
group. The loops that appeared most downregulated in R compared to NR were 
LOOP_105854(UBE2H), LOOP_36217 (LINC00854) and LOOP_88219 (BTLN8)(Figure 
5.14B). It was demonstrated that 2 other loops in this group mapped to UBE2H, 2 
others mapped to BTLN8 and another 2 to TSNAX-DISC1. As 3 loops in this group 
mapped to UBE2H, it is plausible to consider that this gene may be an important 






Figure 5.14 Significantly Up and Down Regulated Loops in R (R vs NR comparison) 
Data analysis was performed by John Cole, University of Glasgow Violin plots of 
significantly up and down regulated loops, (p.adj ≤ 0.05, absolute log2 fold >1). N=12. 
A) Significantly upregulated genes in R at baseline time-point. B) Significantly 
downregulated loops in R at baseline. Loop number highlighted above plot, with closest 
gene to loop site above. Closest gene determined by Bedtools closest function. Pink = 
NR, blue = R  
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Stratification of IR and R was next to be analysed (Figure 5.15). There was a 
degree of separation between IR and R at baseline when using PCA analysis 
(Figure 5.15A). This separation was partly lost at 6m (Figure 5.15B) and at 12m, 
IR and R samples were plotted amongst each other (Figure 5.15C). As with the 
NR and R analysis, heat maps were used to visualise the data and determine if 
any signatures emerged from the data that could differentiate between IR and 
R. There were more significantly different loops between these 2 groups than NR 
and R at baseline and 6m time points (Figure 5.15D,E). Again, there were not 
enough significantly different loops to plot a heat map at 12m. The fold change 
of the signature loops at baseline was more than at 6m. At both time points, 
there were 2 main signatures which differentiated the endotypes; signature 1 







Figure 5.15 Differential Loops Between IR and R at Each Time-point  
Data analysis was performed by John Cole, University of Glasgow. Principal component 
analysis (PCA) of microarray data at A) M0 (baseline), B) 6 months, C) 12 months, Data 
scaled by Z-score transformation. Each dot represents 1 patient sample. Pink = IR, blue 
=R. N=12. D) un-clustered heat map representing significantly different loops between 
NR and R at baseline, E) 6 months. Log2 fold > 1 adj. P value ≤ 0.05. Expression levels of 
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loops represented as z-scores. -2 -3 = loop abundance fold change. Green brackets and 
numbers indicate different signatures. 
 
The most significantly up and down regulated loops between IR and R were 
plotted and mapped to their closest gene (Figure 5.16). Across samples, the 
loops that appeared to be most consistently upregulated in R were Loop_93401 
(HLA-DQA1), Loop_93393 (SNX19) and Loop_38167 (GBP3) (Figure 5.16A). Two 
other genes in the group mapped to SNX19 and HLA-DQ1. Others in the group 
mapped to MICU1 and HLA-DRA. The loops that appeared most downregulated in 
R compared to NR were LOOP_107119 (TNSAX-DISC1), 
LOOP_107121(TSNAX_DISC1) and LOOP_88225 (BTLN3)(Figure 5.16B). Other loops 
in this downregulated group mapped to VAMP4, RP11-345I18.6, FRAS1 and 
BTLN8. Two loops mapping to TSNAX-DISC1 may be an indicator that repression 







Figure 5.16 Significantly Up and Down Regulated Loops in R (IR vs R comparison) 
Data analysis was performed by John Cole, University of Glasgow Violin plots of 
significantly up and down regulated loops, (adj. P value ≤ 0.05, absolute log2 fold >1). 
N=12. A) Significantly upregulated genes in R at baseline time-point. B) Significantly 
downregulated loops in R at baseline. Loop number highlighted above plot, with closest 
gene to loop site above. Closest gene determined by Bedtools closest function. Pink = 
IR, blue = R 
 
The last comparison to be made was between NR and IR (Figure 5.17). PCA 
analysis was once again used to visualise clustering of the 2 groups at baseline, 
6m and 12m. There was a lot of overlap between endotypes at baseline (Figure 
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5.17A). The 2 groups became more separated at 6m, however the endotypes 
were not clustered separately (Figure 5.17B). Similar clustering was observed at 
12m (Figure 5.17C). Once again, heat maps were used to picture the data and 
identify stratifying signatures between endotypes. At baseline, 2 signatures 
emerged from the heat map (Figure 5.17D). The smaller of the 2 signatures (1) 
showed upregulation of loops in NR. The other signature shows upregulated loops 
in IR. At the 6m time point there were less distinct signatures shown in the heat 
map (Figure 5.17E). From the heat map only 1 signature emerged. This signature 
showed a small group of highly upregulated loops in NR. The rest of the heat 
map did not highlight a high level of differentiation between the endotypes. As 
other comparisons have shown, there were not enough significant loops at 12m 







Figure 5.17 Differential Loops Between NR and IR at Each Time-point 
Data analysis was performed by John Cole, University of Glasgow. Principal component 
analysis (PCA) of microarray data at A) M0 (baseline), B) 6 months, C) 12 months, Data 
scaled by Z-score transformation. Each dot represents 1 patient sample. Pink = NR, blue 
= IR. N=12. D) un-clustered heat map representing significantly different loops between 
NR and R at baseline, E) 6 months. Log2 fold > 1 adj P value ≤ 0.05. Expression levels of 
loops represented as z-scores.  -2 – 2 = loop abundance fold change  
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As before, the most significantly up and down regulated loops between the 
endotypes were plotted and closest gene to each, identified (Figure 5.18). The 
loops that appeared to be most consistently upregulated in NR were Loop_93401 
(HLA-DQA1), Loop_93402 (HLA-DQA1) and Loop_88916 (RP4-761I2.5)(Figure 
5.18A). Two other loops in the group mapped to HLA-DQ1. This data suggests 
importance of the expression of this gene in the NR. Others in the group mapped 
to MICU1 and HLA-DRA. The loops that appeared most downregulated in NR 
compared to R were LOOP_113951 (PRUNE2), LOOP_122895 (GUCY2GP) and 
LOOP_99942 (AC018641.7) (Figure 5.18B). Other loops in this downregulated 






Figure 5.18 Significantly Up and Down Regulated Loops in NR (NR vs IR comparison) 
Data analysis was performed by John Cole, University of Glasgow. Violin plots of 
significantly up and down regulated loops, (p.adj ≤ 0.05, absolute log2 fold >1). N=12 A) 
upregulated genes in IR at baseline time point. B) Significantly downregulated loops in 
IR at baseline. Loop number highlighted above plot, with closest gene to loop site 
above. Closest gene determined by Bedtools closest function. Pink = NR, blue = IR 
 
 
5.2.9 SearchLight as second approach to analysis of microarray 
data – RA  
 
As well as identifying stratifying loops and signatures between pairs of endotypes 
across the time points, analysis was conducted to compare all 3 endotypes 
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together at each time point (Figure 5.19). Global PCA analysis of all 3 endotypes 
at baseline demonstrated 2 large clusters, consisting of patients of all endotypes 
(Figure 5.19A). This hints as shared RA pathology between endotypes, but 
highlights the heterogeneity of the RA population. There was no distinct cluster 
based on endotype. To try and identify stratifying signatures between the 
groups, we analysed the data with the use of a heat map (Figure 5.19B). Four 
clear signatures emerged from the heat map. The first clear signature  (1) shows 
upregulation of loops in IR and NR, with downregulation of loops in R. The 
second signature (2) demonstrated highly significant upregulation of loops in IR, 
with downregulation in the other 2 endotype groups. The third signature (3) 
shown upregulation of loops in R with downregulation in NR and IR. The fourth 
signature (4) shows upregulation in R with downregulation in the other 2 
endotype groups, with 2 patients in the IR groups showing upregulation of loops 
at a similar significance to the R group.  
 
 
Figure 5.19 Differential Loops Between R, NR and IR at Baseline  
Data analysis was performed by John Cole, University of Glasgow. Principal component 
analysis (PCA) of microarray data at A) baseline, Data scaled by Z-score transformation. 
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Each dot represents 1 patient sample. Green = IR, blue = NR, pink =R. N=18. B) un-
clustered heat map representing significantly different loops between IR, NR and R at 
baseline, Log2 fold > 1 adj.P value ≤ 0.05. Abundance of loops represented at z-scores. 
Green brackets and numbers indicate different signatures.  
Nos 1-4 represent individual signatures within the heat map 
 
Alike to the analysis conducted between pairs of endotype groups, the most 
significantly different loops between the three groups were investigated, and 
the top 8 plotted (Figure 5.20). LOOP_14360 and LOOP_14364, both mapping to 
DOCK9, appeared to be upregulated in IR and NR samples, compared to R. This 
difference was consistent across time points. This could mean down regulation 
of this gene is important in responding to RA therapy. In contrast, LOOP_24104 
(RP11-282M16.1) and LOOP_64070 (DSCR3) showed highest loop expression in R, 
with similarly lower levels in IR and NR. Overall, the difference between groups 
remained similar across all 3 time points. However, it appeared at baseline, 
some loops showed the biggest difference, as observed in LOOP_24101 (RP11-
282M16.1), LOOP_38537 (PRR11) and LOOP_950095 (SUPT3H). Interestingly, no 
loops that were significantly different in the pairwise analysis, were the most 
significant in the comparison between all 3 groups. This may suggest findings are 
an artefact, or could mean that we captured the slight differences between 
groups, that can’t be captured by analysing the groups all together.  
 
 
Figure 5.20 Significantly Different Loops between R, NR, IR at All Time points  
Data analysis was performed by John Cole, University of Glasgow. A) Violin plots of 
significantly different loops in between R, NR and IR across all time points. Loop number 
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highlighted above plot, with closest gene to loop site above. Closest gene determined 
by Bedtools closest function.  
 
5.2.10 Comparison of analysis approaches 
 
Direct comparison of the analysis pipelines was complex due to the RankProd 
approach focusing on enriched biological pathways, while analysis with 
SearchLight focused on individual genes. Moreover, RankProd analysis focused on 
differences between disease and HC, whilst SearchLight focused on differences 
between endotypes. Yet notably, this was how I approached the analysis, and 
both platforms could be used to approach analysis in different ways. However, 
the EpiSwitchTM data portal visualisation software was used to gather more detail 
about the most significantly changed loops between the endotypes identified 
through the Searchlight pipeline, and identify if genes from Searchlight were in 
regions of other EpiSwitchTM loops (Figure 5.21). Data was available in the portal 
for DOCK9, PRR11 and DNAJB13. In the region of DOCK9, multiple loop anchor 
points could be found, with over 10 loops visualised, interacting between them 
(Figure 5.21A). Of these 3 genes with data in the portal, only DOCK9 was a gene 
that was found to be significant with the RankProd analysis pipeline. This was 
significant in NR and IR. DOCK9 can be seen with an anchor site within the 
RPL17L1P12 locus (Figure 5.21B). Interestingly, there was no interaction with 
histones or SNPs in this region. Only 2 loops could be visualised in the region of 
PRR11 (Figure 5.21C). Both loops have anchor points within the RP11 gene 
region, and loop to anchor points in TRIM37. The loops also overlap with SNPs. 
Again, the circos plot visualisation provides further detail and highlights that the 
loops span 3 and 4 genes (Figure 5.21D). Three loops could be shown in the 
region of DNAJB13 (Figure 5.21E). Two anchor sites within the gene region 
interact with one other anchor site in the region of CDA4. The other loop in this 
region has anchor points either side of the DNAJB13 gene. These loops also 
overlap with SNP sites. The circos plot replicates this data and highlighted one 
loop spans 0.2mb (Figure 5.21F). DOCK9 is clearly an enriched region, and since 
it was a significantly differential loop in both analysis pipelines, it is highly likely 
that this gene is important in RA pathogenesis. Furthermore, using the 
EpiSwitchTM visualisation software, it allowed us to capture this enriched region, 
which may not have been as clear otherwise. However, it should be noted that 
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only comparing 10 genes across platforms is a small number and may not reflect 










Figure 5.21 EpiSwitchTM Data Portal Visualisation of Searchlight Genes 
Most significantly changed genes from Searchlight analysis were searched for in 
EpiSwitchTM data portal. Data was available for 3 genes. Visualised in IGV simulation and 




5.2.11 Identification of candidates for endotype CCS 
 
As one of the aims from this part if the study was to identify loops that have the 
potential to become part of an effective predictive CCS, it was important to 
establish the dynamics of loop significance across the 3 time points. To identify 
the loops with the strongest stratification potential for prediction of endotypes, 
the quality threshold (QT) clustering algorithm was used on the RankProd data. 
This algorithm does not specify the number of clusters a priori, and clusters 
must pass a user-defined quality threshold. To be included in the cluster, a loop 
must have had to be significant in at least 1 time point. Data generated from 
RankProd, which has been explored above, was used in the clustering algorithm. 
Three groups of clusters were produced based on comparison between each 
endotype and pooled HC. Comparison between R and HC produced 9 clusters 
(Figure 5.22). From the 9 clusters, 7 loop dynamic patterns can be observed. 
Two clusters (2 and 5) have statistically significant loops at all 3 time points and 
2 (6 and 9) clusters have significance at baseline and 12m but not at 6m. The 
cluster with the most loops (2511), had loops with statistical significance only at 
6m. In the interest of stratification significance over 12 months, cluster 2 would 
be the choice cluster to be taken for further analysis. Loops from this cluster 







Figure 5.22 QT clustering of Loops in R  
Data analysis conducted by Ewan Hunter, OBD. Raw microarray data from R and pooled 
HC comparisons was used for the QT clustering algorithm. To pass the quality threshold 
loops had to have significance, ≤0.2 FDR. Data with most potential for an endotype 
stratification signature highlighted in yellow square.   
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Comparison between NR and pooled HC revealed 9 clusters (Figure 5.23). 
Clusters 2-9 had 121 loops or more identified. In contrast, cluster 1 had 1729 
loops identified. This cluster, along with cluster 4 and 6 are made of loops with 
statistical significance at all time points. The 6 remaining clusters have unique 
dynamics ranging from significance only at baseline to significance only at 12m 
These clusters are made of 4 and 3 loops respectively. Cluster 1 would be the 
cluster of choice to be taken forward for further analysis based on strong 







Figure 5.23 QT clustering of Loops in NR  
Data analysis conducted by Ewan Hunter, OBD. Raw microarray data from NR and pooled 
HC comparisons was used for the QT clustering algorithm. To pass the quality threshold 
loops had to have significance, ≤ 0.2 FDR. Data with most potential for an endotype 




Clustering of IR and pooled HC comparison data revealed 8 clusters (Figure 
5.24). Again, cluster 1 had considerably more loops than the other clusters with 
1566 loops compared to the second highest cluster made up of 228 loops. Cluster 
1, 4 and 8 had loops with statistical significance at all time points. The 
remaining 5 had dynamics unique to each cluster. Of these 5 clusters, the cluster 
with significance at baseline and 12m had the least loops (18). Based on stable 
significance throughout 12m, data from cluster 1 would be the most promising 






Figure 5.24 QT clustering of Loops in IR  
Data analysis conducted by Ewan Hunter, OBD. Raw microarray data from IR and pooled 
HC comparisons was used for the QT clustering algorithm. To pass the quality threshold 
loops had to have significance, ≤ 0.2 FDR. Data with most potential for an endotype 








The work in this chapter has alluded to the presence of several molecular 
endotypes, specifically 3D chromatin endotypes, that exist in early RA. 
Moreover, the data suggests that there may be loops present in each endotype 
at baseline that may be able predict which trajectory a patient will follow. 
Analysis also revealed that some loops were present in all endotype groups at all 
time points, revealing a RA signature that suggests a baseline level of 
dysregulation dictated by the 3D structural epigenome. Moreover, as many the 
loops in this group were determined ‘stable’, it implies a core RA state, from 
which important disease relevant pathways can be found. The loops in disease 
were of most interest based on the aim of using stratifying loops to understand 
underlying pathogenesis. 
 
Analysis of the SERA dataset revealed the presence of 3 main response 
trajectories (Figure 5.1). This analysis builds on the interrogation of the SERA 
cohort for the identification of the MTX CCS. Where R, and NR were assessed on 
their clinical scores at 6m, extending analysis to include the 12m time point 
revealed the IR response group, that at 6 months have the same trajectory as R. 
Using these longitudinal samples is a great advantage to this work. These 
trajectories are similar to findings from other RA cohorts. Other studies often 
identify 3 groups of responder; named fast/rapid, slow/gradual or 
non/inadequate-responders354,355. Some studies have even characterised 5 groups 
established on baseline DAS356. However, the R group from our cohort were not 
split into fast or poor responders. Most studies identify the majority (82.6%) of 
patients to be in one of the rapid or gradual responder categories, with only a 
small proportion of patients classed as non-responders (3.3%). In the SERA 
cohort, a similar proportion of patients are R and NR, with a small proportion of 
patients classed as IR. The difference with the SERA cohort, and the patients 
investigated, is the absence of biologic treatment during the 12 months 
explored. The study by Siemons et al355 followed a treat-to-target strategy that 
included the introduction of anti-TNFα biologic, adalimumab, at Week 24, and 
etanercept at Week 48, which would most likely contribute to the increased 
good responder rates. However, one observational cohort study, with patients 
commencing MTX treatment for the first time found non-response rates at 6 
months to be 43%99. Due to the ‘extreme’ responders being chosen for the array, 
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all 6 in the R group could be considered fast responders. The most extreme 
trajectories were chosen as best as possible, however, sample availability from 
the SERA biobank did impact the choice of patients. It was desirable to have all 
patients in each group with as similar a trajectory as possible, to reduce 
confounding factors in the analysis, and this was achieved with R and NR groups. 
Unfortunately, the IR group had different trajectories, with some variation in 
disease activity at all time points. Specifically, there was a combination of high 
and moderate, remission and low, and high and moderate disease activity at 
baseline, 6m and 12m, respectively. Subgroup analysis of the IR trajectories was 
out with the scope of this work, however, it would be of interest to stratify this 
group alone to reveal if differences in disease activity were reflected by 
underlying 3D chromatin structures.  
 
Analysis of baseline demographic and clinical characteristics showed all groups 
were comparable at baseline (Table 5.1). Autoantibody presence was also 
comparable between groups. One of the clearer indications of which trajectory a 
patient would follow was clinical scores at baseline, with NR having the highest 
CDAI and DAS28 CRP at this time point. These findings have been widely 
described in other RA studies357 358 359 with some studies isolating individual joint 
scores as predictors of poorer response360,361. Other studies exploring baseline 
predictors to MTX have indicated female gender and current smoker status as 
associated with a decreased likelihood of achieving a EULAR response after 4 
months362. Moreover, other studies have shown baseline depression and anxiety 
scores to have a negative impact on response to DMARD therapy363. This wasn’t a 
factor that was explored in this work, but would be useful to consider. The only 
current smokers in our array cohort were in the IR group, who all achieved good 
response at 6m. However, with only 6 patients, the effect may not be obvious 
and not all 6 were treated with monotherapy MTX. Interestingly, IR were the 
group with the lowest CDAI and DAS28 CRP at baseline. DAS28 ESR was not 
documented based on values needed to accurately calculate the score missing 
from several patients.  
 
It was also of importance to record the treatment trajectory of each patient as a 
consideration of any inter-endotype differences (Figure 5.2). Understandably, 
most R were treated on monotherapy MTX throughout the 12 months. The 
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differing treatment trajectories could be considered a limitation to this work, as 
it introduces variability in the data. However, it is unrealistic for a NR or IR to 
stay on a drug or combination of drugs that isn’t having a clinically meaningful 
improvement. Of the patients changing drug in the 12m period, there was 
considerable variation in the treatment regimen between patients, which is 
reflective of real-world disease management364. Surprisingly, 3 NR remained on 
monotherapy MTX despite showing no clinical response. On further investigation, 
all patients that remained on a therapy without showing a clinical response were 
found to be enrolled at different study sites, therefore that is unlikely to explain 
the reason for remaining on the drug given at baseline. There are a number of 
other reasons a patient may have had to remain on a given drug, including 
avoidance of exacerbating other conditions, such as cardiovascular disease or 
liver disease365. Moreover, studies have varying conclusions on the best way to 
approach treatment with the 3 csDMARDs, such as the parallel use117 and the 
step-up approach366. Furthermore, the patient perspective should be considered. 
One qualitative study analysed the reasons for patient refusal of DMARDs in 
RA367. Some reservations were due to dangers of medications, disappointment 
with other treatments and denial of disease. Fraenkel et al have demonstrated 
that these feelings can be especially prominent when patients have highly active 
disease368. Even for the small number of patients in our study, trying to fully 
understand the reasons behind treatment assignment could be a complex 
analysis and was out with the scope of the aims of this chapter.  
 
The patients were chosen, and the microarrays run at OBD. Subsequently, the 
first step of analysis was to assess the quality of the data (Figure 5.3). Recording 
the red-green densities of arrays confirmed no outliers were present and that 
Loess normalisation was successful. Moreover, these steps helped to ensure 
information was preserved and no variations in the data were wrongly 
inflated369. Another important QC check was to assess the slide distribution; this 
was done by the generation a PCA plot with the slides labelled. The issue of 
batch effects is widely recognised in microarray studies, especially with human 
samples370. Strategically, patients with the same response trajectory and 
samples from the same time point were not grouped together on the same slide 
to reduce the chance of a batch effect associated with a particular group of 
samples. The PCA plot showed that slides did not cluster together, which was 
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expected. This provided assurance that measures taken to reduce batch effects 
were successful and provided confidence for further data analysis.   
 
Top level analysis of each group, prior to linear modelling revealed some 
grouping based on endotype through PCA plots (Figure 5.4). The results 
suggested that the largest differences between disease groups was at baseline 
and the epigenome would gradually lose stratification ability at subsequent time 
points. The PCA plots also suggested most variance in the dataset came from the 
R group. Of note, PCA visualisation were ultimately an approximation of the data 
distribution and more in-depth analysis was required. 
 
The Limma programme was carried forward and a linear model implemented to 
find contrasts between responder groups, as well as between RA and pooled HC 
(Table 5.2). Importantly, this approach has been used successfully in many 
studies including the MTX CCS that formed the basis for this work and provides a 
flexible platform to analyse experiments with multiple parameters219,371. This 
analysis produced thousands of differentiating loops between groups at all time 
points. The data suggested that there more differences between RA and HC than 
between different RA responder groups, which is not surprising. However, there 
were differences between each pair of endotype group at each time point, 
alluding to the existence of epigenetic endotypes. Further, data suggests the 
biggest difference in the structural epigenome between disease and pooled 
healthy exists at 6m followed by 12m. This is in contrast to the PCA results, 
emphasising the importance of those plots as a guide only.  
 
On reflection of this data and the total number of significant loops, I considered 
that the Limma model was not stringent enough to reveal truly statistically 
significant and biologically relevant stratifying loops. Furthermore, in the 
interests of utilising the data to integrate the underlying biology of all groups, it 
would be useful to begin work with a smaller list of loops to streamline the 
analysis process and find meaningful results. The Limma method of analysis is 
still of importance and produced results which lead to the MTX CCS findings in 
previous work. However, the microarray for this endotype work had a more 
complex design, and therefore it was plausible that an alternative, more 
stringent method was needed. Based on the data available, analysis focused on 
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the differences between each disease group and the pooled HC. Analysing these 
comparisons meant that the disease relevant loops, with removal of any loops 
possibly important in a healthy state would maximise disease relevant 
information.  
 
The analysis method chosen was RankProd 2.0, a Bioconductor package used to 
find differentially expressed molecular profiles. RankProd has several 
advantages which made it an appropriate method for this work, in particular the 
ability to analyse data with a small sample size and sample heterogeneity, which 
is of particular relevance in this study372. These features have been effectively 
demonstrated using a wide variety of sample types, from plants and mouse 
models, to human acute leukaemia samples373.  
 
A similar table to that produced from the Limma model was produced with the 
RankProd results (Table 5.3). As previously discussed, the disease loops were of 
most interest based on the aim of using stratifying loops to understand 
underlying pathogenesis. As such, the number of loops able to stratify disease 
and pooled HC in each endotype group at each time point were quantified. 
Clearly, the RankProd analysis was more stringent and reduced the number of 
stratifying loops considerably, with the highest number of stratifying loops being 
4765 in the NR 6m group and the lowest number of 384 loops in R at baseline. In 
contrast to the global level analysis that suggested the most difference between 
endotype groups was at baseline, this RankProd analysis suggested that the 
biggest difference between groups is present at 6m, which is line with the 
Limma analysis. While the analysis approaches differ, this provides an internal 
validation of the results up to this point. This data highlighting the 6m time 
point alludes to the influence of treatment on the 3D epigenome. Based on the 
number of significant loops, HC appeared most different from NR at baseline, R 
at 6m and IR at 12m. While these results showed that disease and pooled HC are 
epigenetically different throughout the first 12m of treatment, the results also 
revealed the existence of endotypes, as different number of stratifying loops 
between disease and HC exist at each time point, highlighting that some loops 
must have unique statistical significance in each group. As reducing the number 
of loops to analyse was considered beneficial, it was positive that analysis using 
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the RankProd method also reduced the number of loops to investigate for 
biological inference and would streamline the analysis process going forward.  
 
The approach to understanding the biological relevance of the loops found to be 
significant through the RankProd approach was to look at each endotype group 
separately in the first instance. It is important to note that each loop may not 
necessarily be present at each time point in each group, but more likely to be 
compared to HC. And as explored in Chapter 4, the presence of a loop does not 
mean that expression of a gene is increased, a loop may be inhibitory. Yet, 
understanding the pathways for which the genes in proximity to statistically 
significant loops exist is important. For all endotype groups, a Venn diagram was 
generated to show the number of loops that could stratify disease and HC at 
each time point (Figure 5.5, Figure 5.7, Figure 5.9). The Venn diagram allowed 
visualisation of the loops that stayed stable throughout the 12 months of 
csDMARD treatment and also revealed the loops that were unique to a particular 
time point. To focus the analysis, the loops in the centre of the Venn diagram, 
i.e. the most ‘stable’ loops were used for gene enrichment analysis. The closest 
3 genes to each loop were used as an input for this analysis. This approach 
revealed that many of the same pathways were enriched in all endotype groups. 
However, each endotype group had some unique pathways enriched, further 
strengthening the idea that endotypes exist and pathogenesis may be different 
in each group. The overlap of significant pathways between endotypes is 
because we took the loops that were stable over 12 months in each group, but 
not unique to that endotype. Of note, common to all endotype groups was 
enrichment of ‘phagosome’, ‘TCR signalling’, ‘translocation of zap70 to 
immunological synapse’, ‘rheumatoid arthritis’, ‘interferon gamma signalling’ 
and ‘MHC class II antigen presentation’ pathways. These results are not 
surprising, as these pathways are known to be involved in RA pathogenesis.  
 
Some unique pathways of interest to each group were ‘haematopoietic cell 
lineage’ in R, ‘CLEC7A and glucagon signalling’ pathway in NR and ‘HIF 
repressors’ and ‘cell adhesion molecules’ in IR. CLEC7a, or Dectin-1 as it’s 
otherwise known, has been shown to have increased expression in RA synovial 
tissues, potentially contributing to disease severity374. The enrichment of this 
pathway in NR suggests this pathway could be stopping the ability to respond to 
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treatment. Glucagon signalling in RA has been mostly explored in fibroblast-like 
synoviocytes, demonstrating that expression of glycogen metabolites can 
contribute to chronic inflammation375. Our understanding of this in PBMCs has 
yet to be fully explored. Again, this data implies enhanced inflammation could 
be a contributing factor to the non-response endotype. HIF is a transcription 
factor associated the hypoxic environment in RA joints. Interestingly, HIF 
repressors are known to facilitate repression through chromatin remodelling376. 
As this is a pathway we’ve found in the IR group, it alludes to an attempt of 
regulation in the underlying cellular biology.  
 
It is intriguing that in all endotype groups, many of the pathways that are 
enriched are involved in metabolism. In recent years, immunometabolism in RA 
has gained increased interest377. Many metabolic checkpoints are now being 
considered as therapeutic targets378.  
 
Further to the pathway enrichment analysis, as with the approach in Chapter 4, 
we were interested to drill down on some loops and observe the 
epigenetic/genomic environment around these loops to begin to understand the 
possible consequence of loop formation (Figure 5.6, Figure 5.8, Figure 5.10). The 
EpiSwitchTM data portal platform facilitated such an investigation. To narrow 
down on loops we wanted to focus on, we used a network analysis approach to 
help determine some of the central genes involved in the pathways. Cytoscape 
software allowed central nodes to be identified, and this was used as a way of 
finding genes involved in many of the pathways enriched for each group. In 
contrast to the GeneAnalytics analysis, which showed many pathways were the 
same between endotype groups, network analysis produced a more unique 
dataset. Only PPP2CA and WDR12 were common to all endotype groups. PPPC2A 
has been mainly implicated in systemic lupus erythematosus379,380. On the other 
hand, WDR12 polymorphisms have been implicated in cardiovascular events in 
RA patients381.  
 
The top genes unique to each group were BRCA1, TLR4, HLA-DBR1, associated 
with R, NR, IR, respectively. BRCA1 is a tumour suppressor and a mutation in 
BRCA1 is widely recognised as a risk factor for breast cancer, specifically a 
lifetime risk of 80%. Monitoring of this mutation could be considered precision 
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medicine in the oncology field382 383. However, it’s role in RA has not been 
extensively explored. One study has shown miR146a binds to the same site as the 
3’ UTR in the BRCA1 gene and subsequently down-regulated the gene. 
Interestingly, mir146a has been shown to be differentially expressed in 
inflammatory disease, including RA384. As such, it is being considered as a 
potential new therapeutic target. Moreover, similar therapies are being 
considered to treat cancer and inflammatory disease, namely PARP inhibitors385. 
The ability to inhibit DNA repair has made these drugs considered for both 
indications. Based on these findings, this gene being significant in the R group in 
our study may suggest an enhanced inflammatory response mediated by BRCA1 
may contribute to good response to therapy.  
 
The significance of TLR4 in the NR group is interesting. Activation of TLR4 is 
known to exacerbate RA through activation of serval components in the innate 
immune system386. Furthermore, blockade of TLR4 has been investigated as a 
drug target in RA387. Moreover, the endogenous TLR4 receptor agonist, MRP8/14 
was shown to be a promising candidate for the prediction of biologic response in 
RA, with baseline serum levels correlated with HDA388. After defining the central 
gene, this was taken into EpiSwitchTM data portal to visualise other genetic and 
epigenetic features surrounding the loop. Some loops were revealed to be part 
of a ‘hub’ with multiple loops in the same region. Furthermore, some loop 
anchor points overlapped with H3K27ac marks indicating potential for enhanced 
gene transcription activity. Interestingly, disease associated SNPs, did not 
overlap with anchor points, although they were in close proximity to them. 
Evidence has suggested that the closer in proximity epigenetic elements are to 
each other, the more likely they will be to impact each other and influence gene 
regulation389. Further work could be conducted on this data to quantify the 
number of bases each anchor site is from a SNP.  
 
Both R and NR groups had considerably more loops at the 6m time point, 
reflecting the results presented in Table 5.3. However, the IR group had most 
loops at the 12m time point and most loops were shared between the 6m and 
12m time points. Moreover, only 4 loops were present at baseline alone, and 
only 9 common to baseline and 6m. These results are of great interest and allude 
to a major change in the epigenome after 6m. This is reasonable considering the 
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change from remission or LDA to MDA or HDA by 12m. This type of change has 
been mostly explored in the oncology field. Global changes to chromosome 
conformation have been shown to contribute to development of leukaemia, and 
thus a target for therapy390. However, there is evidence for RA drug therapies 
manipulating the epigenome, such as the effect of etanercept and adalimumab 
on multiple histones at the CCL2 promotor site391. Moreover, a recent study has 
shown inhibition of histone enzymes could reduce cytokine production and 
osteoclastogenesis in vitro392. These data also allude to the effect of DMARD 
therapy on the IR group particularly. Furthermore, this indicates the importance 
of this group of significant loops in understanding loss of response in RA, as well 
as flare. A lot remains to be understood about RA flare, and like RA itself, it is a 
multifactorial and heterogeneous process. One of the most interesting loops 
from the group in IR was HLA-DBR1. This gene has been largely explored in RA 
but not in the context of flare or loss of response. The effect of HLA-DRB1 on 
susceptibility to RA has been widely described. It has been shown to contribute 
to radiographic progression and treatment response16. The HLA-DRB1*13 allele 
has been shown to have protective effects in some stages of RA in ACPA positive 
patients393.  
 
Through this analysis, it was discovered that 183 loops were common to all 3 
endotypes, at all 3 time points, creating a ‘stable’ RA signature (Figure 5.11). 
Pathways of interest enriched in this group were osteoclast differentiation, 
negative regulation of MAPK pathway and innate immune system. These 
pathways are well known to be involved in RA pathogenesis, with 
osteoclastogenesis showing evidence of mediation though the MAPK pathway394. 
Enrichment of these pathways indicates that these processes are likely driving 
pathogenesis. Pathways that have been explored less in RA and have appeared in 
this group were nitrogen metabolism and thyroxine production. A recent study 
investigated the role of the thyroid hormone network on RA synovial 
fibroblasts395. They found evidence to suggest TNFα may have a role in the 
degradation of thyroid hormones in the synovial environment. Studies of 




In the RA associated genes, the most connected node was PSMC6. This gene is an 
ATPase subunit and inhibition of this has been recently explored in colon cancer 
397. This is a gene previously has also been shown to be associated with juvenile 
idiopathic arthritis398 and asthma. Upon visualisation, only 2 loops were in the 
region of PSMC6. Loops can be seen in proximity to GPR137C, ERO1A and 
GNPNAT1. Like loops in the different endotypes, anchor point overlap with 
H3K27ac marks observed in with T cells, B cells and NK cells. Similar to endotype 
loops, there was no direct SNP overlap with RA associated genes. ERO1A has 
been reported to have biomarker potential in pancreatic cancer. Data mined 
from microarrays suggested that expression of this gene was negatively 
correlated with poor prognosis. GPR137C encodes a G-protein coupled receptor, 
the downregulation of which has been implicated in several cancers399. Studies 
on these 3 genes in RA are limited, thus further work may be justified to 
understand their context in RA. The lack of studies in the literature which 
implicate PSMC6 in RA, may indicate a novel driver of disease has been found.  
 
Following on from this analysis, the Searchlight platform was utilised compare 
findings and explore if other loops were found to be significant (Figure 5.13 – 
Figure 5.20). While RankProd and Searchlight used different angles to the 
analysis, with RankProd focusing on healthy and disease comparisons, and 
Searchlight comparing pairs of endotypes at all endpoints, they had the same 
aim of understanding the 3D epigenome underlying disease and differences 
between groups of patients. The RankProd and Searchlight data did show some 
broad similarities, but not at the individual loop level. Both analysis approaches 
identified 6m as the time point with the most significant stratifying loops. 
However, the loops found through each method map to different genes, which 
means that the results could be an artefact and the true epigenetic differences 
between endotypes remain unknown. Moreover, for all responder contrasts, 
Searchlight analysis did not identify significant differences at 12 months. This 
may suggest that results from the 12m time point using the RankProd pipeline 
should be interpreted with great caution.  
 
There was some validation that the RankProd and Searchlight data were 
capturing comparable answers when the genes associated with most significant 
loops found in Searchlight analysis, were entered into the EpiSwitchTM data 
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portal and enrichment of loops were found (Figure 5.21). The 3 genes explored 
could be described as ‘hubs’ where multiple loops are present. This alludes to a 
high level of regulation of these genes. Regulatory hubs have been described in 
the literature, where they have also been referred to as ‘cliques’ or frequently 
interacting regions (FIRES)400 401,402. However, it is widely acknowledged that 
defining the role of these hubs in disease mechanisms remains a challenge, and 
additional studies are needed.  
 
DOCK9 was clearly significantly different between endotype groups, and on 
inspection in the data portal, it appears this region is a hub of regulation with 
over 10 loops, and multiple other anchor points present in this region. These 
data suggest this is a highly regulated and important gene in RA. It has been 
previously identified as having increased expression in mouse models of RA403. 
Moreover, a SNP within the DOCK9 locus was shown to be significantly associated 
with RA in a North Indian cohort of RA patients404. Interestingly, compared with 
the other 2 genes visualised in this way, this region has no presence of SNPs. The 
other 2 genes investigated revealed 3 loops in the region, indicating a similar, 
yet slightly less of a regulatory region. In contrast to the DOCK9 region, these 
loops were in the region of SNPs. This visualisation of data provided a validation 
of the importance of Searchlight findings by identifying regulatory hubs which 
may impact pathogenesis. Overall, this demonstrates the valuable resource of 
the 3D epigenome and EpiSwitchTM platform to find novel genes which may drive 
disease or subtypes of disease. 
 
Understanding the loop dynamics over the 12 months was of great interest to not 
only find candidates for a stable biomarker for predicting patient endotype, but 
also to understand loops that lose stratification potential at certain time points, 
which may reveal the influence of csDMARDs on the 3D epigenome (Figure 2.22 – 
Figure 2.24). Recent research has acknowledged determining stability of 
biomarkers in complex disease a challenge and has attempted the development 
of 2 assays to measure this405. We took the decision to use the QT clustering 
algorithm for our analysis. This was considered advantageous based on the 
quality control thresholds required to identify statistically significant findings, 
and the lack of need to identify the number of clusters prior to analysis. All 3 
comparisons revealed similar clustering dynamics. All groups had at least 1 
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cluster with loops that were significant at stratifying disease and HC at all time 
points. This holds potential to take forward for further analysis for a potential 
biomarker. This clustering approach has been used previously to identify miRNA 
combinatorial biomarkers using breast cancer cell lines406. The algorithm has 
also demonstrated it’s precision in the application of mass spectrometry407. As 
other data has shown, R and NR have similar proportions of stable and dynamic 
loops. IR was shown to have alternative dynamics, and this can also be seen with 
the clustering. Both R and NR had 9 clusters, and IR had only 8. Interestingly, IR 
had the largest number of loops that gain significance at 6m, shown in cluster 3 
in the IR group. This data makes sense based on other findings that most loops 
are significant at 6m, with many loops significant and common to 6m and 12m 
time points. 
 
There are several limitations that need to be considered with work in this 
chapter. While significant work and proprietary information was used to design 
an array that would capture meaningful data for RA; by designing the array, 
there was the chance that significantly stratifying loops could be missed. 
Another limitation was the lack of analysis into the loops significant in the HC. 
While disease loops were of most interest, understanding the loops that had 
stratification potential in pooled HC and did not have that ability in disease may 
indicate relevant RA pathogenesis information. Ultimately, this chapter was a 
discovery process and exploratory in nature, and many further exploratory and 
validation steps are required, some of which have already been discussed above. 
 
There is a considerable amount of future investigation that could be carried 
forward from this work. Primarily, biomarker candidates should be taken 
forward for analysis. In the first instance this involves identifying a number of 
loops for PCR analysis from which loops can be statistically refined for a 
predictive endotype CCS. For further validation steps, multiple other samples 
would have to be sourced. In this instance, baseline samples alone would be 
sufficient, which may be available from the SERA cohort. Other cohorts could be 
sourced for this work, such as the TACERA cohort, used in the attempted 
validation the MTX CCS explored in Chapter 3. Furthermore, visualisation of 
epigenetic marks using EpiSwitchTM data portal was limited by the data that was 
included in the system, meaning there could, and very most likely would be 
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other epigenetic marks of interest that would shed more light on the potential 
consequences of loop formation, and association with each endotype. It should 
be noted, that since the generation of the data for this chapter, the data portal 
has been updated with more information, therefore offering the opportunity to 
explore our data further.  
 
Recently published work has built on other studies suggesting that autoantibody 
positive and autoantibody negative RA are 2 distinct diseases and stratifying by 
presence of autoantibodies would help considerably for precision treatment408. 
Overall, around 50% of patients in each endotype group were autoantibody 
positive. It would therefore make sense to pre-stratify patients that way and 
work through the analysis pipeline to find if antibody presence effects 
stratification by chromosomal loops. One group has produced a bioinformatics 
framework to profile biomarkers in ACPA positive and negative patients409. This 
group revealed that differentially methylated regions were found between 
patients with opposite APCA status, as well as common differentially methylated 
regions between the patient groups. This mix of similarities and differences in 
the epigenome is similar to the results produced in this study and enforces the 
key the epigenome may play in ascertaining the underlying pathogenesis in RA. 
Their work was optimised for small samples of twins, so it may be applicable to 
small samples of RA patients, albeit not twins. This methodology also has the 
advantage of a deconvolution to account for the differences in epigenome 
between cell types, primarily T cells, NK cells and neutrophils. It would be worth 
further exploration for this work. 
 
Furthermore, there is extensive other analyses that could be conducted for the 
data gathered. Each endotype group and time point revealed a long list of 
pathways and genes that may be relevant in disease. It would be interesting to 
explore more in depth the genes not already known to be associated with RA 
pathogenesis. Moreover, while the clusters of loops that retain significance over 
12 months is important for biomarker discover, studying the loops that lose 
significance could reveal more about treatment influence on the epigenome. It 
would also be extremely valuable to determine transcription factor binding site 
locations in relation to the anchor points, and ultimately characterise the 
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transcription factors that bind there, to further understand the gene regulatory 





In conclusion, this chapter clearly demonstrates the complexity of RA 
heterogeneity and suggests that 3D epigenetic endotypes exist in the early RA 
population. Interrogation of the biological relevance of stratifying loops found 
known contributors to RA pathogenesis were more likely driving disease in some 
endotypes than others. Moreover, this analysis revealed genes that may be 
driving different endotypes, and RA as a whole. The data presented here 
provides a great basis for development of a CCS biomarker that could predict 
endotype at baseline and provides a chance to understand the complex 








Overall, this thesis sought to investigate the stratification potential of 
chromosome conformation signatures (CCS) in rheumatoid arthritis (RA). In doing 
so, this work also aimed to use CCS to investigate the underlying pathogenesis of 
the disease. Therefore, this thesis aimed to strike a balance between clinically 
important experiments for the implementation of a biomarker and exploratory 
experiments that may allude to novel regulatory pathways of disease. In terms 
of the biomarker discovery pipeline, Chapter 3 demonstrated the validation 
stage of the process, Chapter 4, some exploration and Chapter 5 illustrated the 
discovery stage410,411.  
 
The first aim of the work in this thesis was to validate the methotrexate (MTX) 
CCS biomarker through bioinformatics approaches and in an independent clinical 
cohort. Results showed that in my hands, the biomarker could be validated 
computationally and replicated the high sensitivity and specificity scores that 
would be desirable for a biomarker412. Unfortunately, data gathered from testing 
the MTX CCS in an independent cohort of early RA patients suggests that it was 
not validated, and further exploratory work should be done. Whilst 
disappointing, it is not entirely surprising that it was not validated in the first 
SERA-independent cohort. There is the theory that differences in protocol could 
have contributed to the differences, however, until further work is done this 
cannot be concluded. Moreover, throughout this thesis, it has been 
demonstrated on a number of occasions that more precision medicine studies 
have been conducted in the oncology field than other fields. Yet, despite the 
concentrated work in this area, few biomarkers have made it into the clinic413 
414. The complex biomarker discovery process has also been reported for acute 
liver injury415 and heart failure416,417. These studies exemplify the complexity of 
biomarker discovery and highlight the need for future work to ascertain the 
clinical potential for the MTX CCS.  
 
Complexity of ascertaining the stratification ability of the MTX CCS was further 
demonstrated when testing in a cohort treated with several conventional 
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synthetic disease modifying anti-rheumatic drugs (csDMARDs). The data have 
shown that the 5-loop MTX CCS is specific for MTX alone. Our findings suggest 
that to achieve a clinically significant biomarker for all csDMARDs, a new 
biomarker will have to be found, likely by using a systematic approach similar to 
the discovery process of the MTX CCS. On reflection, as a highly systematic 
approach was employed to find the MTX CCS, it is very plausible that new CCS 
would need be developed for other therapies219. This has been demonstrated in 
prostate cancer, where dynamic chromatin conformation resulted in over 
expression of UBE2C, which could be targeted by several drugs including 
carvacrol418 and Ipatasertib419. However, in the same disease, it was clear that 
other dysregulated regions within the genome had to be rectified with 
alternative therapies, such as cisplatin and niclosamide420,421. Ultimately, I 
believe that with a combination of the data from Carini et al219, and the new 
data gathered here, a more specific, informative biomarker may be found. This 
integrated approach to biomarker discovery has been successfully demonstrated 
by Spiliopoulou et al422.  
 
Whilst understanding how well the MTX CCS could predict response to baseline 
csDMARDs, it was of interest to understand the relationship between the MTX 
CCS and underlying cellular biology. Based on evidence from Walsh et al209 that 
there was a functional difference between responder (R) and (NR) loci, we 
hypothesized that the regulatory environment surrounding these loci may 
differ209. The exploratory approach in Chapter 4 revealed some evidence that 
the regulatory environment within and surrounding the loci of R and NR loops 
differed at the epigenetic level. Specifically, across cell types, loci where loops 
form in NR suggested an inhibitory environment, based on the presence of 
histone modifications that are associated with repression of gene expression. 
Conversely, at loci of loops that form in R, quantification of epigenetic marks 
suggested an environment that could enhance gene expression (Figure 6.1B). 
Evidence of the ability of molecular signatures to differentiate R and NR to RA 
therapy has been demonstrated in a recent study by Tao et al. They showed that 
transcription signatures in peripheral blood monocular cells (PBMCs) differed 
between R and NR to two biologic therapies, Adalimumab and Etanercept423. The 
caveat to our work was that it largely came from healthy samples, and it has yet 
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to be validated by other datasets, either existing, or yet to be created through 
novel wet-lab experiments.  
 
Through observation of disease activity from the SERA cohort, various response 
trajectories were identified, and we hypothesized that 3D epigenetic endotypes 
exist in the early RA population (Figure 6.1A). We employed a systematic 
approach using a novel, custom microarray to ascertain if 3D epigenetic 
endotypes existed, and to identify candidates for a new CCS. The data shows 
that we were successful in identifying 3D epigenetic endotypes in the early RA 
population and we have statistically significant loops that can be taken forward 
for development of a new CCS. Precision medicine remains highly desirable in 
RA, with patients showing non-response to not only csDMARDs but also biologic 
(b)DMARDs. Moreover, a recent study concluded that there is a lack robust 
evidence on how to pharmacologically manage difficult-to-treat RA patients424. It 
could be speculated that many RA patients, if given the correct csDMARD at the 
start of treatment, would be subject to less joint damage, and therefore maybe 
more susceptible to responding to bDMARDs in the future. This exemplifies the 
importance of identifying the endotype of each patient as early as possible to 
facilitate appropriate clinical intervention. 
 
An interesting finding from this data was the ‘stable’ RA loop profile that was 
found through our discovery microarray (Figure 6.1C). This suggested that a 
baseline level of dysregulation exists in all RA patients, regardless of 3D 
endotype. A recent study suggested that a baseline dysregulation of B cells 
exists, which may contribute to autoimmunity in RA312. There is limited data on 
B cells throughout this thesis, but data gathered from a PCHiC dataset, shown in 
Chapter 4, suggested there were significant promotor interactions at the IFNAR1 
loop site in B cells, which is suggestive of enhanced gene expression with loop 
formation in R. There was further evidence to suggest that histone marks 
associated with enhanced gene expression activity are present around other loci 
that were statistically significant in the ‘RA’ group. Our gene enrichment 
analysis suggested that genes in proximity to statistically significant EpiSwichTM 
loops were associated with regulation of the cytoplasm, nucleus and cytosol. As 
the transcription of mRNA into proteins through the nucleus to the cytoplasm is 
crucial for normal gene regulation and physiological function, it may suggest 
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that this is a contributor to the dysregulation in RA patients425. Interestingly, 
nucelo-cytoplasmic transport has recently been suggested to have a role in 
autoimmune neurodegenerative diseases426. Moreover, one of the most 
significant genes found through our analysis was PSMC6, a gene which encodes 
part of the ATPase subunit and is involved in regulation of the proteasome427. As 
such, regulation of this gene has implications on antigen presentation and the 
immune response. Notably, this is a gene that has had reported involvement in 
juvenile idiopathic arthritis (JIA), and asthma in Asian populations428,429. These 
findings suggest further investigation into this gene in RA cohorts is warranted.  
 
It should also be considered that insight from other autoimmune diseases could 
be combined with our findings to provide a more informed picture of 
pathogenesis. Our data suggest this is plausible as statically significant 
stratifying loops were found in regions known to be implicated in other 
autoimmune diseases such as systematic lupus erythematosus (SLE)379,380. This is 
of research interest to many, evidenced by the formation of The Immune-
Mediated Inflammatory Disease Biobanks in the UK (IMID-Bio-UK). This aims to 
bring together biobanks of clinical information and samples from patients with a 
host of autoimmune diseases including RA and SLE into one cohort. It is thought 
that shared pathology can be found through bringing this cohort together.  
 
The strengths of the work detailed in Chapter 5 include the use of longitudinal 
samples430,431,432. Firstly, observing SERA patients past their 6-month time point 
revealed the initial responder (IR) endotype. Based on their disease activity, this 
group appear like the R group at 6 months. Moreover, having epigenetic data 
from 3 time points allowed the possibility of understanding the changing 
pathogenesis over time, and the ability to filter CCS candidates for the most 
statistically significant through time. Furthermore, this study used more patient 
samples per condition than in the study by Carini et al219. Whilst the sensitivity 
and specificity was not replicated with our analysis of the MTX CCS in an 
independent cohort, the work by Carini et al219, the work is still promising. This 
provides confidence that with further work, an even more sensitive and specific 
biomarker will be found through our endotype data.  
 
	 284	
Another strength of this work as a whole is the use of peripheral blood, which is 
a major advantage for future clinical implementation. Recently, there has been 
a focus to transition to the synovium in search for predictive RA biomarkers433. 
However, this often involves using a needle biopsy to retrieve the synovial 
sample. Whilst these biomarkers may show promise, a biomarker found from the 
blood would rely on a less invasive procedure434,435.  
 
 
Figure 6.1 Suggested 3D Epigenetic Regulatory Differences and Similarities 
between RA Endotypes 
Schematic representation of early RA 3D endotypes and the possible functional 
differences and similarities between them, collated from findings in Chapter 4 
and Chapter 5. A) 3 response trajectories (R, NR, IR) from SERA cohort, 
suggestive of different endotypes. B) Epigenetic environment surround MTX CCS 
loci suggests possibility of increased gene expression in loci of R associated 
loops, and suppression of gene expression in NR associated loops. C) Custom 
microarray and analysis with Rankprod revealed 183 shared statistically 
significant loops between all endotypes. Gene enrichment analysis suggested 
these loops were in proximity to genes that were part of the nucleus, cytosol 





The work throughout this thesis has demonstrated the challenges of researching 
the 3D epigenome; this was most obvious in Chapter 3. The attempt to transition 
to a new platform to measure 3C loops was complex and involved many 
optimisation processes, which impacted on time. However, after optimisation, I 
was confident with the robust nature of the protocols.  
 
PMBC heterogeneity is another limitation that has been discussed in all chapters. 
Due to the nature of sample collection, splitting cells was not possible. This is a 
well-recognised limitation, particularly when investigating the epigenome436. 
Studies in the RA field are now taking this into consideration in the sample 
collection process and separating cells into their subtypes before 
cryopreservation to facilitate more informative 3D epigenome analysis. 
Moreover, software is being developed to take into account this 
heterogeneity437. In contrast Liu et al and Glossop et al have argued that a 
mixed cell population would provide an overall accurate picture of the RA 
epigenetic profile438,439.  
 
Sample sizes for different parts of this work have been recognised as a 
limitation, particularly when assessing the stratification ability of the CCS as a 
pan-DMARD predictor. Having such a small sample size, with many patients on 
combination of csDMARDs, the predictive ability of HCQ and SSZ alone could not 
be determined.  
 
6.3 Future Directions 
 
The data described in this thesis, particularly the findings from Chapter 5, 
provide an exciting basis for the development of a baseline CCS that can predict 
endotype at baseline of RA treatment. Using the data discussed in Chapter 3 and 
Chapter 5, this can inform future collaborative studies with OBD to refine the 
CCS for RA.  
 
It would also be useful to consider the use of clinical information in the 
biomarker model. Studies have shown markers of bone metabolism and signalling 
molecules could aid in the prediction of treatment response in RA440,441.  
	 286	
 
Some of the findings from Chapter 4, which revealed different epigenetic 
landscapes in at the sites of R and NR loops, could be tested in vitro using 
appropriate cell lines and subsequently primary RA cells. Interestingly, some 
researchers are now modelling whole cells in-silico442. It is recognised that 
modelling cells in this way requires accurate knowledge of the biology, have 
accurate mathematics and an appropriate simulation platform. However, RA in-
vitro models have been successfully established443. These models have ranged 
from 2D co-cultures and 3D cultures to the less common organ-on-a-chip444,445. 
446. ChIP-Seq is another accessible technique that could hopefully be used to 
replicate our findings. Asadipour et al have used ChIP-Seq successfully to 
demonstrate that that chromatin is accessible in monocytes and lymphocytes. 
Furthermore, ATAC-seq is a technique that has been developed in recent years 
and could complement this work. This is a technique that allows identification of 
open areas of chromatin throughout the genome447. This technique has been 
used to report regulatory landscape in CD4+ T cells448.  
 
As a whole, the clinical application of precision medicine still has a number of 
barriers. One of the substantial barriers is the highly complex technologies and 
methods needed to interrogate the genome and identify the relevant genes 
contributing to drug response, as evidenced through the work in this thesis. To 
overcome this, there has been a rise in the computational methods used to 
interpret this and an increasing number of people with the desired skills188. It 
has been suggested that the burden of cost is not associated with the genomic 
technology itself, but in the interpretation of the data produced and the linking 
of this information with other patient characteristics to make this a relevant 
clinical biomarker. Other challenges include storage of the data that is produced 
from this research, issues with security and ownership of data and the cost to 
the healthcare system 187. Additionally, as previously discussed, the era of 
precision medicine will see a rise in bio-banks that will be essential for 
biomarker studies. This will involve the public being on board with the concept 
and trusting that any samples donated to a bio-bank will be used appropriately. 
 
As alluded to above, this thesis has approached experiments from an exploratory 
and clinically meaningful angle. Going forward, both angles should be 
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considered. Experiments such as HiC and other ‘C’ derivatives could provide a 
wealth of information that could be mined for biologically important findings. 
However, from a clinically implementable biomarker perspective, HiC would not 
be the best method economically. Moreover, 3C has been shown to have 
sufficient specificity and sensitivity, and can be successfully carried out over 48 
hours; it is also financially realistic in a clinical setting. Ultimately, EpiSwitchTM 
CCS continue to demonstrate the applicability across a breadth of therapy areas, 






In summation, this work has clearly demonstrated the heterogeneity of RA at the 
clinical and epigenome level, and highlighted that study of the 3D epigenome 
may provide a novel opportunity to provide insight into RA. It has also shown the 
complexity, and at times difficulty in successfully examining the epigenome. 
Taken together, data has shown that using the EpiSwitchTM CCS platform 
provides an integrated view of gene regulation, providing a more informed 
picture than studying epigenetic modifications separately. This thesis has shown 
that RA endotypes exist at the 3D epigenome level and implies that there is 
dysregulation that underpins RA as a whole. Further work is warranted to take 
this data further and identify if a CCS can be developed that has the capacity to 
stratify treatment naive patients at baseline. It is hoped that this work will 



































Representative gels from qPCR  
Version A (from IFNAR1 60oC) 
 
Version B (from IL23 62oC) 
 












targets_RAall <- readTargets("targets_RA.txt") 
#reading the targets to run analysis as single channel 
targets_RAall2 <- readTargets("targets_RA_2.txt") 
 
# find the files to read in and load them with the same order as the targets file.  
files <- unlist(lapply(targets_RAall$FileName, function(x) list.files("./", pattern = 
x, full.names = T))) 
array_data_read <- utils::capture.output(array_data <- 
limma::read.maimages(files, columns = list(G = "gMedianSignal", Gb = 
"gBGMedianSignal", 
                                                                                                  R = 
"rMedianSignal",Rb = "rBGMedianSignal"), 
                                                                            annotation = 
c("ControlType","ProbeName","SystematicName", "PValueLogRatio"), 
                                                                            source = "agilent")) 
 
####################### 1. Remove agilent control probes 
##################### 
# Remove agilent control probes and output the number of probes removed and 
remain in the log file. #### 
rmcnrl <-which(array_data$genes$ControlType == 0) 




####################### 2. Remove Saturated probes ##################### 
# Remove probes that have a saturated signal above 65525 #### 
satSignal <- 65525 
 
#Find the index of the Red table that has a signal over the satSignal for every 
file. 
indexR <-unlist(apply(gb$R, 2, function(x) which(x>=satSignal))) 
#Find the index of the Green table that has a signal over the satSignal for every 
file. 
indexG <- unlist(apply(gb$G, 2, function(x) which(x>=satSignal))) 
# Create the union of the two indexes. 
indexRG <- union(indexR, indexG) 
# Keep the elements of the RGList (R or G) that do not have signal values over 
the satSignal 
if (length(indexRG)>0){ 
  gbNoSatNew<-gb[-indexRG,] 
}else{ 
  gbNoSatNew<-gb 
} 
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gb <- gbNoSatNew 
 
####################### 3. Background_correction ####################### 
# Call the backgroundCorrect function of the limma package to background 
correct the expression intensities #### 
rg <- limma::backgroundCorrect(gb, method="normexp", offset=50) 
 
 
####################### 4. Normalise_Within_Arrays 
############################# 
# Call normalizeWithinArrays function of the limma package to normalize the 
expression log-ratios with #### 
# the loess method, so that the log-ratios average to zero within each array. 
#### 





#Unlog the M values 
processed_data <- RGq 
unlog_M <- 2^(processed_data$M) 
processed_data$M <- unlog_M   
 
# create the pca plot 
pca <- stats::princomp(stats::na.omit(processed_data$M)) 
 




text(pca$loadings[,1], pca$loadings[,2], labels=as.factor(targets$Slide), pos=3, 
offset=0.22, cex=0.6) 
title("PCA plot of M values for Slide!") 
dev.off() 
 
#just produce the plot 
 
lab <- as.factor(targets_RAall$Group) 
pcaVar <- round((pca$sdev^2 / sum(pca$sdev^2)),4)*100 
plot(pca$loadings[, 1], pca$loadings[, 2], pch = 19, cex = 0.5, col = lab, 
     xlab=paste0("PC1 (",pcaVar[1],"%)"), ylab = paste0("PC2 (",pcaVar[2],"%)")) 
graphics::text(pca$loadings[, 1], pca$loadings[, 2], labels = lab, pos = 3, offset = 
0.22, cex = 0.7) 
title(paste0("PCA plot of M values for ", title)) 
 
 
####################### 7. Merge Probes section #################### 
 
source("/Users/caitlinduncan/Desktop/PhD docs/DATA/duplicateCalculation.R") 
list_of_matrices <- duplicateCalculation(MAdata = processed_data) 
 
# Export the logMedianMatrix matrix #### 
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fwrite(list_of_matrices$logMedianMatrix, 
       file = "logMedianMatrix_M_values.txt", 
       sep = "\t", col.names = T,  
       row.names = T, quote = F,  
       eol = "\n", na = "NA", dec = ".") 
 
########################################### 
If single channel option is selected, individual channel processing will follow   
 
# Split data into individual G & R channels #### 
RGt <-limma::RG.MA(RGq) 







list_of_Splitmatrices <- duplicateCalculation(split_data_RAall) 
 
# Export the logMedianMatrix matrix #### 
fwrite(list_of_Splitmatrices$logMedianMatrix, 
       file = "logMedianMatrix_Channel_values.txt", 
       sep = "\t", col.names = T,  
       row.names = T, quote = F,  
       eol = "\n", na = "NA", dec = ".") 
 
####################### 8. Perform the limma Contrasts  
 
# Use the log median data for the analysis  
logMedianMatrix_s <- list_of_Splitmatrices$logMedianMatrix 
 
#create the design of the analysis 
design<-model.matrix(~0+factor(targetsR2$Cy3)) 
colnames(design) <- c("RA", "HC") 
 
#create the contrasts.matrix 
contrast.matrix <- makeContrasts(RA-HC,levels=design) 
 
#Fit linear model for each gene or attribute, based on the array files given 
linear_model<- lmFit(logMedianMatrix_s, design = design) 
 
#Based on the above linear model fit to microarray data, compute estimated 
coefficients and standard errors for a given set of contrasts. 
contrast_model <- contrasts.fit(linear_model,contrast.matrix) 
 
#Given the microarray linear model fit, compute moderated t-statistics,  
#moderated F-statistic, and log-odds of differential expression by empirical 
Bayes moderation  






# OR to add extra filtration you can also do: 
################# 
#1. Filter with p.value<=0.05 (or adj.P.Val) 
contrasts <- contrasts[which(contrasts$P.Value<=0.05),] 
 
 
#2. Set a cutOff of 1.1 and -1.1 by setting the LS column to 1 or -1 respectively 
and remove the probes with in between values! 
contrasts$LS <- ifelse(contrasts$FC_1>=1.1,1,ifelse(contrasts$FC_1<=-1.1,-1,0)) 
Informative <- which(contrasts$LS!=0) 
contrasts <- contrasts[Informative,] 
 
#4. Calculate the absolute Fold change and sort the table by that column (abs). 
contrasts <- contrasts[order(contrasts$FC_1, decreasing = T),] 
 







bedtools closest [OPTIONS] -a <FILE> \ 
                           -b <FILE1, FILE2, ..., FILEN> 
 
bedtools intersect [OPTIONS] -a <FILE> \ 
                             -b <FILE1, FILE2, ..., FILEN> 
 
 
DeepBlue Epigenome  
 




#request desired experimental data  
experiment = deepblue_list_experiments(type="peaks", 
epigenetic_mark="H3K27ac", biosource=c("peripheral blood mononuclear cell", 
project="ENCODE")) 
#retrieve names of experiments 
experiment 




request_id = deepblue_count_regions(query_id=query_id) 
requested_data = deepblue_download_request_data(request_id=request_id) 
 
#get data on specific experiments, and at the genome region of interest 
query_id = deepblue_select_experiments (experiment_name=c(“” 
 chromosome=“chr6”, start=52161697, end=52172165)  
 
#get the regions the epigenomic mark is in, in a readable format    









#export data as bed file, to folder of choice 
deepblue_export_bed(regions, target.directory = 
"/Users/caitlinduncan/Desktop/DeepBlue_Bed_files", file.name =  
"311019_H3K27ac_peripheralbloodmononuclearcell_IL17Aa_hg38”) 
#export data as tab file, to folder of choice 
deepblue_export_tab(regions, target.directory = 




Coordinates for DeepBlue: 
 
hg38 
“chr6”, start=52161697, end=52172165 
“chr6”, start=52184632, end= 52187067  
“chr4”, start= 77510412, end= 77512093  
“chr4”, start= 77602625, end= 77605433  
“chr16”, start= 27356311, end= 27357534  
“chr16”, start= 27449257, end= 27451508  
“chr12”, start= 56345719, end= 56347275 
“chr12”, start= 56361069, end= 56361825  
“chr21”, start= 33324378, end= 33325411  
“chr21”, start= 33373955, end= 33376515 
 
hg19 
“chr6”, start=52026495, end= 52036963 
“chr6”, start= 52049430, end= 52051865  
“chr4”, start= 78431566, end= 78433247  
“chr4”, start= 78523779, end= 78526587  
“chr16”, start= 27367632, end= 27368855  
“chr16”, start= 27460578, end= 27462829  
“chr12”, start= 56739503, end= 56741059 
“chr12”, start= 56754853, end= 56755609  
“chr21”, start=34696683, end= 34697716  
“chr21”, start=34746261, end= 34748821 
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hg19 – 500kb upstream 
“chr6”, start= 51526495, end= 52026495 
 “chr4”, start= 77931566, end=78431566 
 “chr16”, start= 26867632, end= 27367632 
 “chr12”, start=56239503, end= 56739503 
 “chr21”, start= 34196683, end= 34696683 
 
 
hg19 – 500kb downstream 
 “chr6”, start= 52051865, end= 52551865  
 “chr4”, start= 78526587, end= 79026587 
 “chr16”, start= 27462829, end= 27962829 
 “chr12”, start= 56755609, end= 57255609 




hg38 – 500kb upstream  
“chr6”, start= 51661697, end= 52161697 
 “chr4”, start= 77010412, end= 77510412 
 “chr16”, start= 26856311, end= 27356311 
 “chr12”, start= 55845719, end= 56345719 
 “chr21”, start= 32824378, end= 33324378 
 
hg38 – 500kb downstream  
 “chr6”, start= 52187067, end= 52687067 
 “chr4”, start= 77605433, end= 78105433 
 “chr16”, start= 27451508, end= 27951508  
 “chr12”, start= 56361825, end= 56861825 


















































































ChiCAGO score (used to determine significance in PCHiC dataset) 
Let xi denote the measured value of a quantitative property (such as CHiCAGO 
interaction score or gene expression level) for cell type i ∈ I. Then, the 
specificity score sc for a given cell type c ∈ I is a weighted mean of the 
differences xc – xi for i ≠ c, 
where the weights dc,i are distances between cell type c and cell types i, 
calculated using the complete dataset (e.g., CHiCAGO interaction scores for all 
interactions or expression values for all genes; distances calculated using 
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